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Resumo 
A diabetes é uma doença metabólica cuja prevalência tem aumentado de forma 
alarmante. A neuropatia é uma complicação que ocorre em aproximadamente 50% 
dos doentes diabéticos, dos quais cerca de 25% manifestam queixas de dor 
espontânea, alodínia e hiperalgesia. O estudo dos mecanismos responsáveis pela dor 
neuropática diabética tem-se direccionado para as causas periféricas mas o efeito 
analgésico de fármacos com actuação central e as alterações observadas no sistema 
nervoso central de indivíduos diabéticos sugerem a ocorrência de causas centrais. A 
presente dissertação de Doutoramento tem como objectivo geral estudar os 
mecanismos centrais subjacentes à dor neuropática diabética de modo a desenvolver 
futuramente estratégias preventivas ou de tratamento deste problema.  
Como modelo animal de diabetes utilizámos o rato injectado com estreptozotocina 
(STZ), uma toxina que destrói selectivamente as células β pancreáticas, induzindo 
diabetes com características de tipo 1, tais como hiperglicemia, insulinopenia e 
diminuição dos níveis de IGF1 (insulin-growth factor 1). Utilizámos animais com 4 
semanas de diabetes, dado que a este tempo os animais manifestam sinais 
comportamentais estáveis de hiperalgesia e alodínia mecânicas. 
O trabalho inclui 6 publicações. Na primeira, utilizámos o estudo da indução do proto-
oncogene c-fos em neurónios da medula espinhal para demonstrar que a diabetes 
induz hiperactividade espontânea dos neurónios da medula espinhal e 
hiperexcitabilidade dos mesmos em resposta a estímulos inócuos e nóxicos. Estas 
alterações neuronais podem contribuir para a dor espontânea, hiperalgesia e alodínia 
na neuropatia diabética. Na segunda publicação, estudámos os possíveis mecanismos 
subjacentes às referidas alterações funcionais dos neurónios espinhais. Com base em 
estudos que apontavam para distúrbios no papel do GABA na medula espinhal de 
ratos diabéticos, avaliámos a neurotransmissão GABAérgica espinhal, tendo-se 
verificado aumento na expressão do GABA no corno dorsal da medula espinhal de 
ratos diabéticos. Estudámos a expressão do co-transportador iónico potássio-cloro do 
tipo 2 (KCC2) na medula espinhal dos ratos diabéticos, visto ter sido demonstrado que 
a actividade deste co-transportador contribui para a acção pós-sináptica do GABA. Os 
ratos diabéticos apresentaram menor expressão de KCC2 no corno dorsal da medula 
espinhal. O aumento da expressão de GABA em conjunto com a diminuição de 
expressão de KCC2 poderá inverter o papel inibitório do GABA na medula espinhal e 
contribuir para a hiperactividade neuronal espinhal. 
As duas publicações seguintes destinaram-se a esclarecer os mecanismos indutores 
da diminuição da expressão espinhal do KCC2. Na terceira publicação, colocámos a 
hipótese da microglia e do BDNF (brain-derived neurotrophic factor) serem factores 
determinantes. A activação microglial aumentava significativamente no corno dorsal da 
medula espinhal dos ratos diabéticos, sem que ocorresse aumento de expressão de 
BDNF. A inibição da actividade microglial, por administração intratecal de minociclina, 
normalizou a expressão de KCC2 no corno dorsal da medula espinhal e reverteu 
totalmente a hiperactividade neuronal e hiperalgesia nos ratos diabéticos. O bloqueio 
da acção do BDNF, por administração intratecal de sequestrador de BDNF (TrKB-Fc), 
apresentou efeitos moderados. Este trabalho demonstrou que a microglia tem um 
papel-chave na modulação da actividade neuronal durante a diabetes, através dos 
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seus efeitos na expressão de KCC2. Na quarta publicação, a hipótese colocada foi a 
de que o stress oxidativo constitui outro mecanismo de regulação do KCC2. Os níveis 
de stress oxidativo na medula espinhal de ratos diabéticos estavam aumentados. O 
tratamento antioxidante com ácido alfa-lipóico reverteu o stress oxidativo e a 
hiperactividade neuronal na medula espinhal dos ratos diabéticos e aumentou 
moderadamente a expressão de KCC2. Estes resultados sugerem que o stress 
oxidativo contribui para a hiperactividade neuronal espinhal, através do seu efeito na 
expressão de KCC2.  
As duas publicações finais da tese estudaram a modulação descendente da dor, 
direccionando-se para os efeitos da diabetes em centros-chave de controlo da dor. Na 
quinta publicação, verificámos que a diabetes induz hiperactividade neuronal na 
substância cinzenta periaqueductal (PAG), que era revertida pelo tratamento com 
gabapentina, um anticonvulsivante utilizado no tratamento da dor neuropática 
diabética. Adicionalmente, a gabapentina revertia a hiperalgesia mecânica e a 
hiperactividade neuronal na medula espinhal. Na sexta publicação, estudámos as 
regiões do tronco cerebral que servem de “relay” à PAG na modulação descendente 
da dor, nomeadamente a área serotoninérgica do bolbo rostroventromedial (RVM) e os 
grupos noradrenérgicos A5, A6 e A7. A imunodetecção de enzimas envolvidas na 
síntese de serotonina e noradrenalina, a hidroxilase do triptofano (TpH) e a tirosina 
hidroxilase (TH), respectivamente, mostrou que os ratos diabéticos tinham números 
superiores de neurónios serotoninérgicos no RVM e noradrenérgicos no A5, o que era 
acompanhado por aumento dos níveis espinhais de serotonina e noradrenalina, 
quantificados por ELISA. A actividade neuronal, avaliada pela expressão de formas 
fosforiladas de ERKs (extracelullar-regulated kinases) nos neurónios serotoninérgicos, 
e de CREB (cAMP regulated binding protein) nos neurónios noradrenérgicos, estava 
aumentada no RVM e no A5 dos ratos diabéticos. Este trabalho demonstrou que a 
diabetes afecta o sistema descendente de controlo da dor através da modulação 
serotoninérgica e noradrenérgica. O tratamento dos ratos diabéticos com doses de 
IGF1 que não reverteram a hiperglicemia, normalizou a actividade dos neurónios da 
PAG, preveniu as alterações no sistema serotoninérgico e noradrenérgico, reverteu a 
hiperactividade espinhal e diminuiu os sinais comportamentais de hiperalgesia. 
Colectivamente, os dados obtidos nesta dissertação de doutoramento demonstram 
que a etiologia da dor neuropática diabética não se resume apenas às alterações dos 
nervos periféricos, mas engloba alterações de áreas centrais envolvidas no controlo da 
dor. A diabetes induz hiperactividade e hiperexcitabilidade dos neurónios nociceptivos 
da medula espinhal, para as quais parece contribuir a perda de inibição GABAérgica 
mediada por redução na expressão de KCC2, a qual é provavelmente induzida por 
activação microglial e stress oxidativo na medula espinhal. A hiperactividade espinhal 
deverá aumentar a actividade dos neurónios da PAG e recrutar vias descendentes 
serotoninérgicas e noradrenérgicas envolvidas na modulação da dor, por activação 
dos neurónios do RVM e do A5. Torna-se agora necessário avaliar o papel da 
serotonina e noradrenalina na modulação da transmissão nociceptiva na medula 
espinhal durante a diabetes o que poderá abrir novas linhas de investigação no 
tratamento da dor neuropática diabética. 
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Abstract  
Diabetes is a metabolic disease with an alarmingly increasing prevalence. Neuropathy 
affects about 50% of diabetic patients and is associated with spontaneous pain, 
allodynia and hyperalgesia in 25% of the cases. The study of the mechanisms 
underlying diabetic neuropathic pain has been directed to the peripheral causes but 
considering the analgesic effect of central-acting drugs and the changes detected in 
the central nervous system of diabetic patients it is likely that central mechanisms are 
also involved. This PhD thesis aims at investigating the central mechanisms underlying 
diabetic neuropathic pain in order to develop new preventive or treatment strategies for 
this problem. 
As animal model of diabetes, we used the rat injected with streptozotocin (STZ rats), a 
toxin that selectively destroys pancreatic β cells, inducing type 1 diabetes, 
characterized by hyperglycemia, insulin deficiency and decreased levels of insulin-
growth factor 1 (IGF1). We used the animals at 4 weeks of diabetes since at this time 
the rats show stable behavioral signs of mechanical hyperalgesia and allodynia. 
This dissertation includes six publications. In the first publication, we demonstrated that 
diabetes induces spontaneous hyperactivity and hyperexcitability of spinal nociceptive 
neurons in response to innocuous and noxious stimuli, using the c-fos method. These 
neuronal changes may contribute to spontaneous pain, allodynia and hyperalgesia 
during diabetic neuropathy. In the second publication, we studied the possible 
mechanisms underlying the functional changes occurring at spinal nociceptive neurons. 
Based on studies showing impairments in the role of GABA at the spinal cord of 
diabetic rats, we evaluated the spinal GABAergic neurotransmission and detected 
increased expression of GABA in the spinal dorsal horn of diabetic rats. We studied the 
expression of the ionic co-transporter potassium-chloride type 2 (KCC2) in the spinal 
cord of diabetic rats, as has been demonstrated that the activity of this co-transporter 
contributes to the postsynaptic action of GABA. Diabetic rats presented lower 
expression of KCC2 in the spinal dorsal horn. The increased expression of GABA 
along with the decreased expression of KCC2 may invert the inhibitory role of GABA at 
the spinal cord and contribute to spinal neuronal hyperactivity. 
The following two publications aimed to clarify the mechanisms which induce the 
reduction in the expression of spinal KCC2. In the third publication, we considered the 
microglia and brain-derived neurotrophic factor (BDNF) as key factors. The microglial 
activation increased significantly in the spinal dorsal horn of diabetic rats, with no 
changes in the expression of BDNF. Inhibition of microglial activity by intrathecal 
administration of minocycline, normalized the expression of KCC2 in the spinal dorsal 
horn and reversed completely the neuronal hyperactivity and hyperalgesia in diabetic 
rats. Blocking the action of BDNF by intrathecal administrations of BDNF sequester 
(TrkB-Fc) showed moderate effects. This work demonstrated that microglia have a key 
role in the modulation of neuronal activity during diabetes through its effects on the 
expression of KCC2. In the fourth publication, we considered oxidative stress as 
another mechanism of regulation of KCC2. The levels of oxidative stress on the spinal 
cord of diabetic rats were increased. The antioxidant treatment with alpha-lipoic acid 
reversed the oxidative stress and neuronal hyperactivity in the spinal cord of diabetic 
rats and moderately increased the expression of KCC2. These results suggest that 
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oxidative stress contributes to the spinal neuronal hyperactivity through its effect on 
expression of KCC2. 
The two final publications of the thesis studied the descending modulation of pain, 
focusing on the effects of diabetes in key centers of pain control. In the fifth publication, 
we observed that diabetes induces neuronal hyperactivity at the periaqueductal grey 
matter (PAG), which was reversed by treatment with gabapentin, an anticonvulsant 
used to treat diabetic neuropathic pain. Additionally, gabapentin reversed the 
mechanical hyperalgesia and neuronal hyperactivity at the spinal cord. In the sixth 
publication, we studied the regions of the brainstem that act as relay stations of the 
PAG descending pain modulation, including the serotoninergic rostroventromedial 
medulla (RVM) and the A5, A6 and A7 nordarenergic groups. The immunodetection of 
enzymes involved in the synthesis of serotonin and noradrenaline, tryptophan 
hydroxylase (TpH) and tyrosine hydroxylase (TH), respectively, showed that diabetic 
rats presented higher numbers of serotonergic and noradrenergic neurons at the RVM 
and A5. These changes were accompanied by increased levels of serotonin and 
noradrenaline at the spinal cord, as quantified by ELISA. The neuronal activity, as 
assessed by the expression of phosphorylated forms of extracelullar-regulated kinases 
(ERKs) and cAMP-regulated binding protein (CREB) in serotonergic and noradrenergic 
neurons, respectively, was increased in the RVM and A5 in the diabetic rat. This study 
showed that diabetes affects the pain control descending system by modulating the 
serotoninergic and noradrenergic neurotransmission. The treatment of diabetic rats 
with IGF1, at doses that did not reverse the hyperglycemia, normalized the neuronal 
activity at the PAG, prevented the changes in the serotonergic and noradrenergic 
systems, reversed the spinal hyperactivity and ameliorated hyperalgesia detected in 
STZ rats. 
Taken together, the results present in this PhD thesis demonstrate that the etiology of 
diabetic neuropathic pain is not confined to changes in peripheral nerves, but involves 
changes in central areas involved in pain control. Diabetes induces hyperactivity and 
hyperexcitability of spinal nociceptive neurons, probably due to the loss of GABAergic 
inhibition induced by decreased expression of KCC2, which is mediated by oxidative 
stress and microglial activation at the spinal cord. It is likely that spinal hyperactivity 
increases the activity of PAG neurons, recruiting the serotoninergic and noradrenergic 
descending pathways involved in pain modulation, via activation of neurons at the RVM 
and at the A5. It is now necessary to evaluate the role of serotonin and noradrenaline in 
the modulation of spinal nociceptive transmission during diabetes, which could open 
new lines of research in the treatment of diabetic neuropathic pain. 
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“Life is short, unpleasant and painful…” 
 
 
 
  
 
Excerpt from the Clinical description of diabetes by Aretaeus of Cappadocia (2nd century AD). 
Adapted from Papaspyros NS (1952). The History of Diabetes Mellitus. 
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Diabetes is a major health problem worldwide with an alarming increasing 
prevalence and was considered a pandemia by the World Health Organization (WHO, 
1999). Diabetes is one of the most important leading causes of mortality and morbidity 
in developing countries, due not only to the disease by itself, but also to its 
complications (Ali et al., 2010; Ma and Tong, 2010; Stene et al., 2010). Complications 
of diabetes, such as the cardiovascular diseases, sexual dysfunction, retinopathy, 
nephropathy and neuropathy, are responsible for increased disability and reduced 
quality of life as well as decreased life expectancy among diabetic patients (Ali et al. 
2010; Giacco and Brownlee, 2010; Candido et al., 2010). They represent an enormous 
economic and social burden in most societies (Ali et al., 2010). As stated by the 
International Diabetes Federation “Diabetes is certain to be one of the most challenging 
health problems in the 21st century” (International Diabetes Federation, 2006). 
 
1. Definition and classification of diabetes mellitus 
Diabetes mellitus is a metabolic disease characterized by chronic 
hyperglycemia induced by defects on insulin secretion, insulin action or both (WHO, 
1999).  It is classified as type 1 (T1DM), type 2 (T2DM), gestational or other specific 
types of diabetes (WHO, 1999).  
 
Type 1 Diabetes Mellitus  
T1DM is caused by loss of pancreatic β-cells and comprises autoimmune (type 
1A) and non-autoimmune or idiopathic (Type 1B) diabetes (WHO, 1999; Alberti, 2010). 
The former is accompanied by evidences of autoimmunity, with detection of antibodies 
against insulin, glutamine-acid decarboxilase and/or β-cells (Eisenbarth, 2007; 
Concannon et al., 2009; Alberti, 2010; Delli et al., 2010). The etiology of the type 1B 
diabetes remains unknown (McLarty et al, 1990; Alberti, 2010). 
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T1DM is characterized by lack of insulin secretion and has an abrupt onset. The 
affected patients require insulin replacement, with daily exogenous administrations, to 
maintain normoglycemia (Alberti, 2010; Delli et al., 2010). 
 
Type 2 Diabetes Mellitus 
T2DM is characterized by resistance to insulin action (WHO, 1999; Alberti, 
2010, Yki-Jarvinen, 2010). Initially T2DM patients present hyperinsulinemia, a 
response to overcome the insulin resistance. Insulin deficiency develops with the 
progression of the disease as a consequence of β-cell dysfunction (Alberti, 2010; 
Alsahli and Gerich, 2010). The affected patients are commonly treated with oral 
antidiabetic drugs and do not require insulin replacement to maintain reasonable 
glycemia control. Treatment with insulin could be necessary within the course of the 
disease, due to the crescent deterioration of β-cell function (Alberti, 2010; Alsahli and 
Gerich, 2010). This type of diabetes is closely associated with unhealthy life styles, 
namely those related with food and physical activity habits.T2DM has an important 
hereditary influence, occurring within families and being more prevalent in some ethnic 
groups (Ma and Tong, 2010).   
 
Gestational Diabetes Mellitus 
Gestational diabetes mellitus is defined as hyperglycemia first detected during 
pregnancy (WHO, 1999; Alberti, 2010). In most cases, glycemic levels normalize after 
the delivery, but in high risk patients it can trigger a T2DM. There are several 
gestational complications associated with gestational diabetes mellitus, namely 
intrauterine fetal death, congenital malformations, neonatal hypoglycemia, jaundice, 
prematurity and macrosomia (Dornhorst and Banerje, 2010). 
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Other specific types of diabetes 
The types of diabetes included in this category comprise diabetes induced by a 
wide range of conditions, but account for a small number of cases. Diabetes can occur 
as a result of specific genetic defects in insulin secretion and action, as is the case of 
maturity onset diabetes of the young (MODY) (WHO, 1999; Alberti, 2010, Jones and 
Hattersley, 2010). Additionally, diabetes may also be a consequence of several other 
diseases, such as pancreatitis, hemochromatosis, cystic fibrosis, Cushing syndrome, 
acromegaly, pheochromocytoma, glucagonoma and hyperthyroidism (WHO, 1999; 
Alberti, 2010; Hanley, 2010). Many drugs and chemicals can also cause diabetes 
(Gittoes et al, 2010), as well as some infection diseases, as mumps, congenital rubella, 
coxsackie B and cytomegalovirus (WHO, 1999; Alberti, 2010). There are also several 
genetic syndromes associated with increased risk of diabetes, namely the Down 
Syndrome, Turner Syndrome and Klinefelter Syndrome (WHO, 1999; Alberti, 2010). 
 
2. The Prevalence and Costs of Diabetes 
According to the International Diabetes Federation, diabetes affects more than 
285 million people worldwide and can reach 435 million persons by 2030. It accounts 
now for about 6.8% of total global mortality (International Diabetes Federation, 2009) 
and the increasing prevalence rates worldwide point for a rise in morbidity and 
disability. Life expectancy of diabetic patients is estimated to be about 7-15 years less 
than that of general population (Morgan et al., 2000; Franco et al., 2007). Diabetes is 
believed to induce important loss of human and social resources in almost all societies, 
which is expected to worsen in the next few years (Ali et al, 2010).  
T1DM accounts for approximately 5-10% of world diabetic population. Its 
incidence is increasing about 3-4% per year (Stene et al., 2010). T1DM is associated 
with an approximately 2 - to 10 fold excess risk of premature mortality (Dahlquist and 
Kallén, 2005; Soedamah-Muthu et al., 2006; Stene, 2010) and increased morbidity, 
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which are particularly related with acute and late-onset complications of the disease 
(Stene, 2010). In fact, after about 10 – 15 years of diabetes, microvascular and 
macrovascular chronic diabetes complications start to affect T1DM patients (Stene, 
2010), which, considering that the incidence of this type of diabetes peaks at the 
puberty (DIAMOND Project group, 2006), afflict the patients at very young ages.  
T2DM accounts for 90 – 95% of all cases worldwide and its prevalence has 
been growing rapidly, namely in lower socioeconomic groups (WHO, 1999; Ali et al., 
2010; Ma and Tong, 2010). T2DM has, in most of the cases, a late diagnosis and about 
30 – 50% of T2DM cases are as yet unrecognized (Aschner, 2002; International 
Diabetes Federation, 2009; Ma and Tong, 2010; Ali et al., 2010). The late diagnosis of 
T2DM is thought to be the reason for the high prevalence of diabetic complications in 
this type of diabetes. Most of the patients already present signs of diabetic 
complications at the time of the diagnosis and the majority dies from cardiovascular 
and renal disease (Morrish et al., 2001). 
Overall, diabetes imposes important health, social and economic burdens 
worldwide. It results in an 1.5-5 times increase in health care expenses over the 
general population (Rubin et al., 1992; Henriksson and Jonsson, 1998; Shobhana et 
al., 2000; Ricordeau et al., 2003; Zhang et al., 2004; Koster et al., 2006), with a 
cumulatively total cost of about € 263 billion in 2010 (International Diabetes Federation, 
2009). The elevated costs derive mostly from the treatment of its complications, such 
as stroke, coronary artery disease, renal failure, blindness, amputation and neuropathic 
pain (Ali et al., 2010). 
In Portugal, diabetes affects 7,3% of the general population, with an estimated 
cost of about € 1500 M in 2009, which represents approximately 1% of the Portuguese 
Internal Product and about 9% of the expenses of Portuguese Health Department 
(Observatório Nacional de Diabetes, 2010). 
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3. Complications of diabetes 
All forms of diabetes may develop complications (Giacco and Brownlee, 2010; 
Candido et al, 2010). Diabetes was shown to dramatically increase the risk for coronary 
artery disease, ischemic cerebrovascular disease, myocardial infarction and peripheral 
artery disease (Candido et al., 2010; Amory and Weinberger, 2010; Sillesen, 2010). In 
fact, death from stroke and myocardial infarction remain the major leading causes of 
mortality in T1DM and T2DM (Nathan et al., 2005; Dale et al., 2008; Ali et al., 2010). 
Diabetes also increases the risk of renal dysfunction and is the primary cause of 
dialysis or kidney transplantation in the USA (USRDS, 2008). About one quarter of 
diabetic patients present visual impairments (Ali et al., 2010; Scanlon, 2010). In fact, 
proliferative diabetic retinopathy was shown to affect approximately 67% and 33% of 
T1DM and T2DM patients, respectively (Klein, 1984, Scanlon, 2010). Diabetic 
retinopathy was considered to be the major leading cause of adult blindness in the 
USA and comprises 5% of all cases of blindness globally (Ali et al., 2010).  
Neuropathy is a very common consequence of diabetes. More than 60% of 
diabetic patients develop neuropathy, which may include distal symmetrical 
polyneuropathy, mononeuropathies and autonomic neuropathies that, ultimately, cause 
erectile dysfunction, gastroparesis, foot disorders and altered pain sensations (Wheeler 
et al., 2007; Tesfaye, 2009; Obrosova, 2009; Ziegler, 2010; Tesfaye et al., 2010). 
Erectile dysfunction, which affects approximately 35-50% of men with diabetes, is 
triggered by failure of nitric oxide (NO) – mediated smooth muscle relaxation secondary 
to autonomic neuropathy and endothelial dysfunction (Ziegler, 2007; Price, 2010), while 
the gastroparesis is induced by sympathetic, parasympathetic and enteric neural 
dysfunction (Malagelada, 2007; Tesfaye et al., 2010; Ziegler, 2010).  Foot disorders are 
triggered by the combined consequences of sensory neuropathy, peripheral vascular 
disease and infection and are the major cause of all non-traumatic amputations 
worldwide (Boulton, 2005; Lyons, 2007; Boulton, 2010). Altered pain sensation results 
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from the affectation of somatosensory system and will be addressed in more detail later 
in the text, since it is the focus of the present PhD dissertation.  
 
 
4. Diabetic Neuropathies 
 
The most recent definition and classification of diabetic neuropathy (DN) were 
updated by a panel of experts in the end of 2009 and DNs were separated as typical 
and atypical DNs (Tesfaye et al., 2010).  
The typical DN comprises the sensorimotor polyneuropathy, which is the 
commonest form of diabetic neuropathy, affecting approximately 30% of diabetic 
patients (Shaw et al., 2003; Tesfaye, 2007; Ziegler, 2010). It is characterized by 
symmetrical and length-dependent affectation of peripheral nerves with reduction in 
sensory and motor nerves conduction velocities. Chronic sensory abnormalities are 
very often presented, with neuropathic pain co-existing with loss of sensation. 
Autonomic dysfunction may also be present (Tesfaye, 2007; Tesfaye, 2009; Obrosova 
2009; Ziegler, 2010; Tesfaye et al., 2010).  
Atypical DN comprises the acute painful DN, focal and multifocal neuropathies 
and autonomic neuropathy (Tesfaye et al., 2010).  Acute painful DN is characterized by 
continuous burning pain that affects, predominantly the soles and presents nocturnal 
exacerbation. It is accompanied by allodynia, frequently described as unpleasant 
cutaneous contact with clothes, and hypersensitivity to painful stimuli (hyperalgesia) 
(Ziegler, 2010; Tesfaye et al., 2010). These manifestations have an abrupt onset, but 
subside rapidly and no recurrences are normally observed. It is mostly correlated with 
severe weight loss and insulin treatment onset (Ziegler, 2010). These acute syndromes 
are relatively uncommon when compared with the chronic painful neuropathy 
associated with the sensorimotor polyneuropathy (Ziegler, 2010). Focal and multifocal 
neuropathies comprise a wide variety of conditions, as cranial neuropathy, 
mononeuropathy of the limbs, diabetic truncal neuropathy and diabetic amyotrophy 
(Ziegler, 2010). The large majority of these conditions affects long-term diabetic 
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patients and is usually accompanied by pain symptoms. Almost all cases have partial 
or complete resolution of the manifestations when carefully diagnosed and treated 
(Ziegler, 2010; Tesfaye et al., 2010). Diabetic autonomic neuropathy is a neuropathic 
condition that affects predominantly the autonomic nervous system. It may present 
repercussions in cardiovascular, gastrointestinal, and genitourinary systems and 
sudomotor function (Stevens, 2007; Ziegler, 2007; Malagelada, 2007; Ziegler, 2010; 
Tesfaye et al., 2010).  
 
Central nervous system dysfunction 
 
Little attention has been given to the central nervous system (CNS) during DN.  
Nevertheless, degenerative lesions in the CNS were already reported in diabetic 
patients (Biessels, 2007). Previous studies demonstrated demyelination and loss of 
axon cylinders in the posterior columns (Reske-Nielsen and Lundbaek, 1968; Slager, 
1978; Mizisin et al., 2007), known as myelopathy, degeneration and loss of cortical and 
hypocampal neurons (Reske-Nielsen et al., 1965; Reske-Nielsen and Lundbaek, 1968; 
Li et al, 2002) and abnormalities in the midbrain and cerebellum (Reske-Nielsen and 
Lundbaek, 1968), defined as encephalopathy (Biessels, 2007). Overall those central 
changes may contribute to the higher prevalence of cognitive and memory deficits 
detected in diabetic patients (Schmidt et al., 2004; Brands et al., 2005). Recent findings 
also show an increased occurrence of Alzheimer-like changes during diabetes (Li et al., 
2007), which may also contribute to such deficits. Recently, there were described 
structural and functional impairments at the central pain control system, as the spinal 
cord (Eaton et al., 2001; Pertovaara et al., 2001; Chen and Pan, 2002; Selvarajah et 
al., 2006; Mizisin et al., 2007) and the thalamus (Selvarajah et al., 2008; Sorensen et 
al., 2008; Fischer et al., 2009; Fischer and Waxman, 2010; Selvarajah et al., 2011), 
which were suggested to contribute to the altered pain sensations observed in diabetic 
patients.  
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5. Painful diabetic neuropathy (PDN) 
Pain is the most distressing symptom of DN (Tesfaye and Kempler, 2005; 
Backonja et al., 2007; Boulton, 2007; Tesfaye, 2009; Obrosova, 2009; Ziegler, 2010; 
Tesfaye et al., 2010). Painful diabetic neuropathy (PDN) is defined by IASP 
(International Association for the Study of Pain) as “pain arising as a direct 
consequence of abnormalities in the peripheral somatosensory system in people with 
diabetes.” The pain is commonly distal, symmetrical and with nocturnal exacerbation 
(Tesfaye and Kempler, 2005; Tesfaye, 2007; Tesfaye, 2009; Ziegler, 2010; Tesfaye et 
al., 2010). It is perceived spontaneously and described as prickling, burning, 
lancinating and shooting “like electric shocks”. It is often accompanied by hyperalgesia 
and allodynia (Tesfaye and Kempler, 2005; Tesfaye, 2007; 2009; Obrosova, 2009; 
Tesfaye et al., 2010; Ziegler, 2010). This pain condition may persist for several years 
(Tesfaye et al., 2010; Ziegler, 2010) and is resistant to conventional pain treatments, 
causing considerable disability and impairing the quality of life (Shaw et al., 2003; 
Daousi et al., 2006; Ziegler, 2010), namely by interfering with sleep (Galer et al., 2000). 
PDN may be accompanied by sensory loss and is commonly associated with 
autonomic neuropathy (Tesfaye et al., 2010; Ziegler, 2010). 
The estimates of pain occurrence are quite variable, ranging from 3 to 25% of 
diabetic patients, according the diagnosis criteria used (Tesfaye et al., 2010).  It is 
believed that neuropathic pain affects about one quarter of the population with diabetes 
(Shaw et al., 2003; Tesfaye and Kempler, 2005; Daousi et al., 2006; Tesfaye, 2009; 
Ziegler, 2010; Tesfaye et al., 2010) and is one of the major complains that leads 
diabetic patients to seek health care (Tesfaye, 2009).   
  
The treatment of PDN has been almost symptomatic, since most of drugs 
directed to counteract the pathogenetic mechanisms were shown to present irrelevant 
clinical applicability (Tesfaye, 2009; Ziegler, 2010; Zilliox and Russel, 2011). Currently, 
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only the antioxidant alpha-lipoic acid and epalrestat, an aldose reductase inhibitor, are 
used for PDN treatment in several European countries and in Japan, respectively 
(Tesfaye, 2009; Ziegler, 2010; Zilliox and Russel, 2011). In what concern the pain 
relieving agents it is known that peripherically-acting drugs, as the topical capsaicin 
and the 5% lidocaine patches, have only moderate efficacy in this pain condition 
(Tesfaye, 2009; Ziegler, 2010; Zilliox and Russel, 2011). Central-acting drugs like 
antidepressants (including tryciclic antidepressants and dual serotonin and 
noradrenaline reuptake inhibitors) and anticonvulsants (pregabalin and gabapentin), 
were shown to be the agents with the greatest pain relief effects and have been used 
as first line treatments for PDN (Tesfaye, 2009; Ziegler, 2010; Zilliox and Russel, 
2011). Neverthless, their effects are moderate, eliciting 50% pain reduction in about 
30%-50% of treated diabetic patients (Tesfaye, 2009; Ziegler, 2010; Zilliox and Russel, 
2011). Important concerns exist in the use of such agents during diabetes due to their 
several contra-indications, such as unstable angina, myocardial infarction, heart failure, 
ventricular arrhythmias, hepatic impairment and end-stage renal disease. These health 
complications normally co-exist in patients affected by diabetic neuropathic (Ziegler, 
2010; Zilliox and Russel, 2011). Furthermore, these drugs can elicit important side-
effects that compromise the treatment compliance and may worsen the diabetic 
condition, as dry mouth, sedation, tiredness, somnolence, dizziness, nausea, 
constipation, weight gain and increase in fast blood glucose (Tesfaye, 2009; Ziegler, 
2010; Zilliox and Russel, 2011). These data show that the development of new and 
more efficacious agents is necessary, which can only be achieved upon a deeper 
knowledge of the etiological mechanisms involved in this neuropathic pain condition.  
 
5.1. The pain mechanisms  
The etiology of chronic pain associated to diabetic neuropathy remains unclear. 
Most of the studies on PDN have been focused on the peripheral aspects of pain 
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(Calcutt, 2002; Sima, 2003; Kles and Vinik, 2006; Calcutt and Backonja, 2007; 
Zochodne, 2007; Tavakoli et al., 2008; Obrosova, 2009; 2009a), with central 
mechanisms being scarcely studied (Calcutt and Chaplan, 1997; Calcutt et al., 2000; 
Pertovaara et al.,2001; Chen and Pan, 2002; Selvarajah et al., 2006; Selvarajah and 
Tesfaye, 2006; Malmberg et al., 2006; Ramos et al., 2007; Sorensen et al., 2008; 
Selvarajah et al., 2008; Jolivalt et al., 2008; Cauda et al., 2009; Fischer et al., 2009; 
Fischer and Waxman, 2010; Selvarajah et al., 2011). Pain perception involves complex 
and numerous neuronal networks and mechanisms, with intervention of peripheral 
nerve fibers, spinal cord, brainstem, subcortical and cortical brain areas (Figure 1) 
(Millan, 2002; Vanegas and Schaible, 2004; Heinricher et al., 2009; Ossipov et al., 
2010). 
Nociceptive information is conveyed from the periphery to the spinal dorsal horn 
by primary afferents. At the spinal dorsal horn, afferent terminals release excitatory 
neurotransmitters (such as glutamate, substance P and calcitonin gene related 
peptide- CGRP) which interact with interneurons and projection neurons (Renn and 
Dorsey, 2005; Todd, 2010). Subsequently, the projection fibers ascend through the 
contralateral spinothalamic tract targeting the thalamus and sending collateral 
projections to several areas as periaqueductal grey matter (PAG) and 
rostroventromedial medulla (RVM) (Renn and Dorsey, 2005; Ossipov et al., 2010).  
Pain modulation involves complex neural supraspinal networks which are 
mainly activated by the thalamus. In fact, after targeted by spinal ascending 
projections, the thalamus communicates with cortical areas, as the somatosensory, 
pre-frontal, insular and cingulate cortices and subcortical areas, as the amygdala, 
triggering the activation of the descending pain pathways as well as pathways involved 
in the cognitive and emotional responses to pain (Millan, 2002; Heinricher et al., 2009; 
Ossipov et al., 2010). In fact, the amygdala projects to the cortex and sends feedback 
projections to the thalamus, which was shown to be involved in the integration of 
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cognitive, memory and emotional components of pain (Price, 2002; Neugebauer et al., 
2004; Ossipov et al., 2010). Moreover, descending pathways from the cortex, the 
amygdala and the hypothalamus, reach the PAG, which uses relay stations as the 
RVM and pontine noradrenergic cell groups (the A5, A6 and A7 groups), to indirectly 
modulate the nociceptive transmission at the spinal cord (Bajic and Proudfit, 1999; 
Millan et al., 2002; Vanegas and Schaible, 2004; Renn and Dorsey, 2005; Pertovaara, 
2006; Yoshimura and Furue, 2006; Heinricher et al., 2009; Ossipov et al., 2010).  
Descending projections from the RVM reach the spinal dorsal horn through the 
dorsal lateral funiculus and establish synaptic connections with primary afferent 
terminals, projection neurons and interneurons (Millan, 2002; Ossipov et al., 2010). 
Part of those descending fibers release serotonin, but a considerable proportion is 
glycinergic or GABAergic (Vanegas and Schaible, 2004; Ossipov et al., 2010). 
Although less studied, the glycinergic and GABAergic descending projections from the 
RVM were shown to induce antinociception (Kato et al., 2006). On the other hand, 
serotonin presents a bidirectional role, eliciting pain inhibition as well as facilitation, 
depending on the serotonin receptors at the spinal dorsal horn (Porreca et al., 2002; 
Drogul et al., 2009). Indeed, several studies reported inhibitory effects of serotonin by 
binding to 5-HT1 and 5-HT7 (Vanegas and Schaible, 2004; Lopez-Garcia, 2006; Drogul 
et al., 2009) receptors, while binding to 5-HT3 elicits neuronal excitation (Drogul et al., 
2009).  
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Figure 1 – Schematic representation of the pain pathways. Nociceptive information is 
brought from the periphery by primary afferents to the spinal dorsal horn. Then, 
nociceptive input ascends to the thalamus and sends collateral projections to the PAG, 
RVM and dorsal reticular nucleus (red lines). Interconnections between higher brain 
centers (thalamus, cortical areas and amygdala) trigger the descending modulation of 
pain. Descending pathways project to the PAG, which uses the RVM and pontine 
noradrenergic cell groups (such as A5, A6 and A7) as relay stations to modulate pain 
transmission at the spinal cord. The areas “i–iv” in the small diagram correspond to the 
levels of neuroaxis presented in the larger diagram. BLA - basolateral amygdala; CeA - 
central nucleus of the amygdala; DRt - dorsal reticular nucleus; LA - lateral amygdala; 
LC - Locus coeruleus; PAG - periaqueductal grey matter; RVM -  rostroventromedial 
medulla. Adapted from Ossipov et al., 2010.  
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Neurons located at the A5, A6 and A7 cell groups send descending projections, 
which terminate in the superficial dorsal horn and release noradrenaline (Pertovaara, 
2006; Yoshimura and Furue, 2006). Noradrenaline blocks pain transmission by 
inhibiting the activity of projection neurons and the release of excitatory 
neurotransmitters from primary afferents (Pertovaara, 2006; Yoshimura and Furue, 
2006; Ossipov et al., 2010). These inhibitory actions were shown to be mediated by 
binding of noradrenaline to α2 adrenoreceptors located at the terminals of primary 
afferents, excitatory interneurons and projection neurons (Pertovaara, 2006; Yoshimura 
and Furue, 2006; Ossipov et al., 2010). In addition, noradrenaline was shown to induce 
depolarization of spinal GABAergic and, probably, glycinergic interneurons by binding 
to pre-synaptic  α1 adrenoreceptors, enhancing the release of GABA and glycine, the 
major spinal inhibitory neurotransmitters (Pertovaara, 2006; Yoshimura and Furue, 
2006; Gassner et al., 2009; Ossipov et al., 2010). Therefore, the net effect of 
noradrenaline at spinal cord seems to be inhibitory. 
Dysfunctions on neurotransmitters-receptors systems at spinal cord 
compromise the final effect of descending pain modulation. Changes in the expression 
and activity of spinal serotoninergic and noradrenergic receptors impair the actions of 
serotonin and noradrenaline released by descending projections. Moreover, increased 
expression and binding affinity of glutamate, substance P or CGRP receptors at spinal 
dorsal horn enhance pain transmission, which can be potentiated by impairments in the 
expression and activity of GABA and glycine receptors (Kuner, 2010). Indeed, the 
inhibitory actions of GABA at spinal cord may be diminished by reduced expression or 
impaired activity of GABA receptors (Zeilhofer, 2008; Kuner, 2010; Gwak and 
Hulsebosh, 2011). GABA elicits inhibitory effects at the spinal dorsal horn by binding to 
GABAA and GABAB receptors (Malcangio and Bowery, 1996; Gwak and Hulsebosh, 
2011). The GABAA receptor is ionotropic and when activated induces the opening of 
chloride ion (Cl-) channels located at the membranes of excitatory interneurons and 
projection neurons (Malcangio and Bowery, 1996; Gwak and Hulsebosh, 2011). The 
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increase in the Cl- conductance in those neurons can induce hyperpolarization and 
depolarization, depending on the intracellular Cl- concentration (Payne et al, 2003; 
Coull et al., 2003; Price et al., 2009; Gwak and Hulsebosh, 2011). In the mature 
nervous systems, Cl- concentration is lower in the intracellular compartment than in the 
extracellular space. In such condition, GABA binding to GABAA induces influx of Cl-, 
which results in membrane hyperpolarization and neuronal inhibition. During the 
nervous system development and in some pathological conditions, Cl- accumulates at 
the intracellular compartment due to the low expression and activity of potassium-
chloride co-transporter 2 (KCC2) (Payne et al., 2003; Price et al., 2009). This co-
transporter is markedly expressed at spinal cord and is the responsible for setting low 
neuronal intracellular Cl- concentration (Payne et al., 2003; Coull et al., 2003). Reduced 
expression and activity of KCC2 were shown to induce increase intracellular Cl- 
concentration, which attribute an excitatory role to GABA when binding to GABAA 
receptors, since the activation of those receptors will induce Cl- efflux and, 
consequently, membrane depolarization (Coull et al., 2003; Wake et al, 2007). 
Therefore, a fine homeostasis of Cl- at spinal dorsal horn, achieved by a normal activity 
of KCC2, is mandatory for the inhibitory action of GABA. KCC2 impairment was shown 
to invert the GABA role, which can, ultimately, compromise the effects of descending 
pain modulation. Similar changes are likely to affect the glycinergic neurotransmission 
at the spinal cord, since the activity of glycine receptors also depends on Cl- equilibrium 
(Payne et al., 2003; Price et al., 2005; Zeilhofer, 2005). Moreover, reduced expression 
and activity of GABAB receptors have also an important impact on spinal pain 
transmission, mainly by reducing the inhibition of excitatory neurotransmitters release 
(Malcangio and Bowery, 1996; Enna and McCarson, 2006; Kuner, 2010).   
Recent studies have been shown that neurons are not the only players in pain 
transmission and modulation, with increasing evidences pointing for an important role 
of glia. Neuron-glia crosstalk was shown to be crucial for initiation and maintenance of 
chronic pain conditions at spinal and supraspinal levels (Zhao et al., 2007; Wei et al., 
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2008; Inoue and Tsuda, 2009; McMahon and Malcangio, 2009; Roberts et al., 2009; 
Ren and Dubner, 2010; Gosselin et al., 2010; O’Callaghan and Miller, 2010). In fact, 
spinal microglia was shown to be activated in neuropathic pain involving traumatic 
injuries of peripheral nerves, chemotherapy-induced neuropathies and in animal 
models of diabetic neuropathy (Zhang and De Koninck, 2006; Peters et al., 2007; 
Tsuda et al., 2008). Moreover, treatments with microglia inhibitors were shown to 
prevent and reverse the pain responses in animal models of neuropathic pain (Clark et 
al., 2007), reinforcing its role in pain processing. The events that lead to spinal 
microglia activation are not yet fully elucidated. It was demonstrated that microglia 
responds to the increased release of excitatory neurotransmitters (glutamate and 
substance P), neurotrophic factors (e.g. brain derived neurotrophic factor - BDNF), ATP 
and chemokines (e.g. CCL2 and fractalkine) that occur at the spinal cord of animal 
models of traumatic neuropathic pain (McMahon and Malcangio, 2009). Upon 
stimulation microglia was believed to activate the transcriptional activator nuclear factor 
kβ (NFkβ), which was shown to regulate the microglial production of pro-inflamatory 
cytokines (Rasley et al., 2002; McMahon and Malcangio, 2009). Furthermore, it was 
also observed increased phosphorilation of p38 mitogen activated protein kinase 
(MAPK), which was show to potentiate the synthesis and release of cytokines, to 
increase the transcription of  NFkβ and to augment the expression of interleukynes 1 
(IL-1) and 6 (IL-6) and of the cyclooxygenase 2 enzyme (COX 2). Consistent with the 
p38-mediated microglia effects on pain are the antiallodynic and antihyperalgesic 
effects of p38 MAPK inhibitors in animal models of neuropathic and inflammatory pain 
(Svensson et al., 2003; Ji and Suter, 2007; McMahon and Malcangio, 2009). 
Interistingly, some molecules that activate microglia were demonstrated to be also 
produced by microglia itself. In fact, ATP and BDNF were shown to activate microglial 
cells, but also to be released by them in neuropathic pain condition (Coull et al., 2003; 
2005). Those molecules were shown to interfere with neuronal and astrocytes 
activities, inducing the release of several mediators that affect the microglia 
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responsiveness (McMahon and Malcangio, 2009). It is now consensual that exists a 
continuous crosstalk between migroglia and neurons, which may concur to perpetuate 
the pain condition. Nevertheless, it remains to be ascertained which are the cells and 
molecules that trigger that crosstalk. It is important to mention that microglia activation 
was also observed at supraspinal areas involved in pain control in animal models of 
traumatic neuropathic pain and that the response states of those cells seem to vary 
among the different pain-related brain regions. In fact, microglia was shown to be 
activated in the RVM and thalamus during neuropathic pain (Wei et al., 2008; Zhao et 
al., 2007), while no changes were observed at the PAG or anterior cingulate cortex 
(Zhang et al., 2008). The contribution of microglia activation at the RVM and thalamus 
to pain responses were demonstrated by the prevention or reversal of pain behaviors in 
animals receiving local infusions of p38 MAPK inhibitors (Wei et al., 2008; Zhao et al., 
2007). The mechanisms that mediate the effects of supraspinal microglia activation on 
pain remain unknown. 
5.2. Pathogenesis of painful diabetic neuropathy 
 
Diabetes-induced hyperglycemia affects more dramatically the cells that present 
insulin-independent glucose uptake, such the endothelial and nerve cells. In these 
cells, the intracellular glucose concentrations rise in parallel with hyperglycemia, 
inducing a condition known as intracellular hyperglycemia. This phenomenon damages 
the cells and, consequently, the tissues using 6 major mechanisms: i) increased polyol 
pathway flux; ii) increased formation of advanced glycation end-products (AGEs); iii) 
increased expression and activation of AGEs receptors; iv) activation of protein kinase 
C (PKC); v) increased activity of hesoxamine pathways and vi) increased production of 
reactive oxygen species (ROS) by the mitochondria (Tesfaye, 2009; Obrosova 2009a; 
Giacco and Brownlee, 2010; Ziegler, 2010). 
The increased polyol pathway flux damage the cell by sorbitol-induced osmotic 
stress, reduction in Na/K+ - ATPase activity, increased NADH/NAD+ and decreased 
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NADPH. The decreased in NADPH seems to impair the antioxidant endogenous 
defense of the cell by diminishing the regeneration of reduced glutathione (Obrosova, 
2009a; Giacco and Brownlee, 2010). AGEs are formed by non-enzymatic reactions of 
glucose and AGE precursors (e.g. methylglyoxal and glyoxal) with cytosolic and 
extracellular proteins and lipids, altering their normal function. Furthermore, 
extracellular AGEs bind to their specific receptors (RAGE) presented in several cells 
and tissues, which induces ROS overproduction and activates the transcription of 
NFκB. NFκB transcription induces pathologic changes in gene expression, favouring 
pro-inflammatory conditions (Toth et al., 2007; Obrosova, 2009a; Giacco and 
Brownlee, 2010; Ziegler, 2010). Increased intracellular diacylglicerol, a result of 
increased glucose flux through the glycolytic pathway, along with the effects of RAGE-
AGEs interaction enhances PKC activity (Giacco and Brownlee, 2010), which was 
shown to potentiate the abovementioned impairments (Obrosova, 2009a; Ziegler, 
2010). Activation of the hexosamine pathway by hyperglycemia seems also to cause 
several changes in gene expression (e.g. increases in tumor growth factor α and β 1) 
and in protein function (Giacco and Brownlee, 2010). 
All the above mentioned metabolic effects seem to be triggered by a single 
common process: the mitochondrial overproduction of ROS (Figure 2).   
It is important to mention that n-6 essential fatty acids and prostaglandin 
metabolism is also impaired during diabetes, which was shown to alter nerve 
membrane structure and induce microvascular abnormalities (Obrosova, 2009a; 
Ziegler, 2010). Several other metabolic mechanisms were also shown to affect the 
peripheral nerves during diabetes, such as oxidative stress-independent overactivation 
of poly(ADP-ribose) polymerase (PARP), mitochondrial energy failure, activation of 
MAPKs, increased expression of COX-2 and 12/15-lipoxygenase, downregulation of 
superoxide dismutase activity, altered homeostasis and signaling of calcium (reviewed 
by Obrosova, 2009a). 
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 Figure 2 – Metabolic disarrangements induced by hyperglycemia. The unifying theory- 
overproduction of ROS by mitochondria triggers increased polyol pathway flux, AGEs 
formation, PKC activity and hexosamine pathway flux. From Giacco and Brownlee, 
(2010). 
 
Importantly, all these metabolic and molecular abnormalities seem to be 
interrelated and were shown to affect the vascular and the neuronal elements of the 
peripheral nervous systems during diabetes.  
The occurrence of these impairments at the CNS was less studied, with few 
reports showing spinal cord and brain affectation. Indeed, oxidative stress and cell 
death were shown to occur at the CNS of diabetic rats (Li et al., 2002), as well as 
increased PARP, PKC and p38 MAPK activities (Ramakrishnan et al., 2005; Honda et 
al., 2007; Lupachyck et al., 2011). Furthermore, AGEs-RAGE signaling seems also to 
be potentiated in CNS and contribute to its impairment (Toth et al., 2007). 
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It is important to mention that hyperglycemia was not considered the only culprit 
of diabetic neuropathy. Insulin, insulin-like growth factor I (IGF1) and C-peptide deficits 
were shown to elicit glycemia-independent neuroprotective effects (Ishii, 1995; Jianbo 
et al., 2002; Mohamed-Ali and Pinkney, 2002; Pierson et al., 2003; Brussee et al., 
2004; Sima et al., 2008; Kamiya et al., 2009) counteracting the consequences of 
hyperglycemia. This suggests that these factors also exert an important role in the 
etiology of diabetic neuropathy. The plasma levels of IGF1 are significantly reduced in 
patients with diabetic neuropathy (Migdalis et al., 1995; Guo et al., 1999; Busiguina et 
al., 2000; Jianbo et al., 2002). In nerve tissues of diabetic rats the levels of IGF1 are 
also reduced (Pierson et al., 2003; Sima, 2003). The lower expression and activity of 
IGF1 in type 1 animal models seem to contribute to the higher severity of neuropathic 
abnormalities in these animals when compared with animals with type 2 diabetes (Ishii 
and Lupien, 1995; Zhuang et al., 1996; Schmidt et al., 1999; Pierson et al., 2003; Sima, 
2006). Furthermore, IGF1 administrations, which do not alter the blood glucose 
concentrations, were shown to improve sensory deficits, nerve regeneration and 
autonomic neuropathy in diabetic rats (Ishii and Lupien, 1995; Zhuang et al., 1996; 
Schmidt et al., 1999; Russel and Feldman, 1999; Toth et al., 2006). IGF1 was also 
suggested to be involved in the neurodegenerative processes detected at the 
hippocampus of diabetic rats (Li et al., 2002; 2005). The abovementioned results 
suggest that the IGF1 deprivation may concur to diabetic neuropathy. The effects of 
IGF1 deficits on the spinal cord and brainstem areas involved in pain control were 
never evaluated. Taking into account that those regions present IGF1 receptors (Folli 
et al., 1994), IGF1-mediated effects are likely to occur, with possible repercussions on 
pain modulation mechanisms.  
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5.3. Structural, functional and neurochemical abnormalities at peripheral nervous 
system  
 
Diabetes affects unmyelinated (C) and thinly myelinated (Aδ) fibers as well as 
large myelinated fibers (A β) (Obrosova, 2009, 2009a; Ziegler, 2010). The pattern of 
affectation is length-related, with the longer fibers of the extremities being damaged 
first (“glove and stocking” affectation) and develops as a “dying-back” neuropathic 
process (Ziegler, 2010). Morphologically, the affected nerves show Wallerian 
degeneration accompanied by axonal atrophy, axonal loss and defective nerve 
regeneration (Sima, 2003). Loss of intraepidermal nerve fibers is common and is 
negatively correlated with pain manifestations (Ziegler, 2010; Loseth et al., 2010).  
Reduced peripheral nerve conduction velocities, affecting both motor and sensory 
nerves, were observed both in diabetic patients (Nakamura et al., 1992; Tesfaye, 2009, 
Obrosova, 2009; 2009a; Ziegler, 2010) and in animal models of diabetic neuropathy 
(Carsten et al., 1989; Calcutt, 2004; 2004a; Loseth et al., 2010). In addition, several 
molecular abnormalities were found in the peripheral nerves of animal models of 
diabetes. Increased expression and activity of sodium and calcium channels were 
observed in the peripheral nerves of diabetic rats (Hirade et al., 1999; Craner et al., 
2002; Hong et al., 2004; Umeda el al., 2010), which may be underlying the ectopic 
activity and hyperexcitability of C and Aδ fibers observed during diabetes (Burchiel et 
al., 1985; Alhgren et al., 1994; Khan et al., 2002; Chen and Levine, 2001; 2003). 
Neurotransmitter systems are also affected, with decreased expression of substance P, 
somatostatin, CGRP and vasoactive intestinal peptide detected at the peripheral 
nerves of diabetic rats, along with increased levels of neuropeptide Y, dynorphin and 
glutamate (Noda et al., 1990; Di Giulio et al., 1992; Diemel et al., 1992; 1994; 
Rittenhouse et al., 1996; Jolivalt et al., 2006). The expression and binding affinity of α1 
adrenoreceptors were shown to be augmented in the dorsal root ganglia (DRGs) of 
diabetic rats (Lee et al., 2000; Teasell and Arnold, 2004). Similar increases were 
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detected in the expression of κ-opioid receptors at peripheral nerves (Jolivalt et al., 
2006). Meanwhile, the expression of transient receptor vanniloid type 1 is decreased in 
skin nerve fibers (Facer et al., 2007). The contribution of these changes to PDN and 
the mechanisms of action remain unclear. Furthermore, a loss of neurotrophism was 
observed during PDN, with peripheral depletion of neurotrophic factors as the nerve 
growth factor, neurotrophin-3 and IGF1 (Calcutt, 2002; Sima, 2003; Calcutt and 
Backonja, 2007; Ziegler, 2010), which may explain the impaired capacity of nerve 
regeneration and the degeneration of peripheral nerves during diabetes (Ishii and 
Lupien, 1995; Calcutt, 2002; Sima, 2003; Calcutt and Backonja, 2007). Neurotrophism 
impairment seems also to contribute to the altered neurotransmitters expression (Sima, 
2003). As a consequence of glycation and hyperphosphorilation of proteins from the 
cytoskeleton, axonal transport at peripheral nerves was shown to be reduced (Fink et 
al., 1987; Macione et a., 1989; Fernyhoug et al., 1999), which point for a less efficient 
communication and molecular transport (as neurotransmitters, receptors and 
neurotrophic factors) between axonal terminals and neuronal soma and, consequently, 
to inadequate responses to peripheral stimuli (Laduron and Janssen, 1986). 
The large majority of functional and neurochemical changes summarized above 
were shown to be prevented or reverted by normoglycemia and by approaches that 
inhibit the metabolic effects of hyperglycemia (Sima, 2003; Calcutt and Backonja, 2007; 
Obrosova, 2009a; Ziegler, 2010). Recently, more attention has been directed to the 
glycemia-independent role of insulin, C-peptide and IGF1 (Ishii, 1995; Sima, 2003). 
Treatments with those agents were shown to reverse, prevent or ameliorate the 
peripheral nerve functional abnormalities as well as PDN symptoms (Ishii and Lupien, 
1995; Ishii, 1995; Zhuang et al., 1996; Schmidt et al., 1999; Russel and Feldman, 
1999; Mohamed-Ali and Pinkney, 2002; Jianbo et al., 2002; Toth et al., 2003; Pierson 
et al., 2003; Brussee et al., 2004; Sima et al., 2008; Kamiya et al., 2009).  
The changes affecting the peripheral nerves during diabetes are due to direct 
effects on nerve components (neurons and Schwann cells), but are also potentiated by 
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the impaired blood flow observed at the vasa nervorum, which results from endothelial 
dysfunction (Obrosova 2009a; Ziegler, 2010). Vascular dysfunction of vasa nervorum 
was shown to induce hypoxia in peripheral nerves, contributing substantially to 
increase the oxidative stress burden (Tesfaye and Kempler, 2005; Calcutt and 
Backonja, 2007; Obrosova, 2009a; Tesfaye, 2009; Ziegler, 2010).  
 
5.4. Impairments at central pain control system 
 
Besides the effects on peripheral nervous system, PDN was also shown to be 
associated with impairments at central areas involved in pain transmission, namely the 
spinal cord (Eaton et al., 2001; Pertovaara et al., 2001; Chen and Pan, 2002; 
Selvarajah et al., 2006; Malmberg et al., 2006) and the thalamus (Selvarajah et al., 
2008; Cauda et al., 2009; Fischer et al., 2009, Fischer and Waxman, 2010; Li et al., 
2010; Selvarajah et al., 2011).  
The spinal cord was shown to be affected during PDN in animal models of 
diabetes as well as in humans, showing structural and functional impairments (Carsten 
et al., 1989; Kamei et al., 1990; 1991; Field et al., 1998; Bitar et al., 1999; 2000; Li et 
al., 1999; Suzuki et al., 2000; Gallego et al., 2003; Chen and Pan, 2003; Malmberg et 
al., 2006, Tomiyama et al., 2006; Mizisin et al., 2007; Wang et al., 2007; 2010). 
Neurochemical changes at the CNS have been studied in animal models of diabetes. 
As in the periphery, spinal cord also presents increased expression or/and activity of 
voltage-dependent calcium and sodium channels (Voytenko et al., 2000; Luo et al., 
2002; Craner et al., 2002), which probably concur for the spontaneous hyperactivity 
and hyperexcitability of spinal nociceptive neurons (Pertovaara et al., 2001; Chen and 
Pan, 2002) and support the analgesic effects of anticonvulsants during PDN (Marais et 
al., 2001; Jensen, 2002; Moore et al., 2002). Furthermore, changes in spinal excitatory 
mechanism were demonstrated (Kamei et al., 1990; Field et al., 1998; Li et al, 1999; 
Tomiyama et al., 2006). Despite the decreased spinal glutamate content and release 
(Malmberg et al., 2006), increased spinal glutamatergic neurotransmission was shown 
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to occur, probably mediated by increased expression and activation of glutamate 
receptors (Li et al, 1999; Tomiyama et al., 2006; Li et al., 2010; Daulhac et al., 2011). 
Moreover, pronociceptive actions of substance P are also augmented by increased 
expression of neurokinin 1 receptors (Kamei et al., 1990; 1991; Field et al., 1998). On 
the other hand, spinal inhibitory mechanisms seem to be reduced namely due to 
decreased expression and/or activity of GABAB (Wang et al., 2007; 2011) and µ-opoid 
receptors (Chen et al., 2002), along with impaired spinal release of endogenous 
opioids (Williams et al., 2008).  
More recently, spinal glia was shown to play a role in PDN. Increased activation  
of spinal microglia was observed in diabetic rats during PDN (Daulhac et al., 2006; 
Tsuda et al., 2008; Wodarski et al., 2009) and was shown to increase the production of 
pro-inflammatory mediators (Talbot et al., 2010) and to contribute to pain (Daulhac et 
al., 2006; Tsuda et al., 2008; Daulhac et al., 2011). The effects of spinal microglia 
activation during PDN were not yet fully elucidated and its mechanisms of action are 
almost unknown. Considering that the effects and mediators of microglia activation 
seem to depend on pain condition (McMahon and Malcangio, 2009), the study of 
microglia contribution to the neuropathic pain condition associated to diabetic 
neuropathy should be considered.  
More recently, studies using magnetic ressonance spectroscopy in humans and 
electrophysiological recordings in animals detected thalamic functional impairments 
(Selvarajah et al., 2008; Fischer et al., 2009) during PDN, demonstrating the 
involvement of supraspinal pain-related areas. As reviewed above (item 5.1. “The pain 
mechanisms”), pain control involves several other brain areas, namely brainstem 
regions, which remain to be addressed during PDN.  
 
Despite the high availability of drugs, the treatment of PDN remains a challenge 
for the clinicians, mainly due to the low efficacy of those agents and constraints 
associated with their contra-indications and side-effects. In the future, it will be 
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important to develop pharmacological agents based on the specific pathogenetic 
mechanisms occurring at the pain control system during PDN.  
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6. Objectives and study outline 
Considering the poor knowlege of the central effects of diabetes and their contribution 
to PDN, it is necessary to perform a detailed study of the central pain control system 
during diabetes, in order to develop mechanistic-related pharmacological approaches 
to manage this distressing condition. In the present work, we used STZ rats to study 
the functional and neurochemical changes occurring at the spinal dorsal horn and at 
brainstem areas devoted to descending pain modulation. 
This dissertation includes 6 publications, which are presented according the rationale 
of the overall study. 
In the first study, we evaluated the spontaneous, noxious and innocuous-induced 
activity of the spinal cord neurons in STZ rats with behavioural signs of PDN. We used 
the expression of Fos protein, which is usually synthesized by spinal dorsal horn 
neurons upon peripheral nociceptive stimulation (Coggeshal, 2005), to assess the 
activation pattern of spinal nociceptive neurons.  
In the second study, we aimed to evaluate the role of GABA-mediated pain modulation 
at spinal dorsal horn. We quantified the expression of GABA and its synthesizing 
enzyme (glutamic acid decarboxilase, GAD) at the spinal dorsal horn of STZ rats with 
PDN. We also assessed the expression of the potassium-chloride co-transporter 2 
(KCC2) in order to infer about its contribution for GABA role in this chronic pain 
condition.  
Based on the findings from the previous studies, we developed additional experiments 
aiming the study of possible mechanisms implicated in KCC2 impairment during PDN. 
We focused our study in the role of microglia activation (publication 3) and oxidative 
stress (publication 4). We evaluated the activation of spinal microglia and the levels of 
oxidative stress in the spinal dorsal horn of STZ rats and the effects of their reversal on 
KCC2 expression, neuronal activity and nociception. 
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The study of descending pain modulatory circuits during PDN was a core aim of the 
present work. The publication 5 included a time-course evaluation of spontaneous 
neuronal activity at the PAG and the effects of gabapentin on the activity of neurons 
from spinal dorsal horn and PAG. We further evaluated the changes occurring in the 
serotoninergic and noradrenergic pathways acting as relay stations of PAG descending 
modulation (publication 6) and quantified the serotonin and noradrenaline content at 
spinal cord. Then, we focused our study in the most important brainstem areas that 
receive inputs from PAG and modulate spinal neurotransmission by sending direct 
descending projections to spinal dorsal horn, as the rostroventromedial medulla (RVM) 
and the A5 and A7 noradrenergic cell groups, taking into account the features of the 
noradrenergic innervation of the spinal cord in the rat strain used in the present study 
(Tavares et al, 1997). In the RVM, we assessed the neuronal expression of tryptophan-
hydroxylase (TpH), the rate limiting enzyme in serotonin synthesis, in order to identify 
the serotoninergic neurons. We also evaluated this activity by combining TpH 
expression with the expression of extracellular signal-regulated kinases (ERKs) 
phosphorilated form. The noradrenergic neurons of the A5 and A7 cell groups were 
identified by immunodectection of tyrosine hydroxylase (TH), an enzyme involved in 
noradrenaline synthesis. The activity of those neurons was quantified by double 
immunofluorescence for TH and the phosphorilated form of cAMP element-binding 
protein (CREB), which is suitable for the evaluation of neuronal activity.  
Another aim of the present study was to evaluate other contributing factors for PDN, 
rather than the well-known hyperglycemia. Therefore, in the sixth study we evaluated 
the glycemia-independent role of IGF1 in the functional and neurochemical 
impairments detected in the previous studies.  
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Abstract
Background Pain during diabetic neuropathy is associated with peripheral
nerve damage but recent evidences suggest the occurrence of central effects.
We used the activation of the c-fos protooncogene to study the activity of
spinal dorsal horn neurons in streptozotocin (STZ)-induced diabetic rats in
the absence of stimulation or in response to innocuous or noxious stimuli.
Methods Four weeks after saline or STZ (50 mg/kg) injection, rats were
anaesthetized and either not further manipulated or submitted to innocuous
(gentle touch), noxious mechanical (pinching) or noxious thermal (radiant
heat) stimulation of the hindlimb skin. In each experimental situation, the
numbers of Fos-immunoreactive (Fos-IR) neurons occurring in the superficial
(laminae I–II) or deep (laminae III–V) dorsal horn were compared.
Results In the absence of stimulation, STZ-injected rats presented
significantly higher numbers of Fos-IR neurons than controls, both in the
superficial and deep dorsal horn (DDH). In comparison with the respective
baseline levels, innocuous stimulation did not induce a significant increase in
the numbers of Fos-IR neurons in controls or STZ-rats. Noxious mechanical
and noxious thermal stimuli increased the numbers of Fos-IR neurons, both
in control and STZ-rats, but in a more pronounced manner when diabetic rats
were subjected to noxious mechanical stimulation.
Conclusions The present study demonstrates that the responses of spinal
cord neurons are strongly affected during diabetes. The higher baseline
neuronal activity probably underlies the spontaneous pain detected during
diabetes since the spinal dorsal horn is the major relay station in the ascending
transmission of nociceptive input to the brain. Copyright  2007 John Wiley
& Sons, Ltd.
Keywords diabetes; pain; spinal impairment; mechanical hyperalgesia; thermal
responses; spontaneous pain
Introduction
Pain is an important complication of diabetes and can occur spontaneously or
results from innocuous (allodynia) or noxious (hyperalgesia) stimuli [1–4].
The study of the mechanisms of painful diabetic neuropathy has been mainly
focused at the peripheral nervous system, whereas the central effects of the
disease need to be more deeply addressed [1,5]. Several studies suggested
that the spinal dorsal horn, the first relay station of the nociceptive pathway,
is affected by diabetes. Diabetic patients with distal symmetrical neuropathy
present decreases in the spinal cord area [6]. Electrophysiological recordings
Copyright  2007 John Wiley & Sons, Ltd.
51
C-fos Expression at the Spinal Dorsal Horn 645
in diabetic rats demonstrated higher activity of spinal
dorsal horn neurons both spontaneously or in response to
innocuous or noxious stimulation [7,8]. Neurochemical
changes were also reported at the spinal dorsal horn in
animal models of diabetes, affecting the SP/NK1 system
and the expression of NMDA receptors [9–12].
C-fos expression has been used as an anatomical
marker for neuronal activation by nociceptive-related
stimuli at the spinal dorsal horn level [13,14]. Since
these initial demonstrations of c-fos expression in the
nucleus of neurons at the spinal dorsal horn, multiple
studies have consistently demonstrated that most of the
stimuli used to induce c-fos expression at the dorsal horn
are noxious [15]. Innocuous stimulation can occasionally
result in dorsal horn c-fos expression mainly in chronic
pain conditions and due to central sensitization [16].
The study of c-fos expression allows the evaluation of
the nociceptive activation of large numbers of spinal
neurons and the determination of the pattern of neuronal
activation, according to the stimulus nature and the
laminae of location of c-fos-expressing neurons [15].
Studies with neuropathic pain models due to traumatic
nerve injury reported a significant increase in the numbers
of Fos-immunoreactive (Fos-IR) neurons in the spinal
dorsal horn even in the absence of additional stimulation
[17–19] and following the application of innocuous
stimuli [20–25]. This demonstrates that the installation
of chronic neuropathic pain is associated with plastic
changes at the spinal dorsal horn, which need to be
studied during diabetes, since this is associated with
an important non-traumatic neuropathic condition. C-fos
expression has been used to evaluate neuronal activity
in the brain of streptozotocin (STZ)-induced diabetic
animals. These studies demonstrated that c-fos expression
increases in some brain regions [26,27] and decreases in
others [27–29], showing that c-fos expression is not a
direct result of STZ or a general reaction to the stress
of malnutrition and dehydration during STZ-induced
diabetes, but rather to the diabetic condition per se.
During diabetes, the distinct pain modalities are
differentially affected. The thresholds to mechanical
stimulation are considerably decreased both in patients
and animal models [30–32]. Reports of thermal responses
in diabetic animals are quite variable and include
hypoalgesia [7,31–33], unaltered responses [34], and
hyperalgesia [35, 36]. One possibility to explain this
variability is the lack of correction of thermal responses
to baseline skin temperatures in diabetic rats. In fact,
changes in skin temperatures were shown to affect the
behavioural responses to thermal stimuli and hypothermia
due to blood flow impairment, which is a feature of
diabetes [37–41].
In the present study, we evaluated the responses
of spinal dorsal horn neurons of STZ-injected animals
in baseline conditions and after innocuous, noxious
mechanical or noxious thermal stimuli. In order to
characterize the behavioural responses of diabetic animals
according to the stimulus modality and to confirm
the presence of behavioural signs of neuropathy, we
also studied the mechanical and thermal responses
using respectively the Randall–Selitto and the tail-flick
behavioural tests. Furthermore, we evaluated the effects
of the decreased basal skin temperature of diabetic rats
in behavioural thermal evaluations by correcting these
responses to the baseline skin temperatures.
Materials and methods
Male Wistar rats (Charles River; Barcelona, Spain),
weighing 250–350 g at the beginning of the experiments,
were used. Animals were housed two per cage, in a room
with a constant temperature (22 ± 2 ◦C) and humidity
(55 ± 5%) and with a 12-h light/dark cycle, and received
food and water ad libitum. Experiments were performed
in accordance with the ethical guidelines for the study
of pain in conscious animals [42] and the European
Community Council Directive 86/609/EEC.
Induction of diabetes
Diabetes was induced as described previously [43].
Briefly, the animals received an intraperitoneal (i.p.)
injection of STZ (50 mg/kg body weight; Sigma-aldrich,
St Louis, USA) diluted in 0.9% saline, and were further
provided with 10% sucrose in the drinking solution
to prevent hypoglycaemia. Control rats were injected
with equal volume of saline. Three days after the
injection, glucose concentration was measured in blood
samples collected from the tail vein using Accu Chek
Sensor Comfort (Roche Diagnostics, Germany). Only rats
with glucose concentration higher than 300 mg/dL were
considered diabetic and were included in the STZ-injected
group.
Behavioural assessment of
nociception
A total of 12 animals (6 controls and 6 diabetic patients)
were subjected to a time-course behavioural evaluation
of mechanical and thermal nociception, at the day prior
to STZ or saline injection and at 1, 2, 3, and 4 weeks
post-injection. During the 8 days prior to the onset of
behavioural evaluation, the animals were daily handled
by the experimenter for habituation purposes.
Mechanical nociception was assessed using the Ran-
dall–Selitto test (Ugo Basile; Comerio VA, Italy). Ascend-
ing mechanical forces were applied to the right hindpaw
and the mechanical force (in grams) that induces hind-
paw withdrawal was recorded. The mechanical threshold
of each animal was the average of three consecutive mea-
surements, taken at 5-min intervals. Thermal nociception
was assessed by recording the tail-flick latency using a
tail-flick test apparatus with temperature set for 52 ◦C
(Ugo Basile; Comerio VA, Italy). The response latency for
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each animal was the average of three consecutive mea-
surements, taken at 5-min intervals. The cut-off latency
in the tail-flick test was settled to 24 s in order to avoid
tissue damage. On the basis of previous observations
that the skin temperature affects the outcome of tail-flick
studies [37–41], we recorded the tail skin temperature
of each animal just before thermal behavioural evalua-
tion using a thermoprobe attached to the tail (Sensortek,
USA; Greisinger Electronic, Germany). Tail-flick response
latency data were adjusted for the tail temperatures, as
described previously [37].
The results of the behavioural experiments were
statistically analysed using one-way analysis of variance
(ANOVA), followed by Tukey post-hoc test for multiple
comparisons. Unpaired sample t-test was used to compare
behavioural data between saline and STZ-injected rats.
C-fos evaluation
One day after the final behavioural assessment (4 weeks
after STZ or saline injection), the animals were
anaesthetized with an i.p. injection of 35% chloral hydrate
(1mL/kg body weight). Five saline and five STZ-injected
rats were not subjected to further manipulation and
were used to establish the baseline Fos levels. The
remaining rats (n = 5 per group and per stimulus)
were submitted to innocuous, noxious mechanical
or noxious thermal stimuli of the hindlimb skin
at the internal aspect of the left thigh, according
to previously published protocols [44–46]. Briefly,
innocuous mechanical stimulation consisted of gentle
touch applied manually with the experimenter’s thumb to
the hindlimb skin for 15 s, as described previously [20].
Noxious mechanical stimulation consisted of pinching the
left hindlimb skin for 1–3 s with a rat-tooth forceps.
Noxious thermal stimulation was performed using a
radiant heat source (HLTC-200T, npi electronic GmbH) in
pulses of 30 s, at 65 ± 2 ◦C [44–46]. The temperature was
controlled by the thermoprobe, described in the preceding
text, placed at the skin surface. All the stimuli were
applied every 2 min during 2 h. Reinforcement of the
anaesthesia during the stimulation period was done by an
additional injection of 35% chloral hydrate (0.5 mL/kg
body weight).
At the end of the stimulation period, the animals
were transcardially perfused with 200 mL of phosphate-
buffered saline (PBS), followed by 1000 mL of 4%
paraformaldehyde in 0.1 M phosphate buffer (PB), pH
7.4. Spinal cord segments T13-L3 were removed, post-
fixed for 4 h in the same fixative, and cryoprotected
overnight in 30% sucrose in PB. Coronal sections,
40 µm thick, were obtained using a freezing microtome,
and every fourth section was collected in 0.1 M PBS.
Fos protein was immunohistochemically detected using
the avidin–biotin–peroxidase method, as described
previously [46]. Briefly, the sections were treated with 1%
hydrogen peroxidase for 10 min to inhibit endogenous
peroxidase activity followed by incubation for 2 h in a
blocking solution of 10% normal swine serum in 0.3%
Triton X 25% in PBS (PBST) with 0.1 M glycine. The
sections were then incubated overnight at 4 ◦C in the
rabbit anti-Fos antiserum (Ab5; Oncogene), diluted at
1 : 10 000 in PBST. After being washed in PBST, the
sections were incubated in biotinylated swine anti-rabbit
immunoglobulin (DakoCytomation, Denmark), diluted
at 1 : 200, for 1 h, at room temperature. They were
then washed in PBST, incubated in the avidin–biotin
complex (Vectastain, Vector Laboratories, USA) for 1 h,
and stained with diaminobenzidine (DAB; 10 mg DAB
in 20 mL of tris-HCL 0.05 M, pH 7.6 solution with 5 µL
of 30% hydrogen peroxide). Finally, the sections were
washed in PBS and mounted on gelatine-coated slides, air
dried and coverslipped.
In animals not subjected to further stimulation,
the baseline Fos levels were determined by counting
the numbers of Fos-IR neurons occurring bilaterally in
the dorsal horn of 40 sections randomly taken from
segments T13 –L3 (10 sections from each segment),
with the aid of a camera lucida. Fos-IR neurons were
positioned in two dorsal horn regions: the superficial
dorsal horn (SDH), encompassing laminae I–II and the
deep dorsal horn (DDH), including laminae III–V [47].
According to several previous studies, Fos-IR neurons
were counted when the immunoreaction for the Fos
protein was expressed at the nucleus, independently of
the staining intensity [15,44–46]. Independent sample
t-test was used to compare the mean numbers of baseline
Fos-IR neurons between non-stimulated saline and STZ-
injected rats. In stimulated animals, the same analysis was
performed but counting was performed in the ipsilateral
dorsal horn using 20 sections from L1 –L2 segments (10
sections from each segment). Counting was limited to
these segments since previous studies using the same
stimulation protocol [44,45] showed that they exhibit the
higher Fos expression. Mean numbers of Fos-IR neurons
expressed after innocuous and noxious stimulation in
control and STZ-injected groups were compared by
one-way analysis of variance (ANOVA), followed by
Figure 1. Time-course changes of mechanical response thresh-
olds in control and diabetic rats. Diabetic animals exhibit
mechanical hyperalgesia from 2 weeks after STZ injection
until the end of the experiments. Significance of sym-
bols: ∗ – comparisons of STZ-injected animals with controls;
# – comparisons with initial threshold values. One symbol:
p < 0.05; two symbols: p < 0.01
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Figure 2. Time-course changes of thermal response thresholds in control and diabetic rats (tail-flick test temperature 52 ◦C). Panel
A depicts changes in tail temperatures during the 4 weeks of the experiments. Panels B and C show thermal response latencies
before (B) and after (C) adjustment to the baseline tail temperature. As soon as after 1 week after STZ injection, diabetic animals are
slightly hypothermic (A) but this did not affect the thermal hypoalgesia exhibited by these animals (B–C). Significance of symbols:
∗ – comparisons of STZ-injected animals with controls; # – comparisons with initial threshold values. One symbol: p < 0.05; two
symbols: p < 0.01
Tukey post-hoc test for multiple comparisons. Results are
expressed as mean ± standard error of the mean (SEM).
Results
Three days after STZ injection, the animals devel-
oped hyperglycaemia (blood glucose concentration
>300 mg/dL) and remained hyperglycaemic during
the course of the study. At 4 weeks post-injection,
STZ-injected rats presented blood glucose concentra-
tions higher than saline-injected rats (STZ-injected
group: 484.1 ± 32.21 mg/dL; saline group: 136.9 ±
18.71 mg/dL) and body weights lower than their age-
matched controls (STZ-injected group: 285 ± 13.4 g;
saline group: 420 ± 5.6 g), which agrees with previous
studies using this animal model [31,35,36,43]. STZ-
injected animals presented the typical symptoms of dia-
betes, as previously described in reports of the model
[31,35,36,43], but otherwise appeared normal.
Behavioural results
Before saline or STZ injections, no significant differences
in baseline mechanical or thermal nociceptive responses
were detected (Figures 1, 2).
Mechanical responses
The mechanical threshold of STZ-injected animals
gradually decreased during the 4 weeks of study
(Figure 1). Significant decreases in mechanical thresholds
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were detected from 2 weeks after STZ injection, with
marked hyperalgesic responses at 4 weeks (about 31%
change over initial values).
Thermal responses
The baseline tail temperatures of STZ-injected animals
significantly decreased as soon as 1 week after STZ
injection (Figure 2(a)) and remained lower during the
4 weeks of study. Contrarily, the thermal response
thresholds in the tail-flick test of STZ-injected animals
increased significantly 1 week after STZ injection and
remained higher during the 4 weeks of the study. This was
verified both before (Figure 2(b)) and after (Figure 2(c))
correcting the thermal response latencies to the tail
temperature.
Fos study
Baseline Fos expression
In non-stimulated control rats, only a few Fos-IR neurons
were detected in the spinal dorsal horn. Compared to
the controls, non-stimulated STZ-injected rats presented
more Fos-IR neurons, located bilaterally (Figure 3(b)). In
STZ-injected rats, the numbers of Fos-IR neurons in the
dorsal horn of spinal segments T13–L3 were higher than
the respective values of the control group, mainly in the
SDH (Figure 3(c)), but also in the DDH (Figure 3(d)).
Innocuous and noxious-evoked Fos
expression
Innocuous mechanical stimulation
Innocuous mechanical stimulation did not induce a
significant increase in the numbers of Fos-IR neurons
in the dorsal horn of control and STZ-injected animals
(Figures 4(a), (b), 5(a) and (b)). Although STZ-injected
rats presented significantly higher numbers of Fos-IR
neurons in the SDH than controls after innocuous
stimulation, this was due to the higher baseline Fos
expression observed in the former experimental group and
not due to the effects of innocuous stimulation, since the
numbers of Fos-IR neurons after innocuous stimulation
were similar to those obtained in non-stimulated STZ-
injected rats (Figure 5(a)).
Noxious mechanical stimulation
The numbers of Fos-IR neurons in the SDH and DDH
of control and STZ-injected animals subjected to noxious
mechanical stimulation (Figure 4(c), (d)) were higher
than the values obtained in the respective experimental
groups of non-stimulated animals (Figure 5(c), (d)). The
increase in the numbers of Fos-IR neurons was more
pronounced in the SDH of STZ-injected animals, and
these animals presented significantly higher numbers of
Fos-IR neurons at the SDH than controls.
Figure 3. Baseline Fos expression at 4 weeks post-injection.
The photomicrographs were taken at the L2 spinal segment
of a control (A) and an STZ-injected animal (B). Panels C–D
show the mean numbers of Fos-IR neurons (±SEM) counted
bilaterally in laminae I–II (C) or III–V (D). Even in the absence
of stimulation, diabetic animals presented significantly higher
levels of Fos (arrows) than controls in all the analysed spinal
segments. ∗ – p < 0.05; ∗∗ – p < 0.01. Scale bar in: 100 µm
Noxious thermal stimulation
The numbers of Fos-IR neurons in the SDH of control
and STZ-injected animals subjected to noxious thermal
stimulation (Figure 4(e), (f)) were significantly higher
than the values obtained in the respective experimental
groups not subjected to stimulation (Figure 5(e), (f)),
which did not occur at the DDH (Figure 5(f)). No
differences were detected in thermal noxious–evoked
Fos expression between control and STZ-injected rats
(Figure 5(e), (f)).
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Figure 4. Fos expression at the L2 spinal segment evoked by innocuous (A, B), noxious mechanical (C, D) and noxious thermal
(E, F) stimulation of control (A, C, E) and STZ-injected (B, D, F) animals, at 4 weeks post-injection. Significance of lettering:
Innocuous Stim. – animals submitted to innocuous mechanical stimulation; Mechanical Stim. – animals submitted to noxious
mechanical stimulation; Thermal Stim. – animals submitted to noxious thermal stimulation. Scale bar: 100 µm
Discussion
Using the activation of the c-fos protooncogene to monitor
nociceptive activation of spinal dorsal horn neurons,
the present study is the first to demonstrate spinal
cord impairments during diabetes. The high activity at
the dorsal horn of diabetic animals in the absence of
stimulation is a major finding of the present study and
probably accounts for the spontaneous pain detected
in diabetes [2–4]. This increased spinal activity agrees
with previous electrophysiological recordings in the same
animal model [7,8]. However, due to the specific features
of electrophysiological studies, it was neither possible to
study large neuronal populations nor correlate neuronal
responses with their location at the dorsal horn, an
important issue due to the specific laminar organization
of the spinal cord [48]. The present data show that
both the superficial and the DDH are affected during
diabetes. This generalized effect of diabetes at the dorsal
horn probably affects nociceptive transmission to the
brain, since both the superficial and DDH participate
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Figure 5. Effects of innocuous (A, B), noxious mechanical (C, D) and noxious thermal (E, F) stimulation in Fos expression at
the L1–L2 spinal segments, at 4 weeks post-injection. The graphs show the mean numbers of Fos-IR neurons (±SEM) counted
at the ipsilateral laminae I–II (A, C, E) or III–V (B, D, F). Innocuous stimulation did not increase the baseline levels of Fos in
control or STZ-injected animals. The effects of noxious mechanical stimulation in increasing Fos expression were more pronounced
than those of noxious thermal stimulation. Significance of symbols and lettering: No Stim. – non-stimulated animals; Innocuous
Stim. – animals submitted to innocuous mechanical stimulation; Mechanical Stim. – animals submitted to noxious mechanical
stimulation; Thermal Stim. – animals submitted to noxious thermal stimulation; ∗ – comparisons of STZ-injected animals with
controls; # – comparisons with baseline values. One symbol: p < 0.05; two symbols: p < 0.01
in the main spinofugal pathways [49,50]. Neurons with
increased baseline responses during diabetes were, in
fact, shown to belong to the spinothalamic tract [8]. The
mechanisms underlying the increased baseline activity of
spinal neurons probably relate to the constant barrage of
peripheral input since peripheral fibres of diabetic rats
show ectopic activity [51]. It may also reflect plastic
changes at the spinal cord and, more interestingly, of
brainstem centres devoted to descending pain modulation
[52–54].
The high baseline activity during diabetes agrees
with previous reports in traumatic neuropathic models
[15]. However, diabetes appears to induce specific
effects in spinal cord neurons in what concerns the
responses to innocuous stimulation. In several traumatic
neuropathic models, innocuous stimuli induce c-fos
expression [15,20,23–25], whereas in our diabetic rats
the innocuous mechanical stimulus failed to increase c-fos
expression in relation to baseline levels, in spite of the long
duration of stimulus delivery. Since mechanical allodynia
is a feature of diabetic neuropathy [7,8,32], it is likely that
the high baseline Fos levels in diabetic animals uncovered
any innocuous-evoked increases in c-fos expression
induced by innocuous mechanical stimulation.
Noxious mechanical stimulation significantly increased
the numbers of Fos-IR neurons relative to non-stimulated
diabetic rats, both at the SDH and DDH. This stimulus also
increased c-fos expression in relation to control animals
subjected to the same stimulation protocol. The effects
of thermal noxious stimulation in c-fos expression at the
dorsal horn were only seen at the SDH, both in control
and STZ groups, with no significant differences between
them. The higher effects of noxious stimulation in the
superficial dorsal horn, which mimic the pattern of c-fos
expression in normal conditions, appear to be a specific
feature of this chronic pain model since, in inflammatory
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pain and some neuropathic traumatic conditions, an
important contingent of activated neurons are located
at DDH laminae [15].
Several studies showed a positive correlation between
the magnitude of behavioural pain responses and spinal
c-fos expression evoked by those behavioural tests
[55–57]. It would be interesting to search for similar
correlations in our diabetic animals which were not done
in the present study due to the fact that the tests used in
behavioural assessment do not induce c-fos expression
[13,46]. Incidentally, since the results of mechanical
hyperalgesia match the noxious mechanical–evoked
increases in c-fos expression, the thermal hypoalgesia is
hard to conciliate with thermal-evoked increases in c-fos
expression [7,31–33]. On the basis of reports showing
that it is necessary to correct the thermal latency responses
to the tail temperature [37–41], it was proposed that the
decreased skin temperature of diabetic rats could account
for the thermal hypoalgesia of diabetic animals [7]. By
showing that, even after adjusting the thermal response
latencies to the decreased baseline tail temperature,
diabetic animals exhibited thermal hypoalgesia, we
demonstrate that thermal hypoalgesia should be due to
factors other than hypothermia. Since c-fos is expressed
in neurochemically heterogeneous spinal neurons, most
of which contain inhibitory neurotransmitters [58] or
are under strong inhibitory actions [46], it is possible
that thermal stimulation activates spinal c-fos expression
mainly in inhibitory spinal neurons.
In conclusion, the present study demonstrates that
the baseline activity of spinal dorsal horn neurons is
strongly increased 4 weeks after induction of diabetes.
In addition to the structural changes at the spinal cord
of diabetic patients [6], the present and previous [7,8]
functional evaluations demonstrate that neuronal activity
at the spinal cord is strongly affected during diabetes. The
present results are putatively relevant to the treatment
of pain during diabetes, suggesting the importance of
pharmacological approaches directed to the spinal dorsal
horn and prevention of possible supraspinal alterations
induced by the spinal functional impairment.
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Painful diabetic neuropathy is a frequent complication of diabetes.
It is characterized by spontaneous pain and increased sensitiv-
ity to mechanical and chemical stimuli [11,29,31]. It has been
proposed that hyperexcitability and spontaneous hyperactivity of
primaryafferents [1,6,7,13] andspinal dorsal hornneurons [5,24,27]
detected in streptozotocin (STZ)-induced diabetes, might account
for those signs of diabetic neuropathy. The neurobiological mech-
anisms associated with the spinal hyperactivity remain, however,
unclear. Glutamate seems to be involved since an increase in bind-
ingafﬁnityanddensityofNMDAandAMPAreceptorsweredetected
in the spinal cord of diabetic rats [15,33], in spite of the decrease
in glutamate levels [19]. A higher glutamatergic excitation is also
supportedbypharmacologic studies showing thathyperalgesia and
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63associated to hyperexcitability and spontaneous hyperactivity of spinal
athophysiological mechanisms are not clear. Increases in excitatory neu-
d, involving glutamate and SP, seem to account for the abnormal neuronal
ces were never evaluated. This study aims to analyse the expression of
glutamic acid decarboxylase (GAD) and the potassium chloride cotrans-
rsal horn of streptozotocin (STZ)-induced diabetic rats. Four weeks after
on, animals were sacriﬁced and the spinal segments L2–L3 were removed
GAD and KCC2, or processed for western blotting for KCC2. Densitometric
n the superﬁcial dorsal horn (laminae I, II and III) of immunoreacted sec-
STZ rats presented a signiﬁcant increase of GABA expression in laminae II
ontrol animals, while no differences were detected in GAD expression. A
ressionwas detected by immunohistochemistry in laminae I and II, which
ting. Increased GABA levels, along with decrease in KCC2 expression, may
al activity detected in the spinal cord of diabetic rats. Reduction in KCC2
o increases in intracellular chloride concentration and, in such condition,
r inducesmembrane depolarization, provoking neuronal excitation rather
ﬁndings, we propose that a loss of GABA-mediated inhibitory tone at the
nal hyperexcitability and spontaneous hyperactivity during diabetes.
© 2008 Elsevier Ireland Ltd. All rights reserved.allodynia in diabetic animals is reversed by NMDA and non-NMDA
receptors antagonists [2,17]. The increase in excitation is further
reinforced by similar changes of the SP/NK1 system. The dimin-
ished release of SP from primary afferents in the spinal dorsal horn
of diabetic rats appears to be counterbalanced by an increase in the
expression ofNK1 receptors [14]. Little is knowabout the inhibitory
modulation of spinal nociceptive transmission during diabetic neu-
ropathy. In the adult nervous system, GABA is the major inhibitory
neurotransmitter involved in spinal modulation of pain. However,
GABA can also have an excitatory role in immature neurons [8,25]
and during pathological conditions like neuropathic pain [9,26].
GABA may exert its function on spinal cord neurons through acti-
vation of ionotropic post-synaptic GABAA receptors, which will
promote input or output of chloride from the neuron depending
on intracellular concentration of the anion. The inﬂux of chloride
into the neuron results in hyperpolarization, while the opposite
occurs with chloride exit. In mature neurons, chloride homeosta-
sis is mainly set by two cotransporters: Na+–K+ Cl−cotransporter
1 (NKCC1) and K+ Cl−cotransporter 2 (KCC2). The former imports
ence LC. Morgado et al. / Neurosci
chloride into the cell and is present in dorsal root ganglion neurons
and glia [26], but is scarce in spinal dorsal horn neurons [23]. KCC2
exports chloride out of the neuron and is expressed by nociceptive
spinal neurons [9,26]. KCC2 has, therefore, a more important role
in setting low chloride concentration in nociceptive neurons of the
superﬁcial dorsal horn, accounting for the inhibitory role of GABA.
A reduction in the expression of KCC2 in the superﬁcial spinal dor-
sal horn in chronic pain models induced by peripheral nerve injury
[9] or inﬂammation [37] was recently proposed to induce a shift in
the action of GABA from inhibitory to excitatory [9,20,37].
In order to study the role of GABA in the spinal cord during
diabetes, the present study evaluates the expression of GABA, its
synthesizing enzyme glutamic acid decarboxylase (GAD) and KCC2
in the superﬁcial spinal dorsal horn of rats with diabetes induced
by STZ injection.
A total of 18 male Wistar rats (Charles River, France), weigh-
ing 250–350g, were used. The experiments were performed in
accordance with the ethical guidelines for the study of pain in con-
scious animals [38] and the EuropeanCommunity Council Directive
86/609/EEC. Diabeteswas induced by an intraperitoneal (i.p.) injec-
tion of STZ (60mg/kg body weight; Sigma–Aldrich, St. Louis, USA)
freshly diluted in 0.9% saline (STZ group; n=9). Controls received
equal volumes of saline (control group; n=9). Three days after the
injection, glucose concentration was measured in tail vein blood
samples using a glucose oxidase-impregnated test strip (Accu Chek
Sensor Comfort, Roche Diagnostics, Germany). Only rats with glu-
cose concentrationhigher than300mg/dlwere considereddiabetic
and included in the study. The animals were evaluated once aweek
to conﬁrm the existence of behavioral signs of diabetic neuropa-
thy, as described previously [24] with mechanical and thermal
responses evaluated using, respectively, the Randall-Selitto and the
tail-ﬂick tests. Fourweeks after STZor saline injections, ﬁve animals
from each group were sacriﬁced by perfusion to perform immuno-
histochemistry for GABA, GAD or KCC2 whereas the remaining
four were decapitated for western blotting analysis of KCC2. The
transcardiac perfusions were performed after anaesthesia with an
i.p. injection of 35% chloral hydrate (1ml/kg body weight), using
phosphate-buffered saline (PBS), followed by 4% paraformalde-
hyde. Spinal cord segments L2–L3 were then removed, post-ﬁxed
for 4h in the same ﬁxative, and cryoprotected overnight in 30%
sucrose. Coronal frozen sections, 40m thick, were obtained and
serially collected in four series. Each series was immunohisto-
chemically processed for GABA, GAD 65/67 or KCC2 using the
avidin–biotin–peroxidase method, whereas the fourth was stained
with formol–thionin for laminae delimitation, as described pre-
viously [28]. The sections processed for immunohistochemistry
were treated with 1% hydrogen peroxidase for 10min for inhi-
bition of endogenous peroxidase activity before incubation in a
blocking solution of 10% normal serum in 0.3% Triton X 25% in PBS
(PBST) with 0.1M glycine for 2h. The sections were then incubated
overnight at 4 ◦C in anti-GABA raised in guinea pig (1:4000; Abcam)
or anti-GAD 65/67 (1:2000; Biotrend) or anti-KCC2 (1:20,000;
Sigma–Aldrich), both raised in rabbit. All primary antibodies were
diluted in PBST with 2% normal serum raised in the species were
the respective secondary antibodies were produced. After being
washed in PBST, the sections were incubated during 1h in biotiny-
Table 1
Body weight, blood glucose concentration, mechanical and thermal nociceptive threshold
Body weight (g) Blood glucose (mg/dl)
Control 412 ± 5.6 131 ± 18.7
STZ 282 ± 13.4* 492 ± 32.2*
Data are presented as mean± S.D.
* p<0.05.
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lated secondary antibodies, namely goat anti-guinea pig (1:200;
Vector Laboratories) for GABA or swine anti-rabbit (1:200; DaKo)
for GAD 65/67 and KCC2. The sections were then washed in PBST,
incubated in the avidin–biotin complex (Vectastain, Vector Labo-
ratories) and stained with diaminobenzidine (DAB; 10mg DAB in
20ml of Tris–HCl 0.05M, pH 7.6 solution with 5l of 30% hydro-
gen peroxide). Finally, the sections were washed in PBS, mounted
on gelatine-coated slides, air-dried and coverslipped with xylol.
Sections were observed under a light microscope and the images
were acquired using a high-resolution digital camera coupled to
a computer. Immunolabelling densitometric quantiﬁcation was
performed for spinal laminae I, II and III using the NIH Image
1.52 software (US National Institutes of Health). In the animals
used for western blotting for KCC2 quantiﬁcation, the spinal seg-
ments L2–L3 were immediately removed after decapitation and
homogenized in buffer (50mM Tris, pH 7.6, 100mM NaCl, 0.1% Tri-
ton X 100, 1mM EDTA). The protein concentration was measured
using Bradford Assay (BioRad) and adjustments were performed
to enable equal protein loading on the electrophoresis gel. Sam-
ples were heated at 65 ◦C for 15min and 40g protein per lane
were loaded, electrophoresed on 8% SDS-PAGE and electroblot-
ted onto nitrocellulose membranes. The membranes were blocked
in 5% nonfat milk in Tris-buffered saline with Tween 0.1M, pH
7.2–7.4 (TBST:milk) for 1h, and incubated overnight at 4 ◦C with
the rabbit anti-KCC2 antibody (1:2000; Sigma–Aldrich) diluted in
TBST:milk. The membranes were washed in TBST:milk, incubated
in anti-rabbit secondary antibody conjugated tohorseradishperox-
idase (1:3000), rinsed in TBST, and the signal was detected using a
sensitive chemiluminescence reagent (Pierce Biotechnology). Alfa-
tubulin was used as an internal standard (mouse anti--tubulin,
1:5000; Sigma–Aldrich). Densitometric analysis of the bands was
carried out on digitized images using NIH Image 1.52 software
(US National Institutes of Health). All the statistical comparisons
between values of controls and STZ rats were performed using
non-parametric Mann–Whitney test (body weight, blood glucose,
mechanical and thermal thresholds and optical densities). Results
are expressed as mean± standard error of the mean (S.E.M.).
Three days after STZ injection, the animals developed hyper-
glycemia and remained hyperglycemic until the end of the
study (Table 1). At 4 weeks post-injection, STZ rats presented
body weights signiﬁcantly lower than their age-matched controls
and developed mechanical hyperalgesia and thermal hypoalgesia
(Table 1), which agrees with previous studies using this animal
model [4,17,24,27]. The distribution of GABA and GAD immunore-
action at the spinal grey matter was mainly restricted to laminae
I–III with much more pronounced labelling at lamina II [21,32].
Compared with the control group, the STZ group presented higher
optical density values for GABA at laminae II and III (both with
p<0.05; Figs. 1A, B and 2A). However, increased GABA immunore-
activity in STZ group was not accompanied by differences in the
expression of its synthesizing enzyme, since optical densities in
the sections immunoreacted for GAD 65/67 were similar in STZ
and control groups (Figs. 1C, D and 2B). The immunoreaction for
KCC2 was conﬁned to the grey matter and it was not seen at white
matter, supporting the neuronal expression of KCC2 previously
demonstrated [30]. KCC2 immunoreactionprevailedmainly in lam-
s at 4 weeks after saline or STZ injection
Mechanical threshold (g) Thermal threshold (s)
110 ± 6.7 9 ± 1.4
68 ± 13.8* 21 ± 3.7*
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l segmFig. 1. GABA (A and B), GAD (C and D) and KCC2 (E and F) expression at the L2 spina
bar: 100m.
inae I–III accounting for about 73% of all the immunolabelling and
was mainly concentrated in laminae I (33%) and II (31%). About
15% of KCC2 immunoreaction was located in the ventral horn. STZ
rats showed a signiﬁcant decrease in KCC2 expression when com-
paredwith the control group in laminae I and II (bothwith p<0.05;
Figs. 1E, F and 2C). Immunoblot analysis supports the immunohis-
tochemistry results, showing an important decrease (about 33.8%;
p<0.05) in expression of KCC2 protein in STZ rats (Fig. 3).
The expression of GABA was here shown to be signiﬁcantly
increased in the superﬁcial dorsal horn of diabetic rats when com-
pared with control animals. This ﬁnding is in agreement with
previous studies reporting increased GABA levels in spinal cord
[19] of diabetic rats and may represent an attempt to counterbal-
ance the increased excitatory input in spinal cord due to peripheral
nerveﬁbres spontaneoushyperactivity. IncreasedGABA levelswere
not accompanied by increased GAD expression, which does not
exclude the possible involvement of the enzyme in such deregu-
lation, since its expression cannot be considered a surrogate for
enzyme function [22]. In spite of normal expression, GAD may
be overactive leading to increased synthesis of GABA during dia-
betes. High content of GABA may also be due to reduced removal
of GABA from the synaptic cleft resulting from abnormal function
of GABA transporters (GATs). These are unexplored mechanisms
which must be studied in order to explain the aetiology of GABA
overexpression. Another issue to ascertain is the effect of GABA
overexpression on the function of GABAB receptors. A recent elec-
trophysiological study showed that the functionofGABAB receptors
is reduced in the spinal cordduringdiabetic neuropathy [35],which
65ent of control (A, C and E) and STZ (B, D and F) rats, at 4 weeks post-injection. Scale
may explain the reduced analgesic effect of the GABAB agonist bla-
cofen in experimental models of diabetes [17]. A decrease in the
inhibitory function of GABA in the spinal cord during diabetes is
further indicated by the changes in the actions onGABAA receptors.
Neuronal response induced by GABA binding to GABAA receptors is
determined by intracellular chloride concentration, which mainly
depends on KCC2 function [9,23,26]. In neuropathic pain models
induced by nerve injury it was recently demonstrated that GABA
can act as an excitatory neurotransmitter when binding to GABAA
receptor in the spinal cord, due to a reduction of KCC2 expression.
This affects transmembrane anion gradients in a way that the nor-
mally inhibitory mechanisms induced by GABA become excitatory
[9]. The present study demonstrates a signiﬁcant reduction in KCC2
expression in the superﬁcial dorsal horn of diabetic rats which
was conﬁrmed by other research groups (Nigel Calcutt, personal
communication). Based on the mechanism presented by Coull et
al. [9], these results suggest that in superﬁcial dorsal horn of dia-
betic rats, GABA may act as an excitatory rather than inhibitory
neurotransmitter by binding to post-synaptic GABAA receptors,
concurring to perpetuating of spinal neuronal hyperactivity. This,
along with reduced GABAB receptor function, appears to induce a
loss of GABA-mediated spinal inhibitory tone in painful diabetic
neuropathy. The mechanisms that underlie this change in KCC2
expressionmight involve brain derived neurotrophic factor (BDNF)
action, since BDNF was shown to cause a depolarizing shift in
anion reversal potential in spinal lamina I neurons and blockade of
endogenous BDNF reversed this depolarizing shift in animals with
peripheralnerve injury [10].A recent study inhippocampalneurons
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sensitization, spontaneous pain and hyperalgesia reported duringFig. 2. Immunolabelling optical densities in laminae I–III for GABA (A), GAD (B) and
KCC2 (C). STZ rats presented signiﬁcantly increased expression of GABA in laminae
II and III and decreased expression of KCC2 in laminae I and II. No changes were
detected in GAD expression. *p<0.05.
conﬁrmed a BDNF involvement in the decrease KCC2 expression
and function and suggested that neuronal oxidative stress, one of
the most important consequences of diabetes [31], may also lead
to similar changes [34].
Other issue that deserves consideration is the effects of GABA
and KCC2 changes during diabetes in other neurochemical systems
at the spinal cord. Regarding GABA, it is known that when bind-
ing to GABAB receptors it inhibits the release of glutamate and
neuropeptides from the primary afferent terminals and of glycine
and GABA from interneurons [16,18,36]. The basal levels of glu-
tamate and of noxious-evoked release of substance P (SP) and
glutamate were shown to be lower in the spinal cord of diabetic
rats, but basal SP content were unaltered [3,19]. Diabetic rats do
not present either basal or noxious-evoked differences in the spinal
cord glycine release [3,19]. The increased levels of GABA detected in
the present study may contribute to the tonic depression of gluta-
matergic spinal input and to the reduced evoked glutamate and SP
release detected in diabetic rats, but is unlikely to affect glycinergic
function. Since thepresent studyusedanimalsnot stimulated itwas
not expected anydifference in spinal SP immunoreactivity between
control and diabetic rats. Despite the decrease in excitatory input,
spinal dorsal horn neurons remained hyperactivated [24], sug-
gesting an impairment of spinal nociceptive processing involving
66Fig. 3. KCC2 protein expression in the spinal cord segments L2–L3. Immunoblot-
ting revealed that KCC2 levels were decreased in STZ rats (control vs. STZ: 1.4±0.19
vs. 0.9±0.02; p<0.05). Lines present mean values. Insert presents images of the
immunoblot bands of all the animals used in the present study.
mainly spinal neurons rather then primary afferents. As to KCC2,
the underexpression detected in the present study is expected to
impair glycine-mediated neuronal inhibition during diabetes, since
glycine activates chloride channels [26,30]. Similarly to GABA, its
function is highly dependent on intracellular chloride concentra-
tion and itwas shown to function as an excitatory neurotransmitter
in KCC2 knockout animals [12,26]. A detailed characterization of
neurochemical changes at the spinal cord of diabetic rats is out of
the scope of the present study but possible alterations of several
neurotransmitters related to the here reported alterations in GABA
and KCC2 need to be ascertained in future studies.
In summary, the present data show that diabetes induces a
decrease in spinal KCC2 expression that probably alters neuronal
chloride homeostasis and renders GABA excitatory, as occurs in
neuropathic pain induced by peripheral nerve injury [9] and in
inﬂammatory pain [37]. Therefore, the increase of GABA expres-
sion in the spinal cord of diabetic animals may account for spinaldiabetes.
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Minocycline completely reverses mechanical hyperalgesia in
diabetic rats through microglia-induced changes in the
expression of the potassium chloride co-transporter 2 (KCC2)
at the spinal cord
C. Morgado, P. Pereira-Terra, C. D. Cruz & I. Tavares
Faculty of Medicine of Porto and IBMC, Institute of Histology and Embryology, University of Porto, Alameda Prof. Hernaˆni Monteiro, Porto, Portugal
Aim: Neuronal hyperactivity at the spinal cord during mechanical hyperalgesia induced by diabetes may result from a decrease in the local
expression of the potassium chloride co-transporter 2 (KCC2), which shifts the action of the neurotransmitter γ -amminobutiric acid (GABA)
from inhibitory to excitatory. In this study, we evaluated the effects of spinal microglia inhibition or brain-derived neurotrophic factor (BDNF)
blockade on KCC2 expression, spinal neuronal activity and mechanically induced pain responses of streptozotocin (STZ)-diabetic rats.
Methods: Four weeks after induction of diabetes, the STZ-diabetic rats received daily intrathecal injections, for 3 days, of minocycline (microglia
inhibitor), TrkB/Fc (BDNF sequester) or saline. Behavioural responses to mechanical nociceptive stimulation of STZ-diabetic rats were evaluated
by the Randall-Selitto test. The lumbar spinal cord was immunoreacted against the Fos protein (marker of neuronal activation) or KCC2, which
was also quantified by western blotting. BDNF levels at the spinal cord were quantified by an enzyme-linked immunosorbent assay (ELISA).
Results: Minocycline treatment reversed the mechanical hyperalgesia, increased Fos expression and decreased the KCC2 expression detected
in STZ-diabetic rats to control levels. Treatment with TrkB/Fc was less effective, inducing moderate effects in mechanical hyperalgesia and Fos
expression and only a partial correction of KCC2 expression. BDNF levels were not increased in STZ-diabetic rats.
Conclusions: This study demonstrates that the microglial activation at the spinal cord contributes to mechanical hyperalgesia and spinal
neuronal hyperactivity induced by diabetes, apparently by regulating the KCC2 expression. These effects do not seem to be mediated by BDNF,
which is an important difference from other chronic pain conditions. New targets directed to prevent spinal microglia activation should be
considered for the treatment of mechanical hyperalgesia induced by diabetes.
Keywords: BDNF, c-fos, diabetes, diabetes complications, diabetic neuropathy, experimental pharmacology, glia, minocycline,
neuropharmacology, pain, TrkB/Fc, type 1 diabetes
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Introduction
Diabetic neuropathy (DN) is a major complication of diabetes,
affecting 30–50% of patients. A major reduction of life quality
is because of the spontaneous and mechanical evoked pain,
which is reported as a major complaint by 25% of patients
with DN [1,2]. Chronic pain induced by diabetes represents
a health and economic burden in industrialized countries
because of the increasing prevalence of diabetes and low efficacy
of pharmacological treatments [3].
Pain induced by diabetes is characterized by spontaneous
pain, mechanical hyperalgesia and tactile allodynia [2,4,5],
which are associated with changes at the peripheral and
central somatosensory systems. As to the latter, functional
changes at the spinal cord were shown to be involved in
Correspondence to: Prof. Isaura Tavares, Faculty of Medicine of Porto, Institute of
Histology and Embryology, Alameda Prof. Hernaˆni Monteiro, Porto 4200-319, Portugal.
E-mail: isatav@med.up.pt
this pain conditions [5,6]. In streptozotocin (STZ)-diabetic
rats, nociceptive spinal neurons have higher spontaneous
activity [4,5,7] which have been ascribed to local neurochemical
changes. In the spinal cord of STZ-diabetic rats, a
decrease in the expression of the potassium chloride co-
transporter 2 (KCC2) accounts for a shift in the action
of the γ -amminobutiric acid (GABA) from inhibitory to
excitatory [8,9]. In normal conditions, KCC2 sets a low
intracellular chloride concentration and GABA binding to
GABAA receptors induces chloride influx, inhibiting neuronal
activity [10]. During diabetes, the reduced expression of KCC2
in the spinal cord leads to intracellular chloride accumulation
and GABA binding to GABAA receptors induces chloride
output, which results in neuronal excitation and pain. In fact,
intrathecal administration of bicuculline (GABAA receptor
antagonist) in STZ-diabetic rats elicits antinociceptive effects,
supporting the excitatory role of GABA at the spinal cord
during diabetes [8,9].
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In traumatic neuropathic and inflammatory pain, the spinal
expression of KCC2 was shown to be modulated by the brain-
derived neurotrophic factor (BDNF). The levels of the BDNF
increase at the spinal cord and the blockade of BDNF action
normalizes the KCC2 expression and induces analgesia [11,12].
The increase in the levels of spinal BDNF during traumatic neu-
ropathic pain seems to be caused by microglial activation at the
spinal cord, with an involvement of p38 mitogen-activated pro-
tein kinase (p38 MAPK) [13,14]. As the activation of microglia
was recently described in the spinal cord of STZ-diabetic
rats [15–17] it is important to evaluate if microglia is involved
in the reduction of KCC2 expression during diabetes through
a BDNF-dependent action. These studies are crucial inasmuch
that DN has specific aetiology and underlying mechanisms.
The present study used STZ-diabetic rats to evaluate the
effects of inhibiting spinal microglia or blocking BDNF action
on mechanical hyperalgesia, spinal neuronal activation and
KCC2 expression at the spinal cord. Nociceptive activation
of spinal neurons was evaluated analysing Fos expression,
because of the value of this technique to monitor large nocicep-
tive neuronal populations [18]. Microglia was inactivated by
minocycline, a tetracycline-analogue antibiotic, which inhibits
p38 MAPK [19] and presents analgesic effects in traumatic
neuropathic pain models [20]. BDNF was blocked by intrathe-
cal administration of TrkB/Fc in a dose that was previously
shown to induce analgesia in traumatic neuropathic pain and
normalize KCC2 expression at the spinal cord [11,21,22].
Materials and Methods
Animals
Adult male Wistar rats (12 weeks of age, Charles River;
Barcelona, Spain), weighing 250–300 g at the beginning of
the experiments, were used. The animals were housed two per
cage in a room with a constant temperature (22± 2 ◦C) and
humidity (55± 5%) and 12 h light/dark cycles and received
food and water ad libitum. Experiments were performed in
accordance with the European Community Council Directive
86/609/EEC and the ethical guidelines for the study of pain in
conscious animals [23].
Induction of Diabetes
Type 1 diabetes was induced by an intraperitoneal (i.p)
injection of STZ (60 mg/kg body weight; Sigma-Aldrich,
Barcelona, Spain), dissolved in 0.1 M citrate buffer, pH 4.5.
Control animals received an i.p injection of citrate buffer. The
glucose concentration was measured 3 days after STZ or buffer
injections and before sacrifice in a blood sample from the
tail vein, using Accu Chek Sensor Comfort (Roche Diagnostics,
Berlin, Germany). Only rats with glucose concentrations higher
than 270 mg/dl were considered STZ-diabetic rats.
Treatment Protocols
Four weeks after STZ injection, the animals were injected with
the following substances (n = 10 per experimental group):
saline (STZ+saline group), 100 µg of minocycline (STZ+Mino
group) or 5 µg of TrkB/Fc (STZ+TrkB/Fc group). All sub-
stances were purchased from Sigma-Aldrich. Minocycline and
TrkB/Fc were intrathecally infused once a day, for 3 days, using
treatment protocols adapted from previous studies [20,21].
Briefly, for intrathecal deliveries, the catheters were implanted
into the lumbar subarachnoid space, under deep anaesthesia
by an i.p. injection of a mixture of ketamine (6 mg/100 g)
and medetomidine (0.025 mg/100 g). A laminectomy was per-
formed at T7 –T9 levels and a 3 cm silicone catheter with a
diameter of 3.2 mm (SF1291; SF Medical, Hudson, MA, USA)
was placed into the subarachnoid space, with the tip positioned
at L4 –L5 levels. A 25 µl Hamilton syringe was attached to the
cannula and 25 µl of saline, minocycline solution or TrkB/Fc
was slowly injected, followed by flushing with 25 µl of saline to
assure that all the solution was injected into the subarachnoid
space, as previously described [24,25]. After each administra-
tion, the top of the cannula was carefully sealed. The surgical
procedures lasted approximately 20 min and all incisions were
carefully closed and washed with the povidone–iodine anti-
septic solution. A group of age-matched non-diabetic control
rats was included in the study (n = 10). The position of the
catheter tip was checked during the dissection procedure. Only
the animals with the catheter correctly positioned at L4 –L5
were included in the study.
Behavioural Evaluation of Mechanical Nociception
Mechanical nociception was evaluated by the Randall-Selitto
test (Ugo Basile, Comerio, Italy) on the day prior to STZ or
buffer injections, immediately before the onset of each treat-
ment (pretreatment evaluation) and 90 min after the last drug
delivery (posttreatment evaluation). All animals were handled
daily by the experimenter for habituation purposes for a period
of 8 days prior to the onset of behavioural evaluation. Ascend-
ing mechanical forces were applied to the dorsal surface of the
right hindpaw. The mechanical force (in g) inducing hindpaw
withdrawal was recorded. The paw pressure threshold (PPT)
of each animal was the average of three consecutive measure-
ments, taken with 5-min intervals. Tactile allodynia was also
evaluated using the dynamic plantar aesthesiometer test (Ugo
Basile, Comerio, Italy) in order to better characterize the STZ
model. Additional animals were injected with saline or STZ as
above (n = 4 each) and behavioural evaluation was performed
at the time points referred by the Randall-Sellito test, as pre-
viously described [5]. Briefly, the animals were placed in clear
acrylic boxes with a metal grid floor and stimulation was per-
formed with a 0.5 mm filament, which delivered a linearly
increasing force (2.5 g/s) to the plantar surface of the hindpaw.
The force necessary to elicit a paw withdrawal was recorded and
the paw withdrawal threshold (PWT) was calculated as the aver-
age, in g, of three consecutive tests with at least 5 min between
each test.
Immunohistochemistry
Five rats from each experimental group were anaesthetized
3 h after the last treatment with an i.p. injection of 35% chlo-
ral hydrate (1 ml/kg body weight) and sacrificed by vascular
perfusion with 200 ml of phosphate-buffered saline (PBS),
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followed by 1000 ml of 4% paraformaldehyde in 0.1 M phos-
phate buffer (PB), pH 7.4. Spinal segments L4 –L5 were
removed, postfixed in the same fixative and cryoprotected
overnight in 30% sucrose in PB. Coronal sections 40-µm
thick, were obtained using a freezing microtome. Every
fourth section was collected in 0.1 M PBS and each set was
immunohistochemically reacted for KCC2, Fos protein and
CD11b (microglial marker) [26]. Immunohistochemical detec-
tion using the avidin–biotin peroxidase method was performed
as previously described [4,27]. Briefly, the sections were treated
with 1% hydrogen peroxidase for 10 min to inhibit endogenous
peroxidase activity before incubation for 2 h in a blocking solu-
tion containing 10% normal serum and 0.1 M glycine diluted
in 0.3% Triton× 25% in PBS (PBST). The sections were then
incubated 2 overnights at 4 ◦C in each primary antibody,
namely rabbit anti-KCC2 (1 : 10 000; Sigma-Aldrich), rabbit
anti-Fos (1 : 5000; Ab5; Calbiochem, Darmstadt, Germany) or
mouse anti-CD11b (clone OX-42; 1 : 2000; Millipore, Schwal-
bach/Ts, Germany), all diluted in PBST. After being washed
in PBST, the sections were incubated in biotinylated swine
anti-rabbit (for KCC2 and Fos detections) or rabbit anti-
mouse (for CD11b detection) immunoglobulins, from Dako
(Glostrup, Denmark), diluted in 1 : 200, for 1 h. Sections were
then washed in PBST, incubated for 1 h in the avidin–biotin
complex (Vectastain, Vector Laboratories, Burlingame, CA,
USA) and stained with diaminobenzidine (10 mg in 20 ml of
0.05 M Tris–HCl, pH 7.6 solution with 5 µl of 30% hydrogen
peroxide). Sections were then washed in PBS, mounted on
gelatine-coated slides, air-dried and coverslipped with xylol.
After observation under a light microscope, the images were
acquired using a high-resolution digital camera coupled to a
computer. In 10 randomly taken sections, immunolabelling for
KCC2 and CD11b was quantified by densitometric analysis at
the spinal dorsal horn (laminae I–V), using the NIH Image
1.52 software (US National Institutes of Health), as previously
described [9]. The numbers of Fos-immunoreactive (Fos-IR)
neurons were also counted in laminae I–V, as previously
described [28].
To confirm microglia activation, double immunofluores-
cence for CD11b and phosphorylated form of p38 MAPK
(phospho p38) was performed in spinal sections of con-
trols and STZ-diabetic rats (three animals per group). The
sections were treated with 1% borohydrate for 20 min before
incubation for 2 h in a blocking solution of 10% normal
goat serum in PBST. The sections were then incubated 2
overnights at 4 ◦C in the primary antibodies, mouse anti-
CD11b (1 : 1000) and rabbit anti-phospho p38 (1 : 500;
Cell Signalling, Danvers, MA, USA). After being washed in
PBST, the sections were incubated in fluorescent secondary
antibodies, goat anti-mouse Alexa 488 and goat anti-rabbit
Alexa 594 (1 : 500; Molecular Probes, Carlsbad, CA, USA) for
1 h. Sections were observed using an Apo Tome microscope
(Zeiss, Go¨ttingen, Germany) and the images were acquired
using a high-resolution digital camera coupled to a computer.
Serial optical planes separated by 0.3 µm were collected in the
z-axis and merged images were obtained using the Apo Tome
software.
Western Blotting
The expression of phospho p38 and KCC2 were quantified by
western blotting. Five animals from the Control, STZ+saline
and STZ+Mino experimental groups were used in the western
blotting for phospho p38. For the KCC2 western blotting,
five animals per experimental group were used and all the
experimental groups were considered. After decapitation,
the spinal segments L4 –L5 were immediately removed and
homogenized in buffer (50 mM Tris, pH 7.6, 100 mM NaCl,
0.1% Triton X 100, 1 mM EDTA) added with a proteinase
inhibitor cocktail and a phosphatase inhibitor cocktail (both
at 1 : 100; Sigma-Aldrich). The protein concentration
was measured using Bradford Assay (BioRad, Amadora,
Portugal) and adjustments were performed to equalize protein
concentration. Samples were heated at 65 ◦C for 15 min
and 40 µg protein per lane was loaded, electrophoresed on
10% SDS-PAGE and electroblotted onto the nitrocellulose
membranes. The membranes were blocked in 5% non-fat
milk in Tris-buffered saline with Tween 0.1 M, pH 7.2–7.4
(TBST) for KCC2 and in 5% bovine serum albumin in TBST
for phospho p38 for 1 h and incubated overnight at 4 ◦C
with the rabbit anti-KCC2 antibody (1 : 2000; Sigma-Aldrich)
and rabbit anti-phospho p38 (1 : 1000, Cell Signalling). The
membranes were washed and incubated in antirabbit secondary
antibody conjugated to horseradish peroxidase (1 : 5000;
Jackson Labs, Bar Harbor, ME, USA) and rinsed in TBST. The
signal was detected using a sensitive chemiluminescence reagent
(SuperSignal West Pico Chemiluminescent Substrate, Thermo
Scientific, Waltham, MA, USA). Antibody against phospho p38
was then stripped incubating the membranes with 10% SDS for
15 min. Following blocking, the membranes were incubated
2 overnights with rabbit anti-p38 (1 : 1000, Cell Signalling)
at 4 ◦C. The signal detection was performed as previously
described. Alfa-tubulin was used as an internal standard, using
mouse anti-α-tubulin (1: 10 000; Sigma-Aldrich) as the primary
antibody. Digital images of western blots were analysed by
densitometry using NIH image 1.52 software.
BDNF Quantification
The content of BDNF in the spinal cord of control
and untreated STZ-diabetic rats was determined using the
BDNF Emax ImmunoAssay System (Promega, Madison,
WI, USA) in the supernatant of spinal homogenates from
L4 –L5 segments. Assays were performed according to the
manufacturer’s instructions, using an antibody sandwich
format in 96-well plates. Plates were coated with anti-BDNF
polyclonal antibodies. Samples (10 µl) or BDNF standards
were added to each well and plates were incubated. After
several washes, anti-BDNF monoclonal antibodies were added
and plates were again incubated. After thorough washes,
the amount of bound monoclonal antibody was detected
using IgG-horseradish peroxidase-conjugated antibody. The
unbound conjugate was removed by washing. The plate was
then incubated with 100 µl of substrate solution for 10 min.
Hydrochloric acid was added to stop the reactions. Colour
change was measured with a Synergy HT Microplate Reader
(Bio-Tek Instruments, Winooski, VT, USA) at 450 nm. All
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samples were run in duplicate and values were averaged. BDNF
levels were normalized to the protein concentration in each
sample, quantified by Bradford Assay.
Specificity of Antibodies
The specificity of each primary antibody was previously
demonstrated [9,26,27]. Control experiments were performed
by omission of primary or secondary antibodies. Additionally
for KCC2, p38 and phospho p38 the specificity of the primary
antibodies was demonstrated by western blotting with bands
detected at 140 kDa for KCC2 and at 40 kDa for p38 and
phospho p38.
Statistical Analysis
SPSS statistics version 18 (IBM, Armonk, New York, NY, USA)
was used for statistical analysis. Behavioural, imunohistochem-
istry and western blotting data were compared by ANOVA
followed by Tukey’s post hoc test for multiple comparisons.
BDNF levels were compared by independent sample t-test.
Pretreatment and posttreatment behavioural responses were
compared by paired-sample t-test. Statistical significance was
settled at p < 0.05. Results are expressed as mean ± standard
error of the mean (s.e.m.).
Results
At 4 weeks postinjection, STZ-diabetic rats presented
significantly lower body weights and higher blood glucose levels
than age-matched non-diabetic control animals (Table 1). The
treatments with Mino and TrkB/Fc had no effects on body
weights or glycaemia.
Characterization of STZ-diabetic Rats
STZ-diabetic rats presented a significant increase in the
expressions of CD11b and phospho p38 in microglial cells,
when compared with control animals (figures 1, 2A–C, E).
Table 1. Body weights and glycaemia of experimental groups.
Experimental
groups Body weight (g)
Blood glucose
concentration (mg/dl)
Control 409± 5.4 131± 18.7
STZ+saline 287± 3.8∗ 492± 32.2∗
STZ+Mino 283± 7.3∗ 501± 28.4∗
STZ+TrkB/Fc 285± 4.3∗ 498± 50.3∗
Mean values± standard error of the mean (s.e.m.). STZ, streptozotocin.
∗p < 0.01 vs. control.
Furthermore, the microglia of STZ-diabetic rats presented
morphological changes that match the well-described signs
of microglial activation, namely larger soma and thicker
and shorter processes than control animals (cf. figures 1A,
B, 2B, C). Untreated STZ-diabetic rats presented much lower
PPTs than controls (p = 0.003; figure 3A). Tactile allodynia
was also detected in untreated STZ-diabetic rats (PWT at 4
weeks postinjection: 19.90± 2.04 and 14.10± 0.98 in control
animals and STZ-diabetic rats, respectively; p = 0.019), further
confirming the existence of mechanical hypersensitivity in
our STZ-diabetic rats. As the Randall-Selitto test is highly
predictable of clinical applicability of analgesic drugs [29], the
subsequent behavioural evaluations were performed using only
this test. STZ-diabetic rats presented a higher Fos expression at
the spinal dorsal horn than controls (p = 0.025; figure 3B–D).
The expression of KCC2 decreased in STZ+saline rats in
relation to controls (p = 0.009; figure 3F–H).
Effects of Minocycline
After minocycline treatment, the activation of microglia
detected at the spinal cord of untreated STZ-diabetic rats
was inhibited, with a significant decrease in the expression of
CD11b and phospho p38 (figure 2A, E) and reversal of mor-
phological signs of microglial activation (cf. figure 2C, D). The
mechanical hyperalgesia detected in untreated STZ-diabetic
Figure 1. Microglia activation at the spinal cord of streptozotocin (STZ)-diabetic rats. Panels (A) and (B) show double immunoreactions for CD11b
(marker of microglia; in green) and phospho p38 (marker of microglia activation; in red) in representative sections taken from the L4 spinal segment
in control (A) and STZ-diabetic (B) rats. Panel (C) shows representative blots and the quantification by western blotting of phospho p38 in spinal
homogenates of control and STZ-diabetic rats. STZ-diabetic rats present microglia activation at the spinal cord, demonstrated by morphological changes
of microglia (larger soma and thicker and shorter processes) and increased expression of phospho p38 (significant increase in the ratio between phospho
p38 and total p38). Significance of symbol: ∗p < 0.05. Scale bar in (B): 50 µm (both photomicrographs are at the same magnification).
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Figure 2. Effects of minocycline treatment on microglial activation. Panel
(A) shows the expression of CD11b (marker of microglia) at the spinal
dorsal horn of control and of streptozotocin (STZ)-diabetic rats injected
with saline (STZ+saline) or treated with minocycline (STZ+Mino). Panels
(B–D) show photomicrographs of the L4 spinal sections labelled for CD11b
in the three experimental groups. Panel (E) shows representative blots and
the quantification by western blotting of phospho p38 expression in
the L4 –L5 spinal cord homogenates in the three experimental groups.
Minocycline significantly reduced CD11b and phospho p38 expression,
indicating that the treatment was effective in the reversion of microglia
activation. Significance of symbol: ∗∗p < 0.01. Scale bar in (D): 100 µm
(all photomicrographs are at the same magnification).
rats was reversed to the levels of control rats in the
STZ+Mino group with statistically significant differences in
relation to untreated STZ rats (p = 0.007; figure 3A). The
increased spinal Fos expression, detected in STZ+saline rats,
was also reversed to control levels after minocycline treat-
ment (figure 3B–E) with statistical significant differences only
between the STZ+saline and STZ+Mino groups (p = 0.017;
figure 3B, D, E). The expression of KCC2 was also reversed to
control levels when STZ-diabetic rats were treated with minocy-
cline (figure 3F–I), with statistical significant differences only
between the STZ+saline and STZ+Mino groups (p = 0.007;
figure 3F, H, I). The result of western blotting performed
for KCC2 supported the quantitative immunohystochemical
analysis (figure 3J).
Effects of TrkB/Fc
Blocking the BDNF action in STZ rats by TrkB/Fc ameliorated
mechanical nociception (figure 4A), with statistical significant
differences in relation to untreated STZ rats (p = 0.037).
TrkB/Fc reduced the number of Fos-IR neurons in STZ-diabetic
rats, with significant differences in relation to the STZ+saline
group (p = 0.018; figure 4B–E). The TrkB/Fc treatment
increased KCC2 expression in STZ-diabetic rats in relation to
untreated STZ-diabetic rats (p = 0.029; figure 4F–H). How-
ever, this reversion did not reach control levels, as the statistical
significant differences were detected between STZ+TrkB/Fc
and control animals (p = 0.047; figure 4F–I). western blotting
results for KCC2 confirmed the immunohystochemical data
(figure 4J).
We also evaluated the effects of TrkB/Fc in the activation
of microglia (figure 5). TrkB/Fc treatment induced a signif-
icant reduction of microglia activation in STZ-diabetic rat
(p = 0.019), as demonstrated by the decrease of CD11b expres-
sion (figure 5), but did not reverse it to the levels of control
animals (p = 0.009).
BDNF Levels
The results of the ELISA study are shown in Table 2. BDNF
levels in untreated STZ-diabetic rats were not different from
control rats. Treatment with minocycline or TrkB/Fc did not
alter BDNF levels.
Discussion
The present study shows that the mechanical hyperalgesia and
spinal neuronal hyperactivity detected during diabetes may
be reversed by correcting the KCC2 levels at the spinal cord,
through the inhibition of spinal microglia. BDNF levels at the
spinal cord did not change in diabetic rats and the inhibition
of BDNF did not reverse the KCC2 expression to control lev-
els, indicating that mechanisms besides BDNF are probably
involved in the correction of KCC2 expression by minocycline.
This BDNF-independent effect of microglia on KCC2 expres-
sion differs from other chronic pain models, which suggests
that the mechanical hyperalgesia induced by diabetes is caused
by particular mechanisms and reinforces the need to develop
specific treatments.
Diabetic rats presented marked microglia activation at the
spinal cord, which agrees with recent results in diabetic rats with
different genetic backgrounds [15–17] and demonstrates that
this is a common feature of diabetes. Minocycline was effective
in inhibiting microglial activity, as evidenced by the induction
of resting-state morphology and by the reduction of the spinal
levels of phospho p38 MAPK and CD11b. In neuropathic
and inflammatory chronic models it was shown that activated
microglia at the spinal cord is associated with increased BDNF
levels, which leads to a decrease in neuronal KCC2 expres-
sion [11,12,30,31]. In our STZ-diabetic rats, the significant
microglial activation in the spinal cord did not affect the spinal
content of BDNF. Furthermore, BDNF inhibition by TrkB/Fc
did not correct KCC2 expression in diabetic rats to control lev-
els. Although it could be argued that higher doses or prolonged
treatment with TrkB/Fc should have been used to increase
the effects of BDNF sequestration, the current protocol was
previously shown to significantly decrease BDNF expression at
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Figure 3. Effects of minocycline treatment on mechanical nociception (A), Fos expression (B–E) and KCC2 expression (F–J). Panel A shows the
behavioural responses in the Randall-Selitto test in control and in streptozotocin (STZ)-diabetic rats, before (pretreatment) and after (posttreatment)
injection of saline (STZ+saline) or minocycline (STZ+Mino). Panel (B) shows the mean numbers per section of Fos-immunoreactive (Fos-IR) neurons
at the spinal dorsal horn of the L4 –L5 segments in the three experimental groups (control, STZ+saline and STZ+Mino) and panels (C–E) show
representative photomicrographs of the L4 spinal cord sections. Panel (F) shows KCC2 expression at the spinal dorsal horn of the three experimental
groups and panels (G–I) show representative photomicrographs of the L4 spinal cord sections labelled for KCC2. Panel (J) shows representative blots
of KCC2 in each experimental group. Minocycline treatment completely normalized mechanical nociception, totally reverted spinal hyperactivity and
corrected KCC2 expression to control levels. Significance of symbols: #, comparison with pretreatment STZ+Mino animals; §, comparison with control
animals; ∗∗p < 0.01. Scale bar in (I): 100 µm (all photomicrographs are at the same magnification).
the spinal cord in traumatic neuropathic pain models [21]. In
addition, increasing TrkB/Fc doses could affect motor func-
tions and impair behavioural evaluation because BDNF is
crucial for the function of motoneurons [32]. The suggestion
that during diabetes the microglia-mediated effect on KCC2
expression is independent of BDNF represents a considerable
difference of pain induced by diabetes from other chronic pain
conditions and suggests that it is caused by specific mech-
anisms. Discarded a role for BDNF, several candidates could
mediate the action of microglia in decreasing KCC2 expression,
namely the cytokines interleukin (IL)-1β, tumour necrosis fac-
tor (TNF)-α, IL-6 and prostaglandin E2 (PGE2) [33,34]. In
a recent study, an increase of IL-1β and TNF-α expressions
in the spinal cords of STZ-diabetic rats was normalized after
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Figure 4. Effects of brain-derived neurotrophic factor (BDNF) action blockade on mechanical nociception (A), Fos expression (B–E) and KCC2
expression (F–J). Panel (A) shows behavioural responses in the Randall-Sellito test in control animals and in streptozotocin (STZ)-diabetic rats before
(pretreatment) and after (posttreatment) injection of saline (STZ+saline) or TrkB/Fc (STZ+TrkB/Fc). Panel (B) shows the mean numbers per section of
Fos-immunoreactive (Fos-IR) neurons at the spinal dorsal horn of control, STZ+saline and STZ+TrkB/Fc rats and panels (C–E) show photomicrographs
of representative sections of L4 segment immunoreacted for Fos in the three experimental groups. Panel (F) shows KCC2 expression at the spinal dorsal
horn of control and STZ+saline or STZ+TrkB/Fc rats. Panels (G–I) show representative photomicrographs of the L4 spinal sections labelled for KCC2.
Panel (J) shows representative blots of KCC2 protein for each experimental group. Blocking BDNF action at the spinal cord of STZ rats, ameliorated
mechanical nociception, reverted spinal hyperactivity and increased KCC2 expression but not to the levels of control animals. Significance of symbols:
#, comparison with pretreatment STZ+TrkB/Fc animals; §, comparison with control animals; ∗p < 0.05; ∗∗p < 0.01. Scale bar in (I): 100 µm (all
photomicrographs are at the same magnification).
minocycline treatment [17], indicating an involvement of these
two cytokines. Future studies will be performed to evaluate the
involvement of these cytokines, along with IL-6 and PGE2, in
the changes of KCC2 expression during diabetes.
This study also shows that BDNF inhibition by TrkB/Fc
has beneficial effects on behavioural pain responses and spinal
neuronal hyperactivity during diabetes, despite the moderate
effect on KCC2 expression. A direct effect of TrkB/Fc on
spinal microglia is a possibility suggested by the reduction of
microglial activation detected in the spinal cord of STZ-diabetic
rats treated with TrkB/Fc. This is a new finding which may
be explained by the recent demonstration that microglia
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Figure 5. Effect of brain-derived neurotrophic factor (BDNF) blockade on microglial activation. Panel (A) presents the expression of CD11b (marker
of microglia) at the spinal dorsal horn of control, streptozotocin (STZ)-diabetic rats injected with saline (STZ+saline) or treated with TrkB/Fc
(STZ+TrkB/Fc). Panels (B) and (C) show photomicrographs of L4 spinal sections labelled for CD11b in the STZ+saline and STZ+TrkB/Fc rats. TrkB/Fc
reduced CD11b expression in STZ-diabetic rats, but it remained significantly higher than that from control rats. Significance of symbols: ∗p < 0.05;
∗∗p < 0.01. Scale bar in (C): 100 µm (all photomicrographs are at the same magnification).
Table 2. Brain-derived neurotrophic factor (BDNF) content in L4 –L5
spinal segments.
Experimental groups BDNF (ng/mg protein)
Control 0.47± 0.04
STZ+saline 0.56± 0.08
STZ+Mino 0.49± 0.04
STZ+TrkB/Fc 0.52± 0.05
Mean values± standard error of the mean (s.e.m.). STZ, streptozotocin.
is activated by BDNF, through binding with a truncated
tropomyosin-related kinase B (tTrkB) receptor expressed by
microglial cells [35]. The antinociceptive effects of TrkB/Fc may
also be derived from a BDNF action on spinal neurons. BDNF
facilitates the release of GABA from spinal interneurons [36]
and during diabetes the inhibitory action of GABA shifts to
excitatory at the spinal cord [8,9]. It is, therefore, possible that
BDNF blockade decreased GABA release in STZ-diabetic rats
and, herein, reduced spinal neuronal excitability. Another pos-
sibility to explain the antinociception induced by TrkB/Fc is a
blockade of excitatory neurotransmission at the spinal cord as
BDNF induces the release of excitatory neurotransmitters and
activates spinal glutamatergic receptors [37]. Finally, a direct
action of BDNF on cAMP response element-binding protein
phosphorylation is also possible, because this mechanism was
previously shown to account for BDNF-induced increase in
Fos expression in spinal neurons [37]. The mechanisms medi-
ating the beneficial effects of BDNF in mechanical hyperalgesia
and spinal Fos expression in STZ-diabetic rats needs further
clarification.
In summary, this study shows for the first time that microglia
inhibition corrects KCC2 expression during diabetes by mech-
anisms that are independent from BDNF action. As decreased
expression of KCC2 affects spinal GABA neurotransmission,
eliciting excitatory rather than inhibitory actions when binding
to GABAA receptors [10,13] during diabetes [8], it is likely
that the normalization of KCC2 expression at the spinal cord
by minocycline treatment restored the inhibitory function of
GABA at the spinal cord of diabetic rats. In fact, the relationship
between KCC2 expression and GABA action was clearly demon-
strated previously by showing that control animals intrathecally
treated with a KCC2 inhibitor develop a hyperalgesic pattern
of response similar to that of STZ-diabetic rats [8]. Those pain
responses were totally reversed by GABAA receptor antagonist.
In control animals, with normal expression of KCC2, neither
the antagonist nor the agonist of GABAA receptor affected
mechanical nociception [8]. As minocycline induced a com-
plete normalization of KCC2 expression in our STZ-diabetic
rats it is likely that treating the animals with antagonist or
agonists of GABAA receptor will elicit the effects observed in
control non-diabetic animals.
Translational consequences of the present data showing a
complete reversal of mechanical hyperlagesia by intrathecal
minocycline treatment should be considered in the future.
The systemic or oral delivery of minocycline was shown to
be effective in reversing DN [17,38]. Although these effects
were interpreted only by peripheral actions of the drug and
according to the present results, with intrathecal delivery of
minocycline, the effects may be because of direct spinal actions.
Minocycline is a second-generation antibiotic belonging to
the tetracycline family, approved by the FDA for the treat-
ment of acne vulgaris, some sexually transmitted diseases and
rheumatoid arthritis [39]. In humans, long-term treatment
with minocycline was shown to be generally safe and well tol-
erated. However, gastrointestinal and central nervous system
reversible side effects (e.g. vestibular effects, benign intracranial
hypertension) were reported, along with rare cases of autoim-
mune disorders, such as lupus and hepatitis [40]. Minocycline
is being tested in several neurodegenerative diseases and other
disorders, including spinal trauma and diabetes macular edema
(http://www.clinicaltrials.gov). Clinical trials will be needed to
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confirm the beneficial effects of minocycline on pain during
DN, to evaluate the safety, efficacy and tolerability of this drug
in comparison with the current first-line therapies for painful
DN. These include tricyclic compounds, selective serotonin
and noradrenaline reuptake inhibitors (such as duloxetine)
and anticonvulsants (such as pregabalin or gabapentin), which
present side effects and limited efficacy. New drugs that inhibit
spinal microglia should be developed as a possible next step in
the treatment of pain induced by diabetes.
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α-Lipoic acid normalizes nociceptive neuronal activity
at the spinal cord of diabetic rats
C. Morgado, P. Pereira-Terra & I. Tavares
Institute of Histology and Embryology of Faculty of Medicine of Porto and IBMC, University of Porto, Porto, Portugal
Aim: To evaluate the effects of antioxidant treatment of streptozotocin (STZ)-diabetic rats with α-lipoic acid (α-LA) in neuronal and microglial
activation at the spinal cord, an important relay station of nociceptive transmission. Because of the role of the potassium chloride co-transporter
2 (KCC2) in neuronal activation at the spinal cord and the inﬂuence of microglia in KCC2 expression, we also evaluated the effects of α-LA in
KCC2 expression at the spinal cord.
Methods: Four weeks after STZ injection, the rats received daily intraperitoneal injections of α-LA (100 mg/kg), during 2 weeks. Mechanical
nociception was evaluated before and after α-LA treatment. Spinal cords were immunoreacted against 8-OH-dG (marker of oxidative stress
damage), Fos (marker of neuronal activation) and CD11b (marker of microglia). KCC2 expression was evaluated by immunohistochemistry and
western blotting.
Results: Treatment with α-LA decreased the 8-OH-dG and Fos expressions to controls’ levels, but did not affect CD11b. Treatment with α-LA
alleviated mechanical hyperalgesia and partially corrected KCC2 expression.
Conclusions: This study shows that neuronal hyperactivity at the spinal cord of STZ-diabetic rats can be corrected by α-LA, which may
account for alleviation of mechanical hyperalgesia. These effects are probably partially mediated by KCC2, but are independent from
microglia.
Keywords: α-lipoic acid, animal pharmacology, c-fos, diabetes, diabetes complications, diabetic neuropathy, drug mechanism, KCC2, microglia,
pain, spinal cord, type 1 diabetes
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Introduction
Oxidative stress damage has been implicated in a variety
of pathological processes that underlie diabetic compli-
cations, as retinopathy [1], nephropathy [2] and neuropa-
thy [3]. Diabetic neuropathy affects 30–50% of diabetic
patients, with spontaneous and mechanical-evoked pain
reported as major complaints by about one quarter of the
patients [4]. Diabetes induces oxidative stress in peripheral
nerves, which are probably to contribute to nerve dysfunc-
tion and altered pain sensations observed during diabetic
neuropathy [3,5].
α-Lipoic acid (α-LA) is a powerful scavenger of free radi-
cals and metal chelator [6]. In experimental models of diabetic
neuropathy, antioxidant treatmentwithα-LAnormalizes nerve
blood ﬂow, nerve conduction velocity and nociception [3,5].
In diabetic patients, α-LA signiﬁcantly decreases oxidative
stress [7], improves microcirculation [8] and reduces pain [9].
The mechanisms of action of α-LA on pain have only been
studied at the periphery. Considering the ability of α-LA to
cross the brain–blood barrier [10] and the observation that
α-LA reverses the impairment in kinin (1) receptor expression
Correspondence to: Isaura Tavares, Institute of Histology and Embryology, Faculty of
Medicine of Porto, Alameda Prof. Hernaˆni Monteiro, 4200-319 Porto, Portugal.
E-mail: isatav@med.up.pt
at the spinal cord of insulin-resistant animal models [11], we
hypothesized that α-LA has also central effects in painful dia-
betic neuropathy, namely at the spinal cord. This is important
as it was previously showed that streptozotocin (STZ)-diabetic
rats presented hyperactivity of spinal nociceptive neurons [12].
This increased neuronal activity was shown to be associ-
ated with a decreased expression of the potassium chloride
co-transporter 2 (KCC2) at the spinal cord [13,14], which
accounts for a shift in the action of γ -aminobutiric acid
(GABA) from inhibitory to excitatory in the spinal dorsal
horn of STZ-diabetic rats [13]. Spinal microglia activation
was shown to account for those impairments [15]. Oxidative
stress is an additional mechanism that may underlie changes
in the expression and activity of KCC2 in the spinal cord
during diabetes. In an oxidative stress model of hippocam-
pal neuronal cultures, the expression and activity of KCC2
is decreased [16]. Antioxidants interfere with the inﬂamma-
tory response of microglial cultures [17]. Oxidative stress may,
therefore, trigger KCC2 impairments during diabetes, either
by a direct neuronal action or by interfering with microglial
activation.
This study evaluates the effects of an antioxidant treatment
with α-LA in neuronal and microglial activation at the spinal
cord of STZ-diabetic rats and investigates an involvement of
KCC2.
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Materials and Methods
Animals
Male Wistar rats (aged 12 weeks; Charles River, Barcelona,
Spain), weighing 250–300 g, were used. The animals were
housed in a roomwith controlled temperature (22 ± 2◦ C) and
humidity (55 ± 5%) and 12-h light/dark cycles. The animals
received food and water ad libitum. Experiments were per-
formed in accordance with the European Community Council
Directive 86/609/EEC and the ethical guidelines for the study
of pain in conscious animals [18].
Induction of Diabetes
Type 1 diabetes was induced by an intraperitoneal (i.p.) injec-
tion of STZ (60 mg/kg body weight; Sigma-Aldrich, Barcelona,
Spain), dissolved in 0.1 M citrate buffer, pH 4.5. Control ani-
mals were injected with citrate buffer. Glucose concentration
was measured in a blood sample from the tail vein, using Accu
Chek Sensor Comfort (Roche Diagnostics, Berlin, Germany),
3 days after those i.p. injections and before sacriﬁce. Only
rats with glucose concentrations higher than 270 mg/dl were
included in the STZ-diabetic group.
Treatment Protocols
Four weeks after STZ injection, the rats received daily
i.p. injections of α-LA (STZ + α-LA group) or saline (STZ
+ saline group) during the following 2 weeks. Both experimen-
tal groups included 10 rats. α-LA (Sigma-Aldrich) was used in
a dose (100 mg/kg body weight) settled according to previous
studies [3,5]. Groups of age-matched non-diabetic control rats
and STZ-diabetic animals with 4 weeks of disease (STZ + 4 w
group) were included in the study (n = 10 per group).
Behavioural Evaluation of Mechanical Nociception
All animals were handled daily by the experimenter for habitu-
ation purposes during 8 days prior to the onset of behavioural
evaluation. Mechanical nociception was evaluated using the
Randall-Selitto test (Ugo Basile, Comerio, Italy) at three time-
points: at the day prior to STZ or buffer injections, immediately
before the treatment onset (pretreatment evaluation) and
90 min after the last α-LA or saline injections (post-treatment
evaluation). The paw pressure threshold (PPT)was determined
at the right hindpaw as described previously [15].
Immunohistochemistry
Five rats from each experimental group were deeply anaes-
thetized 3 h after the last treatment with an i.p. injection
of 35% chloral hydrate (1 ml/kg body weight) and per-
fused with phosphate-buffered saline (PBS), followed by
4% paraformaldehyde in 0.1 M phosphate buffer (PB),
pH 7.4 [12,15]. The spinal segments L4–L5 were removed,
post-ﬁxed and cryoprotected overnight in 30% sucrose in
PB. Every fourth coronal frozen section, 40-μm thick, was
collected in 0.1 M PBS. Each section set was immuno-
histochemically reacted for 8-OH-dG (marker of oxidative
stress nucleic acid damage) [19], Fos protein (marker of
nociceptive neuronal activation at the spinal cord) [20],
CD11b (microglial marker) [21] or KCC2 [14], using the
avidin–biotin–peroxidase method. The spinal cord sections
immunoreacted for 8-OH-dG were pretreated with 2 N HCl
during 10 min to denature nucleic acids, followed by 5 min
immersion in Tris-base 1 M. Following treatment with 1%
hydrogen peroxidase for 10 min to inhibit endogenous perox-
idase activity, sections were incubated in a blocking solution of
10% normal serum in 0.3% Triton X 25% in PBS (PBST) with
0.1 M glycine for 2 h. The sections were then incubated two
overnights at 4◦ C in each primary antibody, namely mouse
anti-8-OH-dG (1 : 1600; Trevigen, Gaithersburg, MD, USA),
rabbit anti-Fos (1 : 5000; Ab5; Calbiochem, Darmstadt, Ger-
many), mouse anti-CD11b (clone OX-42; 1 : 2000, Millipore,
Schwalbach/Ts, Germany) or rabbit anti-KCC2 (1 : 10000;
Sigma-Aldrich), all diluted in PBST. After washings in PBST,
the sections were incubated in biotinylated rabbit anti-mouse
(for 8-OH-dG and CD11b detection) or swine anti-rabbit (for
Fos and KCC2 detection), all fromDako (Glostrup, Denmark),
diluted at 1 : 200, for 1 h. After washings in PBST, the sections
were incubated for 1 h in the avidin–biotin complex (Vectas-
tain, Vector Laboratories, Burlingame, CA, USA) and stained
with diaminobenzidine [12,15]. Light microscope images were
acquired by a blind-observer using a high-resolution digi-
tal camera coupled to a computer. In 10 randomly taken
sections, immunolabelling for 8-OH-dG, CD11b and KCC2
was quantiﬁed by densitometric analysis at the spinal dorsal
horn, using the NIH Image 1.52 software (US National Insti-
tutes of Health), as described previously [14]. The numbers of
Fos-immunoreactive (Fos-IR) neurons were counted at spinal
dorsal horn (laminae I–V), as described previously [22].
Western Blotting
The expression of KCC2 was quantiﬁed by western blotting in
spinal homogenates of spinal segments L4–L5 of 5 animals per
experimental group, as described previously [14]. Brieﬂy, the
membranes were incubated with the rabbit anti-KCC2 anti-
body used above (1 : 2000) and alfa-tubulin, used as an internal
standard, was identiﬁed using amouse anti-α-tubulin antibody
(1 : 10000; Sigma-Aldrich, Spain). Digital images were analysed
by densitometry using NIH Image 1.52 software, as described
previously [14].
Speciﬁcity of Antibodies
Control experiments were performed by omission of pri-
mary or secondary antibodies. In the case of Fos experiments,
the speciﬁcity of immunostaining was further conﬁrmed by
lack of immunoreactions in naive animals [22]. Speciﬁcity of
KCC2 primary antibody was also showed by western blot-
ting with band detected at 140 KDa [14]. The speciﬁcities of
the anti-CD11b and anti-8-OH-dG antibodies were previously
showed [19,21].
Statistical Analysis
SPSS Statistics version 18 (IBM, Armonk, NY, USA) was used
for statistical analysis. Behavioural, imunohistochemistry and
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Table 1. Body weights and glycaemia of experimental groups.
Experimental
groups
Body
weight (g)
Blood glucose
concentration (mg/dl)
Control 409 ± 5.4 131 ± 18.7
STZ + 4 w 283 ± 7.3∗ 503 ± 28.4∗
STZ + saline 287 ± 3.8∗ 492 ± 32.2∗
STZ + α-LA 290 ± 2.4∗ 486 ± 61.2∗
Mean values ± s.d. α-LA, α-lipoic acid; STZ, streptozotocin.
∗p < 0.01 versus control.
western blotting data were compared by analysis of variance
followed by Tukey post hoc test for multiple comparisons.
Pretreatments and post-treatments behavioural responses were
compared by paired sample t-test. Statistical signiﬁcance was
settled at p < 0.05. Results are expressed as mean ± standard
error of the mean (s.e.m.).
Results
Characterization of Untreated STZ-Diabetic Rats
Untreated STZ-diabetic rats at 4 weeks post-injection and
saline-injected STZ-diabetic rats presented signiﬁcantly lower
bodyweights and higher blood glucose levels than age-matched
non-diabetic control animals (Table 1). STZ-diabetic rats
presented increased responses to mechanical stimuli, showed
by the lower PPTs in the Randall-Sellito test (ﬁgure 1).
STZ-diabetic rats also presented changes at the spinal dorsal
horn, when compared to controls. The expression of 8-OH-
dG was signiﬁcantly higher in untreated and saline-treated
STZ-diabetic rats in comparison with controls (ﬁgure 2),
demonstrating increased oxidative stress nucleic acids damage
during diabetes. STZ-diabetic rats presented higher numbers
of Fos-IR neurons at the spinal dorsal horn than controls
(ﬁgure 3A–E), indicating higher nociceptive activation of
spinal neurons. The microglia of the former animals presented
larger soma and thicker and shorter processes and increased
expression of CD11b (ﬁgure 3F–J), which is considered an
Figure 1. Effects of α-lipoic acid (α-LA) treatment on mechanical
hyperalgesia. The graph represents the behavioural responses (pawpressure
thresholds in the Randall-Sellitto test) in non-diabetic control animals,
streptozotocin (STZ)-diabetic rats with 4 weeks of the disease (STZ +
4 w) and in STZ-diabetic rats before (pretreatment) and after (post-
treatment) injections of α-LA or saline. The antioxidant treatment with
α-LA ameliorated the mechanical nociception, but without normalization
to the control levels. Signiﬁcance of symbols: § comparison with non-
diabetic control animals; # comparison with pretreatment STZ + α-LA
group; two symbols: p < 0.01.
indication of microglial activation [15]. The expression of
KCC2 was lower in STZ-diabetic rats (ﬁgure 4).
Effects of Treatment with α-LA
Treating STZ-diabetic rats with α-LA had no effects on body
weights or bloodglucose levels (Table 1),which is in accordance
with previous studies using similar α-LA dose and even with
higher treatment duration [3,5].
Behavioural Pain Responses
Treatmentof STZ-diabetic ratswithα-LAamelioratedmechan-
ical nociception, with PPTs values intermediate between con-
trols (p = 0.009) and STZ + saline rats (p = 0.000; ﬁgure 1).
Oxidative Stress Nucleic Acids Damage
Treatment of STZ-diabetic rats withα-LA signiﬁcantly reduced
the expression of 8-OH-dG to the levels of control animals
(ﬁgure 2), showing that α-LA totally reversed the signs of
oxidative stress nucleic acid damage at spinal dorsal horn
during diabetes.
Spinal Neuronal and Microglia Activity
Treatment with α-LA decreased the number of Fos-IR neurons
to the levels of control animals (ﬁgure 3A–E), indicating
a reversal of nociceptive activation of spinal neurons after
treatment. The α-LA had no effects on the CD11b microglial
expression, with microglial cells maintaining the activated
phenotype detected in untreated and saline-treated STZ-
diabetic rats (ﬁgure 3F–J).
Spinal KCC2 Expression
Treatment with α-LA moderately increased the KCC2
immunolabelling to levels intermediate between controls
(p = 0.048) and STZ + saline rats (p = 0.031) (ﬁgure 4A–F).
These results were conﬁrmed by western blotting (ﬁgure 4B).
Discussion
This study showed, for the ﬁrst time, thatα-LA blocks oxidative
stress at the spinal cord and controls the activity of nociceptive
spinal neurons during diabetes. In a manner similar to other
pathologies, oxidative stress induced by diabetes is probably
to decrease KCC2 expression at the spinal cord, which was
blocked here by the antioxidant treatment with α-LA.
Antioxidant treatment with α-LA fully reversed both oxida-
tive stress nucleic acids damage and neuronal hyperactivity
at the spinal cord of STZ-diabetic rats. The mechanisms
used by α-LA to reduce the neuronal hyperactivity at the
spinal cord were investigated in the present study. Treatment
with α-LA interferes with KCC2 expression at the spinal cord
neurons, indicating that this co-transporter accounts for the
α-LA-mediated reversion of neuronal hyperactivity during dia-
betes. Although microglia activation appears to account to the
reduction of spinal KCC2 expression in STZ-diabetic rats [15],
microglia does not appear to be involved in the effects of
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Figure 2. Effects of α-lipoic acid (α-LA) treatment on oxidative stress nucleic acids damage in the spinal dorsal horns. Panel (A) represents 8-OH-dG
expression in control animals, streptozotocin (STZ)-diabetic rats with 4 weeks of the disease (STZ + 4 w) and STZ-diabetic rats treated with saline (STZ
+ saline) or α-LA (STZ + α-LA). Panels (B–E) are representative photomicrographs of L4 spinal cord sections labelled for 8-OH-dG. Damage induced
in the nucleic acids by oxidative stress was signiﬁcantly increased during diabetes and was reversed by α-LA. Signiﬁcance of symbols: * comparison with
non-diabetic control animals and STZ + α-LA rats, two symbols: p < 0.01. Scale bar: 100 μm. All photomicrographs are at the same magniﬁcation.
Figure 3. Effects of α-lipoic acid (α-LA) treatment on neuronal and microglial activity at the spinal dorsal horn. Panel (A) presents the mean numbers per
section of Fos-IR neurons. Panels (B–E) are representative photomicrographs of L4 spinal cord section labelled for Fos (arrows) in control animals (B),
streptozotocin (STZ) + 4 w (C), STZ + saline (D) and STZ + α-LA (E) rats. Panel (F) presents the CD11b expression and panels (G–J) are representative
photomicrographs of L4 spinal cord sections labelled for CD11b in control animals (G), STZ + 4 w (H), STZ + saline (I) and STZ + α-LA (J) rats. α-LA
reversed the neuronal hyperactivity observed in STZ + 4 w and STZ + saline rats to control levels, but had no effect on microglial activation. Signiﬁcance
of symbols: * comparison with non-diabetic control animals and STZ + α-LA rats; § comparison with non-diabetic control group; two symbols: p < 0.01.
Scale bar: 100 μm. All photomicrographs are at the same magniﬁcation.
α-LA over KCC2 expression. As per the KCC2 role in neuronal
function, this co-transporter sets the intracellular chloride con-
centration and inﬂuences the role of GABA when binding to
GABAA ionotropic post-synaptic receptor. In normal condi-
tions, GABA binding to GABAA receptors induces chloride
inﬂux inhibiting neuronal activity [23]. During diabetes, the
reduced expression of KCC2 in the spinal cord leads to intra-
cellular chloride accumulation and GABA binding to GABAA
receptors induces chloride output, which results in neuronal
excitation [13]. In agreement, intrathecal administration of
bicuculline (GABAA receptor antagonist) in STZ-diabetic rats
elicits antinociception [13]. The decrease in KCC2 expression
has been shown to reduce KCC2 activity [16] and increase
neuronal responses in pathological conditions, other than dia-
betes, namely in axotomy, seizures and traumatic neuropathic
pain [23].
The beneﬁcial effects of α-LA treatment on blocking
behavioural signs of diabetic neuropathy have been ascribed to
its actions on peripheral nerve function [3,5]. In our study, we
cannot discard peripheral effects of α-LA treatment as we did
not evaluate nerve function. We used a short α-LA treatment,
which was implemented only after diabetic neuropathy was
established. Although this treatment clearly reversed neuronal
spinal hyperactivity, it was not so effective in mechanical noci-
ception. This is probably because of the fact that peripheral
nerve damage induced by diabetes is marked at the treatment
onset and, therefore, could not be corrected by our proto-
col. Previous studies also reported an incomplete reversal of
diabetes-induced peripheral nerve changes by α-LA, even with
higher doses and longer treatment period [24]. Whether the
higher effects of α-LA on the nociceptive activation of spinal
neurons indicate a preferential site of action of α-LA at the
spinal cordwill be investigated by performing intrathecal deliv-
eries ofα-LA. KCC2 is unlikely to represent the solemechanism
of α-LA action, as the treatment completely reversed neuronal
hyperactivity but elicited only a partial correction of KCC2
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Figure 4. Effects of α-lipoic acid (α-LA) treatment on potassium chloride co-transporter 2 (KCC2) expression at spinal dorsal horn. Panel (A) presents
KCC2 expression detected by immunohistochemistry. Panel (B) shows representative blots of KCC2 protein for each experimental group. Panels (C–F)
are representative photomicrographs of L4 spinal cord sections immunoreacted for KCC2. Antioxidant treatment with α-LA increased KCC2 expression,
but not to control levels. § comparison with non-diabetic control animals; # comparison with streptozotocin (STZ) + 4 w and STZ + saline groups; one
symbol: p < 0.05; two symbols: p < 0.01. Scale bar: 100 μm. All photomicrographs are at the same magniﬁcation.
expression. The inhibitory effects of α-LA on spinal neuronal
activity may also arise from its inhibitory actions on Ca(V)3.2
T-type calcium channels [25]. These channels are probably
to be involved, as painful diabetic neuropathy is reversed
by knockdown of Ca(V)3.2 T-type calcium channels through
intrathecal administration of antisense oligonucleotides [26].
Future studies will evaluate the relative contribution of KCC2
and Ca(V)3.2 T-type channels in the α-LA effects at spinal cord
during diabetes.
In summary, this study shows that α-LA presents central
effects during diabetic neuropathy by reversing the neuronal
hyperactivity at spinal dorsal horn, which could be partially
mediated by its effect on KCC2 expression and seems to be
independent from microglia activity. In a manner similar to
other areas of the central nervous system, it is possible that
oxidative stress in the spinal cord during diabetes decreases
surface expression of KCC2 in spinal neurons, triggered by its
dephosphorylation, which will induce functional changes of
this co-transporter [16]. The beneﬁcial effects of α-LA antiox-
idant treatment in reversing behavioural signs of diabetic
neuropathy in STZ-diabetic rats fully match data with other
antioxidants, namely the resveratrol [27] and vitamin E [28],
pointing to the importance of increasing antioxidant intake by
diabetic patients. As the diabetic neuropathy has common fea-
tures in type 1 and type 2 diabetes, but α-LA increases insulin
sensitivity and decreases glucose levels in the former, which
does not occur in similar treatment protocol of STZ-diabetic
rats [3], it is important to study if the neurobiological basis of
the beneﬁcial effects of α-LA in animal models of type 2 dia-
betes [29] are also based in corrections of KCC2 expression at
the spinal cord. The effects of α-LA are not conﬁned to patho-
logical conditions as α-LA has also beneﬁcial effects on healthy
animals and humans, namely, by: (i) increasing the expres-
sion and activity of antioxidant enzymes [30]; (ii) reducing the
oxidative stress damage [7]; and (iii) preventing neurodegener-
ative diseases [30]. These ﬁndings show that, besides its curative
effects, α-LA is a health promoter by preventing the disease.
Acknowledgements
This work was supported by Fundac¸a˜o para a Cieˆncia e Tec-
nologia (FCT; PTDC/SAU/64643/2006). C. Morgado is a PhD
fellow of FCT (SFRH/BD/21555/2005).
Conﬂict of Interest
C.M.helped in thedesign, conduct/data collection, analysis and
writing of the manuscript. P. P.-T. helped in the conduct/data
collection. I. T. helped in design and writing the manuscript.
All the authors have no conﬂict of interests.
740 Morgado et al. Volume 13 No. 8 August 2011
87
DIABETES, OBESITY AND METABOLISM original article
References
1. Lin J, Bierhaus A, Bugert P et al. Effects of R-(+)-α-lipoic acid on
experimental diabetic retinopathy. Diabetologia 2006; 49: 1089–1096.
2. Obrosova IG, Fathallah I, Lie E, Nourooz-Zadeh J. Early oxidative stress in
the diabetic kidney:effect of DL-alpha-lipoic acid. Free Radic Biol Med
2003; 34: 186–195.
3. Stevens MJ, Obrosova I, Cao X, van Huysen C, Greene DA. Effects of DL-α-
lipoic acid on peripheral nerve conduction, blood ﬂow, energy metabolism
and oxidative stress in experimental diabetic neuropathy. Diabetes 2000;
49: 1006–1015.
4. Quattrini C, Tesfaye S. Understanding the impact of painful diabetic
neuropathy. Diabetes Metab Res Rev 2003; 19: S2–S8.
5. Cameron NE, Jack AM, Cotter MA. Effect of α-lipoic acid on vascular
responses and nociception in diabetic rats. Free Radic Biol Med 2001;
31: 125–135.
6. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant.
Free Radic Biol Med 1995; 19: 227–250.
7. Borcea V, Nourooz-Zadeh J, Wolff SP et al. Alpha-lipoic acid decreases
oxidative stress even in diabetic patients with poor glycemic control and
albuminuria. Free Radic Biol Med 1999; 26: 1495–1500.
8. Haak E, Usadel KH, Kusterer K et al. Effects of alpha-lipoic acid on
microcirculation in patients with peripheral diabetic neuropathy. Exp Clin
Endocrinol Diabetes 2000; 108: 168–174.
9. Ziegler D, Ametov A, Barinov A et al. Oral treatment with α-lipoic acid
improves symptomatic diabetic polyneuropathy. Diabetes Care 2006; 29:
2365–2370.
10. Pop-Busui R, Sima A, Stevens M. Diabetic neuropathy and oxidative stress.
Diabetes Metab Res Rev 2006; 22: 257–273.
11. Lungu C, Dias JP, Franc¸a CE et al. Involvement of kinin B1 receptor and
oxidative stress in sensory abnormalities and arterial hypertension in an
experimental rat model of insulin resistance. Neuropeptides 2007; 41:
375–387.
12. Morgado C, Tavares I. C-fos expression at the spinal dorsal horn of
streptozotocin-induced diabetic rats. Diabetes Metab Res Rev 2007; 23:
644–652.
13. Jolivalt CG, Lee CA, Ramos KM, Calcutt NA. Allodynia and hyperalgesia in
diabetic rats are mediated by GABA and depletion of spinal potassium-
chloride co-transporters. Pain 2008; 140: 48–57.
14. Morgado C, Pinto-Ribeiro F, Tavares I. Diabetes affects the expression of
GABA and potassium chloride cotransporter in the spinal cord: a study in
streptozotocin diabetic rats. Neurosci Lett 2008; 438: 102–106.
15. Morgado C, Pereira Terra P, Cruz CD, Tavares I. Minocycline completely
reverses mechanical hyperalgesia in diabetic rats through microglia-
induced changes in the expression of the potassium chloride co-transporter
2 (KCC2) at the spinal cord. Diabetes Obes Metab 2011; 13: 150–159.
16. Wake H, Watanabe M, Moorhouse AJ et al. Early changes in KCC2
phosphorylation in response to neuronal stress result in functional
downregulation. J Neurosci 2007; 27: 1642–1650.
17. Wong A, Dukic-Stefanovic S, Gasic-Milenkovic J et al. Anti-inﬂammatory
antioxidants attenuate the expression of inducible nitric oxide synthase
mediated by advanced glycation endproducts in murine microglia. Eur
J Neurosci 2001; 14: 1961–1967.
18. Zimmermann M. Ethical guidelines for investigations of experimental pain
in conscious animals. Pain 1983; 16: 109–110.
19. Soultanakis RP, Melamede RJ, Bespalov IA et al. Fluorescence detection of
8-oxoguanine in nuclear and mitochondrial DNA of cultured cells using a
recombinant Fab and confocal scanning laser microscopy. Free Radic Biol
Med 2000; 28: 987–998.
20. Coggeshall RE. Fos, nociception and the dorsal horn. Prog Neurobiol 2005;
77: 299–352.
21. Milligan CE, Cunningham TJ, Levitt P. Differential immunochemical markers
reveal the normal distribution of brain macrophages and microglia in the
developing rat brain. J Comp Neurol 1991; 314: 125–135.
22. Tavares I, Lima D, Coimbra A. Neurons in the superﬁcial dorsal horn of the
rat spinal cord projecting to the medullary ventrolateral reticular formation
express c-fos after noxious stimulation of the skin. Brain Res 1993; 623:
278–286.
23. Payne J, Rivera C, Voipio J, Kaila K. Cation-chloride cotransporters in
neuronal communication, development and trauma. Trends Neurosci
2003; 26: 199–206.
24. Coppey LJ, Gellet JS, Davidson EP, Dunlap JA, Lund DD, Yorek MA. Effect
of antioxidant treatment of streptozotocin-induced diabetic rats on
endoneurial blood ﬂow, motor nerve conduction velocity, and vascular
reactivity of epineural arterioles of the sciatic nerve. Diabetes 2001; 50:
1927–1937.
25. Lee WY, Orestes P, Latham J et al. Molecular mechanisms of lipoic acid
modulation of T-type calcium channels in pain pathway. J Neurosci 2009;
29: 9500–9509.
26. Messinger RB, Naik AK, Jagodic MM et al. In vivo silencing of the Ca(V)3.2
T-type calcium channels in sensory neurons alleviates hyperalgesia in rats
with streptozocin-induced diabetic neuropathy. Pain 2009; 145: 184–195.
27. Ates O, Cayli SR, Yucel N et al. Central nervous system protection by
resveratrol in streptozotocin-induced diabetic rats. J Clin Neurosci 2007;
14: 256–260.
28. Kabay SC, Ozden H, Guven G et al. Protective effects of vitamin E on
central nervous system in streptozotocin-induced diabetic rats. Clin Invest
Med 2009; 32: E314–321.
29. Singh U, Jialal I. Alpha-lipoic acid supplementation and diabetes. Nutr Rev
2008; 66: 646–657.
30. Cantuti-Castelvetri I, Shukitt-Hale B, Joseph JA. Neurobehavioral aspects of
antioxidants in aging. Int J Dev Neurosci 2000; 18: 367–381.
Volume 13 No. 8 August 2011 doi:10.1111/j.1463-1326.2011.01399.x 741
88
  
 
 
 
 
 
 
Publication 5 
Neuronal hyperactivity at the spinal cord and 
periaqueductal grey during painful diabetic neuropathy: 
effects of gabapentin 
 
 
89
  
 
 
 
 
 
 
 
90
Neuronal hyperactivity at the spinal cord and periaqueductal grey during
painful diabetic neuropathy: Effects of gabapentin
Carla Morgado, Patrícia Pereira Terra, Isaura Tavares *
Institute of Histology and Embryology, Faculty of Medicine of Porto and IBMC, University of Porto, Portugal
a r t i c l e i n f o
Article history:
Received 23 July 2009
Received in revised form 4 November 2009
Accepted 27 November 2009
Available online 28 December 2009
Keywords:
c-fos
STZ diabetic rats
Descending modulation
Hyperalgesia
PAG
a b s t r a c t
Painful diabetic neuropathy may be due to impairments in descending modulation of nociceptive trans-
mission at the spinal cord. In the present study, streptozotocin diabetic rats (STZ rats) with neuropathic
symptoms (mechanical hypersensitivity) were used to perform a time-course evaluation of neuronal
activity at the spinal dorsal horn and at the periaqueductal grey matter (PAG), a major brainstem area
of pain modulation. The expression of Fos protein, a marker of nociceptive activation, progressively
increased at the spinal dorsal horn at 4 and 10 weeks. At the PAG, increases in Fos expression were
detected until the 4th week, with a reversal to baseline values at 10 weeks in all areas except the ventro-
lateral PAG. Co-localisation of Fos with NeuN ascertained the neuronal nature of Fos-expressing cells at
the spinal cord and PAG. Four weeks after diabetes induction, the effects of gabapentin (i.p. injection of
50 mg/kg, daily during 3 days) were assessed. Gabapentin decreased Fos expression at the spinal cord and
PAG and reversed mechanical hypersensitivity. The present study shows that diabetic neuropathy is
accompanied by a progressive increase of the spontaneous neuronal activity at the spinal cord. Changes
in descending modulation of nociceptive transmission from the PAG are likely to occur during diabetic
neuropathy, probably with exacerbation of facilitatory actions. The effects of gabapentin in reversing
the behavioural signs of diabetic neuropathy and neuronal hyperactivity in the spinal cord and PAG rein-
force the central causes of diabetic neuropathy and point to the central targets of the drug.
 2009 European Federation of International Association for the Study of Pain Chapters. Published by
Elsevier Ltd. All rights reserved.
1. Introduction
Diabetes is the most common cause of peripheral neuropathy
(Mokdad et al., 2000). It is frequently associated with mechanical
hyperalgesia, tactile allodynia and spontaneous pain (Courteix
et al., 1993; Benbow et al., 1994; Pertovaara et al., 2001). The
peripheral mechanisms of painful diabetic neuropathy are well
established but the effects at the central nervous system remain
poorly understood. The spinal cord is affected during diabetic neu-
ropathy (Pertovaara et al., 2001; Eaton et al., 2001). Using the c-fos
proto-oncogene as a marker of neuronal activation, an increased
activity of spinal dorsal horn neurons was recently detected in
streptozotocin-induced diabetic rats (STZ rats; Morgado and Tav-
ares, 2007). This agrees with electrophysiological recordings show-
ing increased activity of spinal neurons (Pertovaara et al., 2001),
some of which belong to the spinothalamic tract (Chen and Pan,
2002). Our previous c-fos study was performed 4 weeks after dia-
betes induction. It is unclear if the increased c-fos expression is a
transient reaction of spinal neurons to diabetes and if it reverses
with the progression of the disease.
The causes of that spinal nociceptive neuronal hyperactivity
during diabetic neuropathy remain unclear. It may derive from
the constant barrage of peripheral input (Burchiel et al., 1985),
but may also reﬂect impairments of descending modulation. The
midbrain periaqueductal grey (PAG) plays a key role in descending
pain control. It conveys to the spinal cord, pain modulation trig-
gered at higher brain centres (Behbehani, 1995; Vanegas and Scha-
ible, 2004). Increased neuronal activity at the PAG was proposed to
account to traumatic neuropathic pain (Burgess et al., 2002). In STZ
animals, imaging (Paulson et al., 2007) and pharmacology (Kamei
et al., 1992) studies indicate that the PAG appears to be affected.
Microinjection of higher doses of morphine in the PAG is necessary
to induce analgesia in STZ rats when compared to other pain mod-
els, indicating an opioid-dependent dysfunction of the PAG during
diabetic neuropathy (Kamei et al., 1992).
Gabapentin is a centrally-acting drug, frequently used as anal-
gesic in diabetic patients and STZ rats (Cesenã and Calcutt, 1999;
Vinik, 2005). Gabapentin inhibits glutamatergic excitatory neuro-
transmission at the spinal dorsal horn (Patel et al., 2000; Moore
et al., 2002) and acts on brain regions involved in pain control, such
as the locus coeruleus (LC; Hayashida et al., 2008). The effects of
1090-3801/$36.00  2009 European Federation of International Association for the Study of Pain Chapters. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ejpain.2009.11.011
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gabapentin in neuronal activity were never studied in diabetic
neuropathy.
In the present study, we used STZ rats to: (i) perform a time-
course study of neuronal activity at the spinal cord and PAG at 4
and 10 weeks, and (ii) evaluate the effects of gabapentin on behav-
iour and in neuronal activity in the spinal cord and PAG. Neuronal
activity was monitored using the c-fos method since it is a reliable
anatomical marker of activation by nociceptive-related stimuli
(Hunt et al., 1987; Harris, 1998; Coggeshall, 2005). Contrarily to
electrophysiological recordings, c-fos expression allows to evaluate
large neuronal populations and to determine their precise anatom-
ical locations (Coggeshall, 2005).
2. Methods
2.1. Animals
Adult male Wistar rats (12 weeks age, Charles River, Barcelona,
Spain), weighing 250–350 g at the beginning of the experiments,
were used. The animals were housed twice per cage in a room with
a constant temperature (22 ± 2 C) and humidity (55 ± 5%) and
with 12 h light/dark cycle, and received food and water ad libitum.
Experiments were performed in accordance with the European
Community Council Directive 86/609/EEC and the ethical guide-
lines for the study of pain in conscious animals (Zimmermann,
1983).
2.2. Diabetic neuropathy
Type 1 diabetes was induced by an intraperitoneal (i.p.) injec-
tion of STZ (60 mg/kg body weight; Sigma–Aldrich, St. Louis,
USA). Three days later, the glucose concentration was measured
in a blood sample collected from the tail vein using Accu Chek
Sensor Comfort (Roche Diagnostics, Germany). Only rats with glu-
cose concentrations higher than 270 mg/dl were considered dia-
betic (Calcutt, 2004b), being included in the study as the ‘‘STZ”
group.
Mechanical sensitivity is the pain modality more consistently
changed in different models of diabetes (Courteix et al., 1993; Mal-
cangio and Tomlinson, 1998; Fox et al., 1999; Pertovaara et al.,
2001; Calcutt et al., 2004a; Morgado and Tavares, 2007; Morgado
et al., 2008). Mechanical hyperalgesia and allodynia were here
evaluated since they are typical in this rat strain (Malcangio and
Tomlinson, 1998; Pertovaara et al., 2001; Morgado and Tavares,
2007; Morgado et al., 2008; Wodarski et al., 2009). Behavioural
evaluation was performed before diabetes induction (time 0) and
at 4 and 10 weeks using the paw pressure test (PPT, Ugo-Basile;
Comerio, VA, Italy; n = 5) and the dynamic plantar aesthesiometer
(DPA, Ugo-Basile; Comerio, VA, Italy; n = 5). During the 8 days prior
to the tests, the animals were daily handled by the experimenter
for habituation purposes. In the paw pressure test, ascending
mechanical forces were applied to the dorsal surface of right hind-
paw and the mechanical force (in grams) that induced hindpaw
withdrawal was recorded. The paw withdrawal threshold (PWT)
of each animal was the average of three consecutive measure-
ments, taken with 5 min intervals. In the dynamic plantar aesthes-
iometer test, animals were placed in clear acrylic boxes with a
metal grid ﬂoor and acclimatised for 15 min before testing. The
stimulus was applied with a ﬁlament (0.5 mm), which applied a
linearly increasing force (2.5 g/s) to the plantar surface of the hind
paw. The force necessary to elicit a paw withdrawal was recorded.
The PWT was calculated as the average of three consecutive tests
with at least 5 min between each test. The statistical analysis
was performed using One-Way Analysis of Variance (ANOVA) fol-
lowed by Tukey post hoc test for multiple comparisons.
2.3. c-fos Evaluation
For the study of c-fos expression at the spinal cord and PAG, the
STZ rats were deeply anaesthetised with an i.p. injection of 35%
chloral hydrate (1 ml/kg body weight) and sacriﬁced at one of
the following time-points (n = 5 per time-point): 0 (prior to STZ
injection), 4 and 10 weeks. The anaesthesia was performed
30 min after completion of behaviour evaluation. Five addition
STZ rats, naïve as to behavioural evaluation were perfused 4 weeks
after STZ injection to evaluate Fos expression at the spinal cord and
PAG. Vascular perfusion was performed with 200 ml of phosphate-
buffered saline (PBS), followed by 1000 ml of 4% paraformaldehyde
in 0.1 M phosphate buffer (PB), pH 7.4. In order to ascertain the
glucose levels in STZ rats previously assessed by Accu Check Sensor
Comfort, the colorimetric hexokinase assay (Olympus AU5400;
Germany) was performed in 1 ml of blood collected immediately
before vascular perfusion in non-fasting animals. Spinal segments
L4–L5 and the brainstem were removed, post-ﬁxed for 2–4 h in
the same ﬁxative, and cryoprotected overnight in 30% sucrose in
PB. Coronal sections, 40 lm thick, were obtained using a freezing
microtome, and every fourth section was collected in 0.1 M PBS.
Fos protein was immunohistochemically detected using the avi-
din–biotin–peroxidase method, as described previously (Morgado
and Tavares, 2007). Brieﬂy, the sections were treated with 1%
hydrogen peroxidase for 10 min to inhibit endogenous peroxidase
activity before incubation in a blocking solution of 10% normal
swine serum in 0.3% Triton X 100 in PBS (PBST) with 0.1 M glycine
for 2 h. The sections were then incubated during two overnights at
4 C in the primary antibody, rabbit anti-Fos (Ab5; Oncogene; Ger-
many), diluted at 1:10,000 in PBST. After being washed in PBST, the
sections were incubated in biotinylated swine anti-rabbit immu-
noglobulin (Dako, Denmark), diluted at 1:200, for 1 h, at room tem-
perature. The sections were then washed in PBST, incubated for 1 h
in the avidin–biotin complex (Vectastain, Vector Laboratories, USA)
followed by a mixture of 10 mg diaminobenzidine, 5 ll of 30%
hydrogen peroxide in 20 ml of Tris–HCl 0.05 M, pH 7.6. The num-
bers of Fos-immunoreactive (Fos-IR) cells occurring bilaterally in
laminae I–II (superﬁcial dorsal horn) and III–V (deep dorsal horn)
were counted in 20 spinal sections in which laminae delimitation
was performed according to Paxinos and Watson (Paxinos and
Watson, 2005), as described previously (Morgado and Tavares,
2007). The numbers of Fos-IR cells occurring in 10 sections encom-
passing the PAG were counted. The PAG was subdivided in dorsal
medial PAG (DMPAG), dorsal lateral PAG (DLPAG), lateral PAG
(LPAG) and ventrolateral PAG (VLPAG), according to Paxinos and
Watson (Paxinos and Watson, 2005). Mean numbers of Fos-IR cells
per section were compared by ANOVA followed by Tukey post hoc
test for multiple comparisons.
In order to determine the neuronal nature of Fos-IR cells, a dou-
ble immunoﬂuorescence reaction using NeuN as a neuronal marker
was performed in one additional set of spinal and brainstem sec-
tions from animals with 4 and 10 weeks of diabetes. Brieﬂy, the
sections were treated with 1% borohydrate for 20 min before incu-
bation in a blocking solution of 10% normal goat serum in PBST
with 0.1 M glycine for 2 h. The sections were then incubated during
two overnights at 4 C in a mixture of the rabbit anti-Fos referred
above (1:5000) and mouse anti-NeuN (1:300; Chemicon, Ger-
many). After being washed in PBST, the sections were incubated,
for 1 h at room temperature, in a mixture of two ﬂuorescent sec-
ondary antibodies: goat anti-rabbit Alexa 488 and goat anti-mouse
Alexa 594 (both at 1:1000; Molecular Probes, USA). Sections were
observed using an Apo Tome microscope (Zeiss, Germany) and the
images were acquired using a high-resolution digital camera cou-
pled to a computer. For the acquisition of higher magniﬁcations,
serial optical planes separated by 0.5 lm were collected in the z-
axis. Merged images were obtained using the Apo Tome software.
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2.4. Gabapentin treatment
Four weeks after STZ injection, the rats received a daily i.p.
injection of gabapentin (‘‘GBP” group, 50 mg/kg; Merck, Portugal)
or saline (‘‘saline” group) during 3 days. The gabapentin dose was
deﬁned based on the analgesic effects in several pain models,
including diabetic neuropathy (Cesenã and Calcutt, 1999; Wodar-
ski et al., 2009). The behavioural responses were evaluated
30 min after the last gabapentin injection using PPT and DPA tests,
as described above. An additional non-diabetic age-matched con-
trol animal group, not submitted to any treatment, was also eval-
uated (‘‘control” group).
All animals were sacriﬁced by vascular perfusion about 1 h after
the last gabapentin injection. The spinal segments L4–L5 and the
brainstems were removed, and immunohistochemically processed
for Fos detection. Fos-IR cells in the spinal cord and PAG were
counted following the experimental protocols mentioned above
(see c-fos evaluation). The mean numbers of Fos-IR cells per section
were compared by independent sample t test. Behavioural data
analysis was performed by ANOVA followed by Tukey post hoc test
for multiple comparisons.
3. Results
3.1. Characterisation of experimental groups
STZ rats presented signiﬁcant lower body weights and higher
blood glucose concentrations at 4 and 10 weeks when compared
with values obtained prior diabetes induction (Table 1). In the
two behavioural tests (PPT and DPA), the PWTs of STZ rats were
signiﬁcantly decreased at 4 week post-injection and remained
low until the 10th week, conﬁrming the painful neuropathic
condition. No differences in PWTs were detected from 4 to
10 weeks (Table 1).
3.2. c-fos Expression at spinal cord and PAG
Only a few Fos-IR cells were detected prior to STZ injection in
the spinal dorsal horn (Fig. 1A, B and E). Statistically signiﬁcant in-
creases in the numbers of Fos-IR neurons were detected at 4 weeks
(Fig. 1A, C and F), and even in a more pronounced manner at
10 weeks (Fig. 1A, D and G), with statistical differences between
the two time-points. The increases in Fos expression affected sim-
ilarly the superﬁcial (laminae I–II) and deep dorsal horn (laminae
III–V). No differences in Fos expression in the spinal cord were de-
tected between STZ rats subjected to behavioural evaluation and
STZ rats naïve as to behavioural evaluation (superﬁcial dorsal horn:
evaluated rats 46.2 ± 16.4 vs. 43.9 ± 16.2 in non-evaluated; deep
dorsal horn: evaluated rats 158.0 ± 69.0 vs. 131.0 ± 69.4 in
non-evaluated).
In all PAG sub-regions, the expression of Fos was very low
before STZ injection (Fig. 2A, B and E). Signiﬁcant increases in the
numbers of Fos-IR cells were detected in all PAG sub-regions at
4 weeks (Fig. 2A, C and F), which persisted only at the VLPAG at
the 10th week, whereas in other PAG areas a reversal to baseline
levels was detected (Fig. 2A, D and G). No differences in Fos expres-
sion in the PAG were detected between STZ rats subjected to
behavioural evaluation and STZ rats naïve as to behavioural evalu-
ation (DMPAG: evaluated rats 43.0 ± 5.1 vs. 36.0 ± 15.2 in non-
evaluated; DLPAG: evaluated rats 48.0 ± 7.0 vs. 45.5 ± 21.2 in
non-evaluated; LPAG: evaluated rats 122.0 ± 9.7 vs. 92.2 ± 42.2 in
non-evaluated; VLPAG: evaluated rats 65.8 ± 9.1 vs. 67.0 ± 23.5 in
non-evaluated).
Double-immunostaining for Fos and NeuN at the spinal cord
(Fig. 3A–C) and PAG (Fig. 3D–F) conﬁrmed that the expression of
Fos was conﬁned to neurons, since a total co-localisation was de-
tected both at 4 and 10 weeks post-injection.
3.3. Effects of gabapentin treatment
Gabapentin treatment improved mechanical nociception,
restoring PWTs to values similar to age-matched non-diabetic con-
trol rats both in the PPT (Fig. 4A) and the DPA (Fig. 4B) behavioural
tests. The glycemic values and body weights of gabapentin-treated
rats were similar to STZ rats with the same time of diabetes (blood
glucose concentration (mg/dl): STZ rats: 824 ± 98.7 vs. Gabapen-
tin-treated STZ rats: 787 ± 86.2; body weights (g): STZ rats:
282 ± 13.4 vs. Gabapentin-treated STZ rats: 286 ± 10.6).
Gabapentin-treated rats presented signiﬁcant decrease in spinal
Fos expression when compared with saline-treated rats, both at
the superﬁcial and deep dorsal horn (Fig. 4C). The numbers of
Fos-IR neurons in all PAG sub-regions were also reduced by gaba-
pentin treatment (Fig. 4D).
4. Discussion
This study demonstrates that diabetes is associated with over-
time increases in Fos expression at the spinal cord. In the PAG,
the increases in Fos expression occurred in all regions at 4 weeks
whereas at 10 weeks they were maintained only at the VLPAG.
Gabapentin treatment at 4 weeks prevents the increases in Fos
expression and reverses the behavioural signs of diabetic
neuropathy.
Our study shows that Fos expression at the spinal cord and PAG
of diabetic rats occurs exclusively in neurons. This is important
since Fos expression may occur in glia (Reissig et al., 2008) and
glial activation increases in diabetic rats (Wodarski et al., 2009;
Tsuda et al., 2008). The increased neuronal activity at the spinal
cord of STZ diabetic rats detected agrees with previous reports
(Pertovaara et al., 2001; Chen and Pan, 2002; Morgado and Tavares,
2007) whereas the increased neuronal activity at the PAG of dia-
betic rats was here reported for the ﬁrst time. The value of the
analysis of Fos expression to monitor the nociceptive activity of
large neuronal populations is solid (Coggeshall, 2005) and is rein-
forced by the present ﬁndings. Fos expression was previously dem-
onstrated at the spinal cord in several chronic pain models in the
absence of additional stimulation, which also occurred in STZ rats
(Williams et al., 1991; Kajander et al., 1996; Catheline et al., 1999;
Tokunaga et al., 1999; Bester et al., 2000; Dai et al., 2001; Kosai
et al., 2001; Tsai et al., 2002; Coggeshall, 2005; Jergova and Cizk-
ova, 2005; Morgado and Tavares, 2007). In the brain of STZ rats,
Fos expression was shown to increase in some regions (Zheng
et al., 2002; Revsin et al., 2005) and decrease in others (Zheng
et al., 2002; Jang et al., 2003; Gouty et al., 2003), showing that it
cannot be a direct result of STZ or indicate putative physiological
disturbances of diabetic animals. That the gabapentin treatment
decreased Fos expression at the spinal cord and PAG and reversed
Table 1
Body weights, glycemia and PWT of experimental groups.
STZ rats Week 0 Week 4 Week 10
Weight (g) 303 ± 8.6 282 ± 13.4a 286 ± 10.4a
Glycemia (mg/dl) 118 ± 6.3 824 ± 98.7a 666 ± 66.3a
PWT (g) PPT 110 ± 6.7 68 ± 13.8a 69 ± 10.9a
DPA 24 ± 1.4 14 ± 1.1a 13 ± 1.1a
Time-course changes at weights, glycemia and mechanical nociceptive behavioural
responses (PPT and DPA behavioural tests) of STZ rats along the time of diabetes.
Mean values ± SEM.
a p < 0.01 vs. week 0.
C. Morgado et al. / European Journal of Pain 14 (2010) 693–699 695
93
mechanical hyperalgesia in STZ rats further reinforces that Fos
expression is independent of the diabetic condition.
Previous studies showing increased activity of spinal neurons
only evaluated one time-point and did not perform time-course
analysis (Pertovaara et al., 2001; Chen and Pan, 2002; Morgado
and Tavares, 2007;). By showing that Fos expression at the spinal
cord increases along the time of diabetes (4 and 10 weeks), the
present study indicates, for the ﬁrst time, that spontaneous neuro-
nal activity at the spinal cord increases along the time of the dis-
ease. Another new result of the present study is the higher
increase in Fos at the deep dorsal horn of L4–L5 segments when
compared with our previous reports at T13–L3 segments (Morgado
Fig. 1. Time-course changes in Fos expression in the spinal dorsal horn of segments L4–L5. Panel A depicts the mean numbers (SEM) of Fos-IR neurons per section and panels
B–D show diagrams of L4 illustrating Fos immunoreaction in rats prior (B) and at 4 (C) and 10 (D) weeks after induction of diabetes. Each dot represents two Fos-IR neurons.
Panels E–F are photomicrographs of Fos labelled neurons in rats prior to diabetes induction (E) and at 4 (F) and 10 (G) weeks post-induction. The numbers of Fos-IR neurons
increased signiﬁcantly at 4 and 10 weeks after diabetes induction, affecting the superﬁcial (laminae I–II) and deep (laminae III–V) dorsal horn. Signiﬁcance of symbols:
p < 0.01, week 4 vs. all other time-points, ##p < 0.01, week 10 vs. the other time-points. Scale bars in G: 100 lm (all photomicrographs are at the same magniﬁcation).
Fig. 2. Time-course changes in Fos expression at PAG. Panel A presents the mean numbers (SEM) of Fos-IR neurons per section in the DMPAG, DLPAG, LAPG and VLPAG. Panels
B–D show diagrams of the PAG illustrating the distribution of Fos immunoreaction in STZ rats prior (B) and 4 (C) and 10 (D) weeks after diabetes induction. Each dot
represents two Fos-IR neurons. Panels E and F are photomicrographs showing Fos labelled neurons in rats prior to diabetes induction (E) and at 4 (F) and 10 (G) weeks post-
induction. A signiﬁcant increase in Fos levels was observed at VLPAG in STZ rats at 4 and 10 weeks. Comparison with time-point 0 weeks. One symbol: p < 0.05, two symbols:
p < 0.01. Scale bars in G: 100 lm (all photomicrographs are at the same magniﬁcation).
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and Tavares, 2007). It is possible that these differences are related
to the fact that L4–L5 segments receive input from the hindlimb
and a prevalence of a distal affectation occurs in diabetes (Calcutt,
2004b). The overtime increase in spinal c-fos expression was not
accompanied by parallel increases in mechanical sensitivity. Sev-
eral explanations may be raised for the dissociation between Fos
Fig. 3. Photomicrographs of sections with double immunodetection of Fos (green, A, D) and NeuN (red, B, E) at the spinal dorsal horn (A–C) or VLPAG (D–F) of rats 4 weeks
after diabetes induction. In C and F the merged images demonstrate the total co-localisation of Fos and NeuN. The insets show details of the labelling after optical sectioning
(18 optical sections). Scale bar in C and F: 50 lm; scale bar of insets: 25 lm.
Fig. 4. Effects of gabapentin (GBP) treatment in paw withdrawal thresholds (A, B), and Fos expression at the spinal dorsal horn (C) and PAG (D). Gabapentin signiﬁcantly
increased the paw withdrawal threshold to levels similar to the non-diabetic ‘‘control” group both in PPT (A) and DPA (B) behavioural tests. Fos expression at the spinal dorsal
horn and PAG was signiﬁcantly lower in STZ rats treated with gabapentin than in saline-inject STZ rats. Signiﬁcance of symbols: /p < 0.05/p < 0.01 – Gabapentin- vs. saline-
injected rats.
C. Morgado et al. / European Journal of Pain 14 (2010) 693–699 697
95
expression and behavioural analysis. A positive correlation be-
tween the magnitude of spinal Fos expression and behavioural re-
sponses is only achieved if Fos is directly evoked by the
behavioural tests (Presley et al., 1990; Bullit et al., 1992; Herdegen
and Leah, 1998). In the present study, Fos expression was not elic-
ited by the behavioural tests since no differences were detected be-
tween diabetic rats naïve to behavioural evaluation and diabetic
rats that underwent behavioural analysis. This agrees with our pre-
vious results showing that innocuous stimulation during 2 h does
not increase Fos expression in the spinal cord (Morgado and Tav-
ares, 2007). Diabetic neuropathy appears to differ from inﬂamma-
tory pain, in which a brief innocuous stimulus is enough to trigger
Fos expression at the spinal cord (Ma and Woolf, 1996; Pinto et al.,
2007). The need to evaluate if spontaneous pain increases along
the time of diabetes, as suggested by the present data, may be im-
paired by the lack of reliable methods to study spontaneous pain in
animals, a major caveat of basic pain research (Chizh et al., 2009).
Another issue to evaluate is if the increase in Fos expression in the
spinal cord of STZ rats is accompanied by Fos increases at the dor-
sal root ganglion (DRG) neurons, which seems likely since other
pain studies demonstrate parallel increases in the spinal cord
and DRGs (e.g. Zhang et al., 2009). Since diabetic rats present in-
creased spontaneous primary afferent activity (Burchiel et al.,
1985) it is expected that DRGs neurons of these animals present
higher Fos expression.
The data on increased neuronal activation at the PAG of STZ rats
deserves a special analysis since it was recently suggested that
neuronal activity at the PAG of STZ rats is reduced using a blood-
ﬂow dependent imaging technique (Paulson et al., 2007). Besides
differences in animal strain, dose of STZ for diabetes induction
and the time-point evaluated (6 weeks), the opposite ﬁndings
may be due to some limitations of blood-ﬂow dependent tech-
niques to study the diabetic brain, inasmuch that impaired brain
ﬂow and vasoreactivity occur during diabetes (Last et al., 2007).
The magnitude and time-dependent increases in Fos expression
at the PAG exhibited regional changes that may be explained by
the role of the PAG sub-regions. Only the VLPAG maintained higher
Fos expression at 10 weeks. The VLPAG is the area that conveys the
majority of descending modulatory input (Behbehani, 1995; Keay
and Bandler, 2004). It is likely that increased facilitation of noci-
ceptive transmission from the PAG occurs during diabetic neurop-
athy, in a manner similar to other chronic pain models (Vanegas
and Schaible, 2004; Lovick, 2008). The PAG, long considered to in-
hibit pain transmission at the spinal cord, was recently shown to
exert also facilitation (Vanegas and Schaible, 2004; Lovick, 2008).
Besides the increase in facilitation, a decrease in the inhibitory ef-
fects of the PAG could also occur. This is supported by the fact that
an important contingent of VLPAG neurons is made of GABAergic
interneurons that express opioid receptors (Vaughan et al., 1997;
Commons et al., 2000) and higher doses of morphine need to be in-
jected in the PAG of STZ rats to induce analgesia (Kamei et al.,
1992). Studies that assess the neurochemical nature of Fos-IR neu-
rons at the VLPAG, along with pharmacological manipulations of
the VLPAG will be performed to fully evaluate the implications of
the present ﬁndings. Besides indicating that nociceptive modula-
tion from the VLPAG is progressively impaired during diabetes,
our results show increases in Fos expression in other PAG areas
only at 4 weeks, namely at the LPAG, DMPAG and DLPAG. The LPAG
is involved in responses to ‘‘escapable” physical stressors, such as
acute noxious stimulation (Keay and Bandler, 2004) whereas the
DMPAG and DLPAG are mainly activated in response to fear and
anxiety (Behbehani, 1995; Keay and Bandler, 2004). These results
suggest that it is important to evaluate if those physiological
parameters (stress, fear and anxiety) are higher at 4 than at
10 weeks of diabetes or if the decreases at 10 weeks are due to
adaptation of CNS to such conditions.
Gabapentin was shown to reduce neuronal activity at the spinal
cord and PAG and strongly ameliorate mechanical nociception. The
mechanisms of the analgesic action of gabapentin during diabetic
neuropathy are unclear. Our study suggests that the inhibition of
neuronal hyperactivity at the spinal cord and PAG could account
for the analgesic efﬁcacy of gabapentin in diabetic neuropathy.
The present study does not clarify the local of action of gabapentin.
It may act directly on the spinal cord, reducing ascending transmis-
sion of nociceptive input. Gabapentin may also reduce neuronal
activity at the PAG activity and decrease neuronal activation at
the spinal cord, by depressing descending facilitation. An action
of gabapentin in other brain areas cannot be excluded inasmuch
that is know to target brain areas devoted to pain control, such
as the LC (Hayashida et al., 2007, 2008). Instillation of gabapentin
in the PAG and intrathecal administration will be performed in
STZ rats. Besides determining the central targets of gabapentin in
diabetic neuropathy, we will also study the role of glia. A role for
microglia in the increase of neuronal activity at the spinal cord
was demonstrated in several neuropathic pain models (Cao and
Zhang, 2008; Inoue and Tsuda, 2009; Owolabi and Saab, 2006),
namely of diabetic neuropathy (Tsuda et al., 2008; Wodarski
et al., 2009). Taking into account that gabapentin reverses microg-
lia hyperactivity in the spinal cord of diabetic rats (Wodarski et al.,
2009), it is important to evaluate if gabapentin-induced decrease in
neuronal spinal activity is mediated by inhibition of the microglia.
In conclusion, diabetes induced long-term hyperactivity at the
spinal dorsal horn and PAG, which seems to be due to central ef-
fects of the disease. It is now important to study more deeply the
central mechanisms namely to establish if they are only caused
by the increased bidirectional transmission between the spinal
cord and the brain, as in several chronic pain conditions (Terayama
et al., 2000; Pinto et al., 2006) or if speciﬁc features of diabetes,
such as insulin deprivation, may also affect the function of spinal
and PAG neurons (Freychet, 2000). The knowledge of the central
mechanism involved in pain during diabetic neuropathy can pro-
vide the substrate for the development of more effective and selec-
tive pharmacological analgesics for painful diabetic neuropathy.
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Painful diabetic neuropathy (PDN) induces neuronal hyperactivity at the spinal cord and periaqueductal gray
(PAG), a key area in descending nociceptive modulation. Since the PAG uses relay stations at serotoninergic
and noradrenergic brainstem areas, we determined the serotonin and noradrenaline levels at the spinal cord
of streptozotocin-diabetic rats and at those brainstem areas (serotoninergic rostroventromedial medulla and
noradrenergic A5 and A7 cell groups). Since, during diabetes, the levels of insulin growth factor 1 (IGF1)
decrease, reducing its neurotrophic effect in the brain, we also studied the effects of IGF1 treatment. Oneweek
after diabetes induction, subcutaneous injections of IGF1 (2.5 mg/kg) were performed during 3 weeks. Body
weights, glycemia, and mechanical nociception were weekly evaluated until the end of the study, the time
when the animals were subjected to a modiﬁed formalin test to study chemical allodynia. Serotonin and
noradrenaline levels were quantiﬁed by ELISA at the spinal cord, whereas at the brainstem, the quantiﬁcation
was performed by immunohistochemistry against, respectively, tryptophan hydroxylase (TpH) or tyrosine
hydroxylase (TH). STZ-diabetic rats exhibited mechanical hyperalgesia and chemical allodynia, along with
higher spinal levels of serotonin and noradrenaline and higher numbers of neurons expressing TpH at the
RVM and TH at the A5 noradrenergic cell group. Treatment with IGF1 prevented the behavioral signs of PDN
and reversed the neuronal hyperactivity at the spinal cord and ventrolateral PAG and the neurochemical
changes at the spinal cord and at the brainstem. Based on the facilitatory role of serotoninergic and
noradrenergic descending modulation during chronic pain, the increased serotonin and noradrenaline
innervation of the dorsal horn in STZ-diabetic rats may probably account for enhanced pain during PDN. The
beneﬁts of IGF1 in PDN are probably due to blockade of the increased peripheral input to the somatosensory
system, but direct central actions cannot be discarded. The value of IGF1 in PDN treatment deserves further
evaluation.
© 2011 Elsevier Inc. All rights reserved.
Introduction
Neuropathy affects a large portion of diabetic patients. Their quality
of life is further reduced due to pain complaints, which occurs in about
onequarter of patientswith diabetic neuropathy (Quattrini and Tesfaye,
2003; Tesfaye, 2009). Painful diabetic neuropathy (PDN) is character-
izedbyspontaneouspain,mechanical hyperalgesia, and tactile allodynia
(Tesfaye, 2009). It is accompanied by functional and neurochemical
changes at peripheral nerves, spinal cord, and supraspinal pain control
areas (Sima, 2003; Selvarajah et al., 2006, 2008; Morgado and Tavares,
2007; Morgado et al., 2010). Streptozotocin-diabetic rats (STZ-diabetic
rats) present spontaneous activity of spinal dorsal horn neurons
(Pertovaara et al., 2001; Chen and Pan, 2002; Morgado and Tavares,
2007; Morgado et al., 2010). Increased neuronal activity was recently
demonstrated in a key brainstem center of pain modulation—the peri-
aqueductal gray matter (PAG; Morgado et al., 2010). The PAG does not
project directly to the spinal cord but uses relay stations located at the
brainstem, with a well-known involvement of the rostroventromedial
medulla (RVM; Millan, 2002; Heinricher et al., 2009). Descending
nociceptive modulation is performed by the release of serotonin and
noradrenaline at the spinal cord (Millan, 2002). Serotoninergic
innervation of the spinal dorsal horn is mainly originated from the
RVM.Noradrenergic innervation derivesmainly from theA5, A6, andA7
cell groups of the brainstem, with variable contributions of each area in
different rat strains (Proudﬁt, 2002).Whereasdescendingmodulation is
known to inhibit acute pain, during chronic pain situations, an
imbalance of inhibitory and facilitatory actions occurs (Porreca et al.,
2002). Impairment of descending inhibition and enhancement of
facilitation are proposed to increase nociceptive transmission at the
spinal cord during chronic pain (Tracey and Mantyh, 2007). The
participation of the RVM and noradrenergic cell groups in potentiating
chronic pain was demonstrated in inﬂammatory (Howorth et al., 2009)
and traumatic neuropathic pain models (Ma and Eisenach, 2003;
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Hayashida et al., 2008), butwith variable degrees depending on the pain
condition (Porreca et al., 2002). During PDN, the role of serotoninergic
and noradrenergic areas in descending modulation was never studied.
Inconsistent results were obtained as to the levels of serotonin in the
brainstem and spinal cord of STZ-diabetic rats (Sandrini et al., 1997;
Padayatti and Paulose, 1999; Gallego et al., 2003). As to the
noradrenergic system, diabetes-induced increases in the levels of
noradrenaline were reported at the brainstem and spinal cord (Bitar
et al., 1999; Bitar and Pilcher, 2000). However, the brainstem areas that
are affected by diabetes and account for those changes were never
evaluated. Supporting a role of descending serotoninergic and norad-
renergic systems in PDN, antidepressant drugs that act on the reuptake
of serotonin and noradrenaline are effective in PDN treatment (Tesfaye,
2009).
Hyperglycemia is no longer considered the exclusive etiological
factor of PDN (Sima, 2003; Pierson et al., 2003). It has been suggested
that insulin growth factor 1 (IGF1) deprivation, which occurs in type 1
diabetes, may account to the higher severity of PDN in this type of
diabetes, in comparison to type 2 (Ishii, 1995; Schmidt et al., 1999;
Sima and Kamiya, 2006; Zhuang et al., 1996). Further supporting a
role of IGF1 in diabetic neuropathy, it was shown that the reduction of
circulating levels of IGF1 is greater in patientswith neuropathy than in
those without neuropathic complaints (Migdalis et al., 1995; Guo
et al., 1999). IGF1 exhibit glycemia-independent neuroprotective
effects, preventing peripheral nerve damage and promoting nerve
regeneration, which may account for the analgesic ability of IGF1
during PDN (Ishii, 1995; Schmidt et al., 1999; Zhuang et al., 1996; Piriz
et al., 2009). Suppression of IGF1 actions and downregulation of IGF1
receptors was demonstrated in the brain of diabetic rats (Li et al.,
2005; Zhang et al., 2008; Sima et al., 2009), but no studies were ever
directed to the speciﬁc brainstem areas involved in descending pain
control. Considering the aforementioned information and the occur-
rence of IGF1 receptors at the brainstem (Folli et al., 1994), we
performed a double-goal study. First, wewanted tomeasure the levels
of serotonin and noradrenaline in the spinal cord of STZ-diabetic rats
and the respective contribution of the serotoninergic and noradren-
ergic brainstem centers referred above. Second, we aimed to evaluate
if treatmentwith IGF1 doses that do not reverse hyperglycemia affects
the behavioral signs of PDN, neuronal hyperactivity at the PAG and at
the spinal cord, and serotoninergic and noradrenergic brainstem
systems.
Materials and methods
Animals
A total of 40maleWistar rats (Charles River Laboratories, Barcelona,
Spain), weighing 280–300 g at the beginning of the experiments, were
used. The experiments were performed in accordance with the ethical
guidelines of the European Community Council Directive 86/609/EEC
and of the International Association for the Study of Pain in conscious
animals (Zimmermann, 1983).
Animals were housed 2 per cage, in a room with constant
temperature (22±2 °C) and humidity (55%±5%) and a 12-h light/
dark cycle, and received food and water ad libitum. The animals were
daily handled by the experimenter for habituation purposes and were
used according to the general experimental procedures summarized in
Fig. 1.
Induction of diabetes
Diabetes was induced in 20 rats by an intraperitoneal (i.p.)
injection of STZ (60 mg/kg body weight) dissolved in 1 M citrate
buffer (pH=4.5). Twenty rats received equal volumes of the vehicle
(control group). Three days after the injections, glucose concentra-
tion was measured in tail vein blood samples using a glucose oxidase
impregnated test strip (Accu Chek Sensor Comfort, Roche Diagnos-
tics, Germany). Only rats with glucose concentration higher than
270 mg/dl were considered diabetic and included in the STZ group.
All the animals were weekly weighed and daily observed during the
study.
Treatment protocol
One week after vehicle or STZ injection, the rats were injected
subcutaneously with 2.5 mg/kg body weight of recombinant human
IGF1 (STZ+IGF1 group; n=10; control+IGF1 group; n=10) or
300 μl of saline (STZ+saline group; n=10; control+saline group;
n=10). All animals were injected 3 times per week during 3 weeks.
The injectionswere performed at the same time of the day (10 h, a.m.)
and were evenly distributed throughout the week (Mondays,
Wednesdays, and Fridays). Immediately before the injections of
IGF1 or saline, blood glucose concentrations were measured as above
Fig. 1. Schematic overview of the experimental procedures. Each experimental group included 5 animals. Behavioral evaluation was performed using the Randall–Selitto (RS) and
formalin (FT) tests. Animals were sacriﬁced at 4 weeks post-injection by vascular perfusion or decapitation. Spinal cord and brainstem sections were immunoreacted against Fos
protein, TpH, or TH and noradrenaline and serotonin contents were quantiﬁed in lumbar spinal cord homogenates.
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to conﬁrm the maintenance of hyperglycemia in STZ-diabetic rats.
Prior to the sacriﬁce, 1 ml of blood was collected by cardiac punction
and non-fasting glucose levels were quantiﬁed by the colorimetric
hexokinase assay (Olympus AU5400; Germany), as described previ-
ously (Wright et al., 1971).
Behavioral tests
Mechanical nociception was weekly evaluated using the Randall–
Selitto test (Ugo-Basile, Comerio, Italy), as described previously
(Morgado et al., 2010). Brieﬂy, an increasing pressure was applied
onto the dorsal surface of right hindpaw with a cone-shaped plunger.
The paw withdrawal threshold (PWT) was deﬁned as the force, in
grams, at which the rat withdrew the paw. The PWT of each animal
was the average of three consecutive measurements, taken at 5-min
intervals.
At the day after the last injection of IGF1 or saline, a formalin test
modiﬁed to evaluate chemical allodynia in STZ-diabetic rats was
performed as described previously (Freshwater and Calcutt, 2005).
Brieﬂy, the animals were injected with 50 μl of 0.2% formalin into the
right hindpaw dorsum, immediately placed in an individual open
Plexiglas chamber (10×20×24 cm) and their behavior was recorded
during the following 60 min. The total number of paw ﬂinches of the
injected paw or hindquarters was counted by an investigator unaware
of the experimental design. Contrary to the original formalin test, this
modiﬁed test with a low formalin concentration does not evoke the
characteristic 3 phases of responses (Freshwater and Calcutt, 2005).
The modiﬁed formalin test induces almost no behavioral effects in
control rats whereas in STZ-diabetic rats it triggers a marked
monophasic period of ﬂinching that ceases within an hour of injection
(Freshwater and Calcutt, 2005). The value of the test to evaluate
chemical allodynia has been described (Calcutt, 2004; Freshwater and
Calcutt, 2005).
Sacriﬁce of the animals
Two hours after formalin injection, the animals were deeply
anesthetized with an i.p. injection of 35% chloral hydrate (1 ml/kg
body weight) and sacriﬁced by transcardiac vascular perfusion or
decapitation (n=5fromeachexperimental groupandsacriﬁcemethod).
Vascular perfusion was performed with 200 ml of phosphate-buffered
saline (PBS), followed by 1000 ml of 4% paraformaldehyde (4% PFA) in
0.1 M phosphate buffer (PB), pH 7.4. The spinal segments L4–L5 and the
brainstems were removed and post-ﬁxed for 2–4 h in 4% PFA and
cryoprotected overnight in 30% sucrose in 0.1 M PBS at 4 °C or im-
mediately storage at−80 °C.
ELISA
Serotonin and noradrenaline contents were evaluated in lumbar
spinal cord homogenates from all animals, using the following
research ELISA kits from LDN, Germany: BA E-5900 for serotonin
and BA 10-5200 for noradrenaline. ELISA assays were performed
according manufacturer's instructions.
Immunohistochemistry
Coronal sections, 40 μm thick, were obtained using a freezing
microtome. One of each 4 sections of spinal cord and brainstem levels
comprising the PAG were immunoreacted against Fos protein, as
previously described (Morgado et al., 2010). Brainstem sections
comprising the RVMwere processed for immunodetection of TpH and
those encompassing the A5–A7 noradrenergic cell groups were
immunoreacted for TH. Brieﬂy, all sections were treated with 1%
hydrogen peroxidase for 10 min to inhibit the activity of endogenous
peroxidase before incubation in a blocking solution of 10% normal
serum in 0.3% Triton X 25% in PBS (PBST)with 0.1 M glycine for 2 h. The
sections were then incubated two overnights at 4 °C in rabbit anti-Fos
(1:10,000; Ab5, ref. PC38; Calbiochem, Germany), sheep anti-TpH
(1:1000; ref. AB1541; Millipore, Spain), or rabbit anti-TH (1:6000; ref.
OPA1-04050; Afﬁnity BioReagents, Germany) primary antibodies. After
beingwashed in PBST, the sectionswere incubated in biotinylated swine
anti-rabbit immunoglobulin for Fos andTH(ref. E0353;Dako,Denmark)
and in donkey anti-sheep immunoglobulin for TpH (ref. B-7390; Sigma-
Aldrich, Spain), all diluted at 1:200, for 1 h, at room temperature.
Sections were then washed in PBST, incubated for 1 h in the avidin–
biotin complex (Vectastain, Vector Laboratories, USA), and stainedwith
diaminobenzidine (10 mg diaminobenzidine in 20 ml of Tris–HCl
0.05 M, pH 7.6 solution with 5 μl of 30% hydrogen peroxide). Sections
weremountedongelatin-coated slides, air-dried, and coverslippedwith
xylol. Fos-immunoreactive (Fos-IR) neurons occurring in the spinal
dorsal horn (laminae I–VI) ipsilateral to the stimulated hindlimb were
counted in 10 sections. For the PAG, countings were performed in 10
randomly selected sections. Only the ventrolateral part of the PAG
(VLPAG) was counted since it is the PAG area with more pronounced
increases in Fos expression during PDN (Morgado et al., 2010). Twenty
brainstem sections comprising the RVM were processed for immuno-
detection of TpH and 20 sections that encompassed the A5–A7
noradrenergic cell groups were immunoreacted for TH. Neurons
immunoreactive for TpH (TpH-IR) were counted in all immunoreacted
sections encompassing the RVM. Neurons immunoreactive for TH (TH-
IR) were quantiﬁed in all sections presenting A5 and A7 noradrenergic
cell groups. The A6 noradrenergic cell groupwas not quantiﬁed since, in
Wistar rats, this nucleus does not contribute strongly to the noradren-
ergic innervation of the spinal cord (Tavares et al., 1996, 1997) and a
lower participation in such innervation implies a reduced contribution
for pain modulation (West et al., 1993). Delimitation of spinal cord
laminae, VLPAG, RVM, A5, and A7 noradrenergic cells groups was
performed according to Paxinos and Watson (2005).
In order to ascertain the neuronal nature of the immunoreactive
cells for Fos, TpH, or TH, each immunoreaction was combined with
immunostaining for the neuronal marker NeuN. Double immunoﬂu-
orescence reactions were performed in additional spinal and
brainstem sections of STZ-diabetic rats. Brieﬂy, the sections were
treated with 1% borohydrate, for 20 min, before incubation in a
blocking solution containing 10% normal horse serum in PBST with
0.1 M glycine, for 2 h. The sections were then incubated during 2
overnights at 4 °C in a mixture of a mouse anti-NeuN (1:300; ref.
MAB377; Chemicon, Germany) and each primary antibody referred
above for single immunoreactions, but in a higher concentration
(anti-Fos at 1:5000; sheep anti-TpH at 1:500; rabbit anti-TH at
1:3000). After being washed in PBST, the sections were incubated, for
1 h at room temperature, in a mixture of two ﬂuorescent secondary
antibodies: goat anti-mouse Alexa 488 (ref. A-11001) for NeuN
combined with donkey anti-rabbit Alexa 594 (ref. A-21207) for Fos or
TH and donkey anti-sheep Alexa 568 (ref. A-21099) for TpH. All
secondary antibodies were diluted at 1:500 (Molecular Probes, USA).
Sections were examined using an ApoTome microscope (Zeiss,
Germany) and the images were acquired using a high-resolution
digital camera coupled to a computer. For the acquisition of higher
magniﬁcations, serial optical sections, separated by 1 μm, were
collected in the z axis. Merged images were obtained using the
ApoTome software.
Considering the role of extracellular signal-regulated kinases
(ERKs) and cAMP response element-binding protein (CREB) as
promoters of TpH and TH mRNA synthesis, respectively (Wood and
Russo, 2001; Shimizu et al., 2004), and as markers of neuronal
activation (Ma and Quirion, 2001; Pancaro et al., 2003; Obata and
Noguchi, 2004), we quantiﬁed the expression of phosphorylated ERKs
(pERKs) and phosphorylated CREB (pCREB) in the TpH and TH-
labeling neurons. This was done to assess if the expression of TpH and
TH during diabetes is also mediated by these promoters and to infer
277C. Morgado et al. / Neurobiology of Disease 43 (2011) 275–284
103
Author's personal copy
about neuronal activation of serotoninergic and noradrenergic
neurons. Double immunoﬂuorescence reactions were performed to
compare the expression of pERKs in TpH-IR neurons along with the
expression of pCREB in TH-IR neurons between control and untreated
STZ rats. Brieﬂy, the sections were treated with 1% borohydrate for
20 min before incubation during 2 h in a blocking solution of 10%
suitable normal serum in PBST. One set of sections were then
incubated with rabbit anti-pERKs (1:200; ref. 4370; Cell Signaling,
Germany) and sheep anti-TpH (1:500; Millipore, Germany) and other
set was incubated with rabbit anti-pCREB (1:1000; Millipore,
Germany) and mouse anti-TH (1:2000; ref. T1299; Sigma-Aldrich,
Spain), during two overnights at 4 °C. After being washed in PBST, the
sections were incubated in donkey anti-rabbit Alexa 488 (ref.
A21206) for pERKs, donkey anti-sheep Alexa 568 for TpH, goat anti-
rabbit Alexa 488 (ref. A11034) for pCREB, or goat anti-mouse Alexa
594 (ref. A-11005) for TH (Molecular Probes, USA) ﬂuorescent
immunoglobulins diluted at 1:500, for 1 h at room temperature.
Sections were observed using an ApoTome microscope (Zeiss,
Germany) and the images were acquired using a high-resolution
digital camera coupled to a computer. Serial optical planes separated
by 1 μm were collected in the z-axis and merged images were
obtained using the ApoTome software. The numbers of TpH-IR
neurons and cells double-labeled for TpH and pERKs (TpH+pERKs+
neurons) were counted at the RVM. Neurons immunoreactive for TH
and those presenting double labeling (TH+pCREB+ neurons) were
quantiﬁed at A5 and A7 noradrenergic cell groups. The percentage of
double labeling in the respective neurochemical type was compared
between control and untreated STZ animals. The percentages of
control animals were considered as the basal levels (equal to 1) and
the results for STZ group are presented as fold-increase over the
control percentages.
Speciﬁcity of antibodies
The speciﬁcity of each primary antibody was previously demon-
strated (Haycock, 1989; Pinto et al., 2007; Pinna et al., 2007; Riedel
et al., 2008; Wu et al., 2009; Malleret et al., 2010). Negative control
experiments included the omission of primary or secondary
antibodies.
Drugs
Streptozotocin was purchased from Sigma-Aldrich (Barcelona,
Spain) and recombinant human IGF1 (mecasermin; Increlex®) was
kindly donated by Ipsen Portugal.
Statistical analysis
SPSS Statistics version 18 (IBM, Armonk, New York, USA) was used
for statistical analysis. Data were compared by one-way analysis of
variance (ANOVA) followed by Fisher LSD post-hoc test for multiple
comparisons. Time-course analysis of behavioral data was compared
by ANOVA repeated measures for each experimental group. Chi
square test (χ2 test) was used for analysis of proportions of double
immunoﬂuorescence results. Statistical signiﬁcance was settled as
pb0.05. Results are presented as mean±SEM.
Results
All STZ-diabetic animals developed hyperglycemia at 3 days post-
injection. Saline-treated STZ rats presented a progressive slight
weight loss (±5 g per week) during the study (Fig. 2A). IGF1
treatment did not affect the blood glucose concentration in STZ rats,
which remained above 270 mg/dl during all the study (Table 1) but
attenuated the body weight decrease, without normalization to the
levels of non-diabetic control rats (Fig. 2A). IGF1 treatment of non-
diabetic rats had no effects in body weight (Fig. 2A).
Behavioral responses
STZ-diabetic rats presented a signiﬁcant decrease in PWTs at
1 week post-injection of STZ (Fig. 2B). The PWTs of STZ+saline rats
decreased progressively during the 4 weeks of study. The PWTs of
STZ-diabetic rats treated with IGF1 remained unchanged after
treatment onset. At 4 weeks post-injection, STZ+IGF1 rats presented
signiﬁcantly higher PWTs than STZ+saline rats, but signiﬁcantly
lower than non-diabetic control rats treated with IGF1 or injected
with saline (Fig. 2B). IGF1 treatment had no effects on PWTs in non-
diabetic control animals (Fig. 2B).
Paw ﬂinches induced by formalin injections in STZ+saline rats
were signiﬁcantly higher than in non-diabetic control animals
(Fig. 3A), indicating the existence of chemical allodynia, as described
in previous studies (Freshwater and Calcutt, 2005). Treatment with
IGF1 prevented the increase in the number of paw-ﬂinches in STZ-
diabetic rats since STZ+IGF1 rats presented responses similar to
control animals (Fig. 3A). IGF1 treatment had no effects in the
responses to formalin injections in non-diabetic control animals
(Fig. 3A).
Fig. 2. Body weights and mechanical nociception of the experimental groups. Panel A
presents the body weight changes of saline-treated (control+saline; white squares) and
IGF1-treated (control+IGF1; black squares) control rats and saline-treated (STZ+saline;
white circles) and IGF1-treated (STZ+IGF1; black circles) STZ-diabetic rats. Panel B
presents the time-course changes inmechanical nociception in the 4 experimental groups.
Treatment with IGF1 prevented the progressive weight loss and mechanical hyperalgesia
observed in STZ+saline rats. Signiﬁcance of symbols: # indicates comparison between
controls and STZ groups; * indicates comparisonbetweenSTZ+saline andSTZ+IGF1.One
symbol: pb0.05; two symbols: pb0.01.
Table 1
Blood glucose concentrations of experimental groups.
Experimental group Blood glucose concentration (mg/dl)
Control+saline 121±7.1a
Control+IGF1 129±9.1a
STZ+saline 785±87.3
STZ+IGF1 777±91.4
a pb0.001 vs. STZ groups.
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Spinal cord and VLPAG neuronal activity
Double-immunostaining for Fos and NeuN at the spinal cord
(Fig. 3B, a–c) and VLPAG (Fig. 3C, a–c) demonstrated that the
expression of Fos was conﬁned to neurons since Fos was exclusively
expressed in cells with NeuN immunoreactivity. The numbers of Fos-
IR neurons were signiﬁcantly higher in STZ+saline rats than in all
other experimental groups, both at the spinal dorsal horn (Fig. 3D–G)
and at the VLPAG (Fig. 3I–L). Treatments with IGF1 reversed Fos
expression to the control levels at the spinal dorsal horn (Fig. 3D–H)
and VLPAG (Fig. 3I–M) in STZ-diabetic rats, but had no effects in non-
diabetic control animals.
Serotoninergic and noradrenergic pain control system
In STZ+saline rats, serotonin content was higher at the lumbar
spinal cord than in control animals (Fig. 4A). The neuronal nature of
TpH-IR cells was evident by the morphology of these cells, which
presented stained soma and dendrites (Fig. 4C). The neuronal nature
of TpH-IR cells was further conﬁrmed by double-immunostaining for
TpH and NeuN. All TpH-IR cells were also labeled for NeuN (Fig. 4D).
The numbers of TpH-IR neurons at the RVM were signiﬁcantly higher
in STZ+saline rats in comparison with non-diabetic controls (Fig. 4B,
E–G). The proportion of TpH-IR neurons labeled for pERKs (TpH+
pERKs+ neurons) was higher in STZ+saline rats when compared
with control animals (Fig. 5A and B). Treatments with IGF1 prevented
the increased levels of serotonin at the spinal cord (Fig. 4A) and RVM
(Fig. 4B) in STZ-diabetic rats (Fig. 4B, E–H), but had no effects on non-
diabetic control animals (Fig. 4B and F).
The content of noradrenaline in the spinal cord of the STZ+saline
group was signiﬁcantly higher than in control rats (Fig. 4I). TH
immunoreactivity was conﬁned to neurons as demonstrated by the
neuronal phenotype of the TH-IR cells (Fig. 4K) and by the exclusive
expression of TH in NeuN-IR cells (Fig. 4L). The numbers of TH-IR
neurons in the pontine A5 noradrenergic cell group were signiﬁcantly
higher in STZ+saline animals than in non-diabetic controls (Fig. 4J,
M–O). No differences in the numbers of TH-IR neurons were detected
at the A7 noradrenergic cell group between STZ+saline animals
and non-diabetic controls (Fig. 4J). The proportion of TH-IR
neurons that were also pCREB-IR (TH+pCREB+ neurons) was
higher in the A5 noradrenergic cell group of STZ+saline injected
rats (Fig. 5C and D). No differences in the proportions TH+pCREB+
at A7 noradrenergic cell group were detected between the
experimental groups (Fig. 5E and F). Noradrenaline levels at spinal
Fig. 3. Formalin-induced behavioral responses and neuronal activity at spinal cord and ventrolateral periaqueductal gray (VLPAG). Panel A presents total countings of paw ﬂinches in
saline-treated (control+saline) and IGF1-treated (control+IGF1) control rats and saline-treated (STZ+saline) and IGF1-treated (STZ+IGF1) STZ-diabetic rats. Panel B shows the
co-localization (Bc) of NeuN (green; Ba) and Fos (red; Bb) at the spinal cord. Panel C shows the co-localization (Cc) of NeuN (green; Ca) and Fos (red; Cb) at VLPAG. Panels D and I
show the total number of activated neurons (Fos-IR) at spinal dorsal horn of L4–L5 segments and VLPAG, respectively. Panels E–H and J–Mare representative photomicrographs of L5
spinal segment (E–H) and VLPAG (J–M) immunoreactive for Fos. The modiﬁed formalin, used to evaluate chemical allodynia, induced signiﬁcantly higher numbers of paw ﬂinches
and Fos-IR neurons (arrows) at spinal dorsal horn and VLPAG of STZ+saline rats. Those changes were prevented by IGF1 treatment. Signiﬁcance of symbols: ** indicates pb0.01.
Scale bar in B and C: 50 μm; scale bar in E–H and J–M: 100 μm.
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cord were normalized to control levels by IGF1 administration
(Fig. 4I). Treatment with IGF1 also prevented the increase in the
numbers of TH-IR neurons at the A5 noradrenergic cell group in
STZ-diabetic rats (Fig. 4J, M–P). In non-diabetic control rats, IGF1
administration induced a signiﬁcant decrease in spinal noradren-
aline content (Fig. 4I), along with a non-signiﬁcant tendency for a
reduction in the numbers of TH-IR neurons at the A5 noradrenergic
cell group (Fig. 4J and N).
Fig. 4. Changes in the serotoninergic and noradrenergic pain control system. Panel A shows the content of serotonin in L4–L5 spinal cord segments for all experimental groups and
panel B presents the number of TpH immunoreactive neurons (serotoninergic neurons) at the RVM of saline-treated (control+saline) and IGF1-treated (control+IGF1) control rats
and saline-treated (STZ+saline) and IGF1-treated (STZ+IGF1) STZ-diabetic rats. Panel C is a representative photomicrograph of TpH-IR neuron at the RVM showing the neuronal
morphology of the labeled cells (somata and dendrites). Panel D shows the co-localization of TpH (red) and NeuN (green) immunoreactions (arrows). Panels E–H are representative
photomicrographs of RVM showing TpH immunoreactivity in each experimental group. Panel I presents the levels of noradrenaline in L4–L5 spinal cord segments of all experimental
groups and Panel J presents the number of TH labeled neurons (noradrenergic neurons) at A5 and A7 noradrenergic cell groups. Panel K is a representative photomicrograph of TH-IR
neuron at the A5 cell group showing the neuronal morphology of the labeled cell (soma and primary and secondary dendrites). Panel L shows the co-localization of TH (red) and
NeuN (green) immunoreactions (arrows). Panels M–P are representative photomicrographs of A5 cell noradrenergic group labeled for TH. STZ+saline rats presented a signiﬁcant
increase in the spinal content of serotonin and noradrenaline (A and I), which was accompanied by increased numbers of TpH and TH immunoreactive neurons at RVM (B, G) and A5
(J, O), respectively. IGF1 fully prevented those changes. *pb0.05; **pb0.01. Scale bar in C, D, K, and L: 50 μm; scale bar in E–H and M–P: 100 μm.
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Discussion
The present study shows, for the ﬁrst time, that, during diabetes, an
increase in the numbers of serotoninergic and noradrenergic neurons in
key brainstem centers for descending pain is associated with increased
levels of serotonin and noradrenaline at the spinal cord. Based on the
facilitatory role of serotonin and noradrenaline in other chronic pain
conditions, our study suggests that PDN can probably be due to
impairments in descending painmodulation. This study also shows that
treatment with IGF1 normalizes the levels of serotonin and noradren-
aline, reverses the behavioral signs of PDN, and decreases neuronal
activation at the VLPAG and spinal dorsal horn.
Monoaminergic systems during PDN
Regarding the serotoninergic system, higher numbers of TpH-
expressing neurons were detected in the RVM of STZ-diabetic rats. By
performing a study directed to a speciﬁc brainstem serotoninergic
area (the RVM), we demonstrated, for the ﬁrst time, that the RVM can
account for the increased levels of serotonin in the brainstem of
diabetic rats (Padayatti and Paulose, 1999). This is important since the
RVM is the main relay station used by the PAG in conveying pain
modulation from higher brain centers, such as the amygdala and the
anterior cingulate cortex (Heinricher et al., 2009; Tracey and Mantyh,
2007). The expression of TpH, the enzyme marker of serotoninergic
neurons (Grahame-Smith, 1964), is known to be regulated by the
activation of the ERK pathway (Wood and Russo, 2001). We
demonstrated that the percentages of TpH-IR neurons that expressed
pERKs were higher in the RVM of STZ-diabetic rats than in control
animals. Since, at the cerebral cortex, serotonin levels were previously
shown to decrease in STZ-diabetic rats (Sandrini et al., 1997), it will be
important to study if there is suppression in the expression of pERKs
in the cortex during diabetes. Such evaluation, in conjunctionwith the
present data, could demonstrate a pERK-inducible increase in
serotonin expression during diabetes.
As to the noradrenergic system, we detected higher numbers of
TH-expressing neurons at the A5 noradrenergic cell group of STZ-
diabetic rats, alongwith increased levels of noradrenaline at the spinal
cord. These results nicely match the fact that the A5 noradrenergic cell
group is the main contributor to the noradrenergic innervation of the
spinal cord in the rat strain used in the present study (Tavares et al.,
1996, 1997). The increase in noradrenaline levels could be a speciﬁc
effect of diabetes in noradrenergic metabolism since the mRNA levels
for TH were previously shown to increase in the brain of diabetic rats
and to normalize after euglycemic insulin treatment (Figlewicz et al.,
1996). Further supporting a speciﬁc effect of diabetes in noradren-
ergic metabolism, the levels of noradrenaline were previously shown
to increase in other organs of diabetic rats, namely the heart (Ganguly
et al., 1986). However, the increased expression of TH could also be a
response to chronic pain installation since it was also reported in
traumatic neuropathic models in the A6 noradrenergic cell group (Ma
and Eisenach, 2003). The expression of the mRNA for TH is known to
be regulated by the activation of the CREB pathway (Shimizu et al.,
2004). Incidentally, it should be noted that the percentages of TH-IR
neurons that were also labeled for pCREB were higher in the A5
noradrenergic cell group of STZ-diabetic rats than in control animals.
This did not occur in the A7 noradrenergic cell group, where the
numbers of TH-IR neurons also did not change in STZ-diabetic rats.
These ﬁndings suggest a pCREB-dependent increase in TH expression
during diabetes by molecular mechanisms that remain to be
determined.
Since pERKs and pCREBs are markers of neuronal activation (Ma
and Quirion, 2001; Pancaro et al., 2003; Obata and Noguchi, 2004), the
increased expression of these factors in serotoninergic neurons of the
RVM and in noradrenergic neurons of the A5 cell group, respectively,
indicates that PDN involves a higher recruitment of descending
modulation from these areas. The VLPAG, generally considered a key
regulator in pain modulation from the brain, also showed higher
neuronal activation in our STZ-diabetic rats, as shown by the higher c-
fos expression. Since the VLPAG projects both to the RVM and the A5
noradrenergic cell group (Bajic and Proudﬁt, 1999), it remains to
ascertain if the VLPAG triggers the putatively increased neuronal
activation at those serotoninergic and noradrenergic neurons.
Collectively, the data point to an increased activity in pain modulatory
centers of the brain which is in agreement with the increased
modulation in other chronic pain models (Danzinger et al., 1999).
However, the net balance of increased descending modulation in PDN
should be facilitation of nociceptive transmission. These results agree
with other chronic pain models in which an imbalance of inhibition
Fig. 5. Expression of pERKs or pCREB on TpH-IR or TH-IR neurons, respectively, in
control+saline and STZ+saline rats. Panel A presents the fold-increase over the
control percentage of double labeled neurons for TpH and pERKs (TpH+pERKs+) in
saline-treated rats (STZ+saline) when compared with control animals at the RVM.
Panel B is a representative photomicrograph of RVM neurons double labeled for TpH
(red) and pERKs (green). Panels C and E present the fold-increase over the control
percentage of double labeled neurons for TH and pCREB (TH+pCREB+) in STZ+saline
rats when compared with control animals at the A5 (C) and A7 (E) noradrenergic cell
groups. Panels D and F are representative photomicrographs of A5 (D) and A7 (F)
neurons double labeled for TH (red) and pCREB (green), showing details of the labeling
after optical sectioning (20 optical sections). Control percentages were considered as
the basal levels (equal to 1) and results for STZ+saline group are presented as the fold-
increase over control percentages. STZ+saline rats present higher proportions of
double labeled neurons in RVM and A5 noradrenergic cell groups than control animals.
Signiﬁcance of symbols: **pb0.01. Scale bar: 50 μm.
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and facilitation occurs, with a large prevalence of facilitation
(Porreca et al., 2002). This has been extensively demonstrated for
the RVM in traumatic neuropathic pain and in inﬂammatory pain
models (Heinricher et al., 2009). Our STZ-diabetic rats exhibited
mechanical hyperalgesia, chemical allodynia, and increased nociceptive
responses of spinal neurons. This indicates that, during diabetes, the
increased descending drive by serotonin and noradrenaline is eliciting
pronociceptive effects which may be explained by 1) reduction of the
release of serotonin and noradrenaline at the spinal cord due to
accumulation in axonal terminals; 2) decrease in the expression and/or
activity of serotonin and/or noradrenaline receptors; and 3) changes in
the role of serotonin and noradrenaline in pain modulation due to the
preferential action on receptors that induce pain facilitation. Favoring
the ﬁrst two hypotheses, during diabetes, the release of serotonin and
noradrenaline at spinal cordwas shown tobe impaired (Suh et al., 1996;
Bitar et al., 1999) and the expression and binding afﬁnity of subtypes of
serotonin and noradrenaline receptors is altered (Bitar et al., 1999;
Padayatti and Paulose, 1999). Considering that descending pain
modulation from the RVM exerts dual inﬂuences upon nociception,
the third hypothesis should alsobe considered. Serotonin releasedat the
spinal cord from the RVM inhibits pain transmission through the
activation of spinal 5-HT7 receptors and enhances pain through spinal
5-HT3 receptors (Drogul et al., 2009). Pain facilitation fromtheRVMwas
also demonstrated by the analgesia detected after silencing serotonin-
ergic RVM neurons (Wei et al., 2010). Together, the results suggest that
the increased activation of serotoninergic neurons at the RVM, along
with the increased serotonin content at the spinal cord observed in STZ-
diabetic rats, may contribute to spinal neuronal hyperactivity and
increased pain behavioral responses detected in this model of chronic
pain. This hypothesis will be evaluated in a near future.
In what concerns descending noradrenergic modulation, it is
known that noradrenaline acts upon post-synaptic α1 adrenergic
receptors, inducing GABA and glycine release (Pertovaara, 2006;
Gassner et al., 2009). The high noradrenaline levels at the spinal cord
of STZ-diabetic rats are likely to increase GABA release at the spinal
cord. During diabetic neuropathy, GABA is known to elicit excitatory
effects rather than inhibitory (Jolivalt et al., 2008; Morgado et al.,
2008). The release of GABA by α1 adrenoreceptor-mediated actions
during diabetes will, therefore, enhance the activity of spinal neurons
and account for an increase in pain behavioral responses in STZ-
diabetic rats. This pain facilitation mediated by noradrenaline during
diabetes can further be reinforced by noradrenaline actions upon α2
adrenergic receptors. During diabetes, the expression and function of
spinal α2 adrenergic receptors are impaired (Bitar and Pilcher, 2000).
Since, in normal conditions, noradrenaline acts upon spinal pre-
synaptic α2 adrenergic receptors, inhibiting the release of excitatory
neurotransmitters, any dysfunctions in these receptors will attenuate
the antinociceptive effect of noradrenaline at the spinal cord.
Therefore, the inhibitory effects of IGF1 on noradrenergic descending
neurotransmission could probably concur for the reduction in spinal
neuronal activity and hyperalgesia/allodynia in STZ-diabetic rats.
Intrathecal administration of agonists and antagonists of serotonin
and noradrenaline receptor subtypes will be performed to elucidate
the role of these neurotransmitters during PDN. Such study could
provide important data to design new drugs that are more directed to
the relevant serotonin or noradrenaline receptors affected at the
spinal cord during PDN, without the generalized effects of antide-
pressants that act upon serotonin and noradrenaline reuptake.
Effects of IGF1
A striking ﬁnding of the present study was the observation that
IGF1 prevented the increases in serotonin and noradrenaline levels
and normalized behavioral responses and neuronal hyperactivity at
the VLPAG and spinal cord in STZ-diabetic rats. The improvement of
behavioral signs of diabetic neuropathy after IGF1 treatment has
been previously described, even with lower IGF1 doses and later
onset of treatment (Ishii, 1995; Schmidt et al., 1999; Zhuang et al.,
1996; Piriz et al., 2009). Since these studies demonstrated that IGF1
has a peripheral effect by reducing peripheral nerve damage, it is
likely that a decrease in peripheral input was induced in our STZ-
diabetic rats by the IGF1 treatment. In a previous study, this decrease
in peripheral input failed to show central consequences at the
somatosensory cortex (Piriz et al., 2009) whereas, in our IGF1-
treated STZ-diabetic rats, the decrease in behavioral signs of PDNwas
accompanied by a reversion of neuronal hyperactivity at the VLPAG
and by normalization of the levels of serotonin and noradrenaline in
the brainstem. Besides blocking the peripheral input from the
periphery, as proposed by the studies referred above, IGF1 may act
directly at the brain since circulating IGF1 crosses the blood–brain
barrier, reaches the brain (Carro et al., 2000), and IGF1 receptors
occur in the analyzed brainstem areas (Folli et al., 1994). It is,
however, unlikely that IGF1 had a direct action on the RVM and A5
neurons of STZ rats since IGF1 has been shown to increase
monoamine levels (Hoshaw, 2008) and the reverse effect was
never reported. This is further supported by the lack of effects of
IGF1 in the serotoninergic system of control rats. Curiously, in these
animals, IGF1 decreases spinal levels of noradrenaline without
signiﬁcantly reducing the numbers of TH-IR neurons at the A5 cell
group. This does not support a direct action of IGF1 at the A5 and is
rather explained by an IGF1-mediated enhancement of cathecola-
mine breakdown, which was already proposed in previous studies
with PC12 rat pheochromocytoma cells (Bach and Leeding, 2002).
We cannot exclude a direct effect of IGF1 at the VLPAG which would
decrease the hyperactivation of local neurons and, herein, depress
the recruitment of descending modulatory drive through the
serotoninergic and noradrenergic relay brainstem stations. Support-
ing this possibility, IGF1 has been shown to elicit long-term
depression in cultured neurons by downregulating AMPA receptor
signaling (Wang and Linden, 2000). The methodological constraints
of performing continuous infusions of IGF1 at the VLPAG in STZ-
diabetic rats to test this hypothesis will be circumvented by blocking
the peripheral effects of IGF1 using an anti-IGF1 antibody (Glasper
et al., 2010) and studying the effects of IGF1 treatment. An interesting
issue about IGF1 is its interaction with growth hormone (GH). IGF1 is
mainly produced by the liver upon the GH stimulation. GH levels
were shown to be decreased in STZ-diabetic rats, which may concur
for IGF1 deﬁcits in this animal model (Yang et al., 1990; Boujon et al.,
1995). Therefore, it is likely that a treatment with GH would raise
blood IGF1 concentrations in STZ-diabetic rats and could induce
similar effects to those of the current IGF1 protocol. This cannot,
however, be tested due to ethical constraints. STZ-diabetic rats have
reduced liver GH receptor expression, which makes these animals
less responsive to GH treatment (Menon et al., 1994). To effectively
raise IGF1 levels, it will probably be necessary the administration of
high doses of GH, which induces renal hypertrophy (Landau et al.,
2003). On the contrary, the IGF1 treatment does not induce any
impairment in animal welfare.
In summary, we demonstrated an increased recruitment of descend-
ing nociceptivemodulationduringPDN,which affects the serotoninergic
and noradrenergic systems. The importance of IGF1 in mediating
functional plasticity in the brain during normal conditions and in several
pathologies (Torres-Aleman, 1999), such as diabetes, deserves further
investigation. The beneﬁts of an early treatmentwith IGF1 in preventing
the signs of PDN may be considered in the future after clarifying the
mechanisms of its putative actions in pain modulation from the brain.
Since diabetic patients present spontaneous pain (Tesfaye, 2009), it will
be important to evaluate if IGF1 relieves spontaneous pain in STZ-
diabetic rats, in a manner similar to the improvement of evoked pain
(allodynia and hyperalgesia). The lack of behavioral tests to evaluate
spontaneous pain is a limitation of current experimental pain research
(Mogil et al., 2010) that needs to be circumvented in the future.
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The studies included in this PhD Thesis provide evidences for the existence of 
central effects induced by diabetes at the somatossensory system, namely in the spinal 
cord and in pain control areas of the braintem. The spinal dorsal horn was shown to be 
affected, since our data suggest spontaneous hyperactivity of neurons located in 
laminae involved in nociceptive processing (Publication 1). This neuronal hyperactivity 
is probably due to a shift in the inhibitory role of GABA, since the expression of the 
KCC2 is reduced at the spinal dorsal horn and this impairs the post-synaptic action of 
GABA (Publication 2). The reduction in KCC2 expression is probably mediated by 
activation of microglia (Publication 3) and oxidative stress (Publication 4), since a 
correction of these factors increases KCC2 expression, reverses spinal neuronal 
activity and decreases behavioral signs of PDN. In addition, our results show that key 
pain control areas in the brain are affected during diabetes. Neurons at the PAG were 
shown to be activated during PDN (Publication 5), which was accompanied by an 
increase in the number and activity of serotoninergic and noradrenergic neurons, 
respectively, in the RVM and A5 cell group, two important relay stations of PAG-
mediated pain modulation (Publication 6). In addition, the spinal levels of serotonin 
and noradrenaline were shown to be increased (Publication 6). These findings show 
the affectation of the serotoninergic and noradrenergic descending pain modulatory 
systems during PDN, which may also account for the increased spinal cord activity 
detected in STZ rats. 
 
1. Central neurobiological mechanisms of painful diabetic neuropathy 
The studies included in this Thesis provided, for the first time, a simultaneous 
analysis of the spinal cord and supraspinal pain control areas, along with behavioral 
evaluation of signs of PDN. This comprehensive approach provides some data 
regarding the central mechanisms that may subserve PDN, which are centered at the 
spinal cord and pain control areas of the brainstem. 
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1.1. The spinal dorsal horn during diabetes 
By studying the expression of the Fos protein, we showed that PDN is 
associated with spontaneous hyperactivity of nociceptive neurons, affecting all spinal 
dorsal horn laminae (Publication 1). This finding suggests a general change in spinal 
nociceptive neurotransmission, which probably enhances the responses to both 
noxious and innocuous peripheral stimuli. Our data corroborate the findings from 
electrophysiological recordings showing hyperactivity of wide-dynamic neurons of the 
spinal dorsal horn (Pertovaara et al., 2001), some of which are engaged in supraspinal 
transmission of nociceptive information since they belong to the spinothalamic tract 
(Chen and Pan, 2002). Besides the increased peripheral barrage due to primary 
afferent hyperexcitability (Burchiel et al., 1985; Ahlgren et al., 1994; Chen and Levine, 
2001; Khan et al., 2002; Chen and Levine, 2003), the spinal neuronal hyperactivity may 
involve alterations in local spinal circuits and descending pain modulatory mechanisms 
(Millan, 2002; Vanegas and Schaible, 2004; Pertovaara, 2006; Heinricher et al., 2009; 
Ossipov et al., 2010). The supraspinal influences will be discussed in item 1.2 (“The 
pain modulatory system of the brainstem during diabetes”). As to the spinal 
mechanisms, the increased spinal GABA levels along with the decreased expression of 
KCC2 (Publication 2), suggests an inversion of the post-synaptic role of GABA from 
inhibitory to excitatory. This has been previously demonstrated in other pain models 
(Payne et al., 2003; Coull et al., 2003; Mantyh and Hunt, 2004; Price et al., 2005). It 
was also demonstrated in STZ rats after our quantitative data about GABA/KCC2 were 
published (Publication 2). Jollivalt and collaborators (2008) showed that bicucculine, 
the antagonist of post-synaptic ionotropic GABAA receptor, elicits antinociceptive 
effects (Jolivalt et al., 2008). Altogether, the changes on the excitatory mechanisms 
and on the pre-synaptic action of GABA that affect the spinal cord of STZ rats (Kamei 
et al., 1990; Calcutt and Chaplan, 1997; Malcangio and Tomlinson, 1998; Li et al., 
1999; Calcutt et al., 2000; Li et al., 2002; Tomiyama et al., 2005; Malmberg et al., 2006; 
Wang et al., 2007), in addition with the impairment on post-synaptic GABA role, are 
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likely to culminate in spinal hyperactivity and exacerbation of pain behavioral 
responses.  
As to the mechanisms which may subserve the decreases in the expression of 
KCC2 in STZ rats, the results of this PhD Thesis indicate an involvement of microglia 
and oxidative stress. The cross-talk between microglia and neurons has been 
extensively addressed in the last decade. Studies in animal models of traumatic 
neuropathic pain and inflammatory pain showed that microglia is involved in neuronal 
function and affects the nociceptive processing (reviewed by Inoue and Tsuda, 2009; 
McMahon and Malcangio, 2009; O’Callaghan and Miller, 2010; Gosselin et al., 2010; 
Gao and Ji, 2010; Ren and Dubner, 2010). During diabetes, microglia activation was 
described at the spinal cord (Tsuda et al., 2008; Wodarski et al, 2009; Talbot et al, 
2010). Microglia activation is probably involved in PDN, since gabapentin, an analgesic 
drug used in PDN treatment, reduces microglia activity at the spinal cord (Wordaski et 
al, 2009) and microglia inhibition ameliorates behavioral signs of PDN (Tsuda et al., 
2008). The results of the studies included in Publication 3 also support the 
involvement of microglia in the hyperalgesia detected in the STZ rats, probably through 
its effect on KCC2 expression at the spinal cord. It will be important to elucidate the 
molecular mechanisms underlying the effects of microglia in KCC2 expression during 
diabetes, since, in our study, microglia-mediated reduction of KCC2 expression was 
BDNF-independent. This is a specific feature of PDN inasmuch that BDNF-mediated 
effect of microglia was demonstrated in other chronic pain models (Yajima et al., 2002; 
Coull et al, 2005; Ramer et al., 2007; Miletic and Miletic, 2008; Zhou et al., 2011).  
As to oxidative stress, a frequent consequence of diabetes that affects several 
tissues, namely peripheral nerves (Stevens et al., 2000; van Dam, 2002; Obrosova et 
al., 2003; Pop- Busui et al., 2006; Lin et al., 2006), we showed that it also occurs 
centrally, affecting the spinal dorsal horn. Oxidative stress influences the activity of 
nociceptive neurons at the spinal cord of STZ rats, which seems to be partially 
mediated by its effect on KCC2 expression (Publication 4). Since the antioxidant 
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treatment with α-lipoic acid was performed systemically, we can not exclude that it also 
acts in areas of the somatossensory system, other than the spinal cord. However, 
since oxidative stress affects the phosphorylation and expression of KCC2 (Wake et 
al., 2007), this probably accounted for the decreases in KCC2 expression at the spinal 
cord (Publication 4). Collectively, the studies addressing the changes at the spinal 
cord during diabetes indicate neuronal hyperactivity which is likely to affect spinofugal 
transmission of nociceptive information. The increased arrival of nociceptive input from 
the spinal cord to the brain is likely to have important impacts on spinal 
neurotransmission since several supraspinal pain control areas form reciprocal loops 
with the spinal cord (Almeida et al., 2006; Ossipov et al., 2010). 
 
1.2. The pain modulatory system of the brainstem during diabetes  
The studies included in the last 2 publications of this Thesis indicate 
impairments in key pain control centres of the brain during diabetes. PAG neurons 
were shown to be hyperactivated in STZ rats (Publication 5) and increased neuronal 
activity was detected in the thalamus in the same animal model of diabetes (Fischer et 
al., 2009; Fischer and Waxman, 2010). The increased thalamic neuronal activity 
appears to be independent from the peripheral barrage since blocking the peripheral 
input does not block thalamic activity. This has been used to propose that during PDN 
the thalamus becomes a “pain generator/amplifier” (Fischer et al., 2009; Fischer and 
Waxman, 2010). It will be important to perform similar studies at the PAG by blocking 
peripheral input when the PAG has increased neuronal activity to ascertain the moment 
when PAG hyperactivity is independent from the peripheral barrage. After this 
timepoint, PDN treatment exclusively directed to peripheral causes is unlikely to be 
effective.  
The activation of descending pain modulation pathways at PAG relay stations 
was also demonstrated in the present PhD Thesis (Publication 6). Neurons at the 
RVM and A5 noradrenergic group, two important brainstem areas targeted by PAG 
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projections and involved in descending modulation of spinal nociceptive transmission 
(Behbehani, 1995; Bajic and Proudfit, 1999; Vanegas and Schaible, 2004; Ossipov et 
al., 2010), were shown to be activated in STZ rats. Neurons at the RVM and A5 project 
to the spinal dorsal horn, where they release serotonin and noradrenaline, respectively 
(Millan, 2002; Pertovaara, 2006; Heinricher et al., 2009; Ossipov et al., 2010). The 
increase of serotonin and noradrenaline levels in the spinal cord of STZ rats confirms 
the activation of serotoninergic and noradrenergic descending pathways (Publication 
6). Serotonin may elicit inhibitory and facilitatory effects, depending on the targeted 
serotonin receptors at the spinal cord (Drogul et al., 2009). Noradrenaline was shown 
to be exclusively inhibitory by binding to α2 adrenoreceptors and inhibiting the release 
of excitatory neurotransmitters and to α1 adrenoreceptors but increasing the release of 
GABA and glycine at the spinal cord (Pertovaara, 2006; Gassner et al., 2009). It is 
important to ascertain the net pain modulatory effect of each neurotransmitter at the 
spinal cord during PDN. Considering the spinal hyperactivity detected in STZ rats, the 
increased behavioral responses and the changes in spinal GABA neurotransmission 
(item 1.1. “The spinal dorsal horn during diabetes”), pain facilitation is likely to 
prevail over inhibition. It is important to mention that disturbances at 5-HT receptors 
were reported in STZ rats (Padayatti and Paulose, 1999), which may alter serotonin 
actions, probably by reducing its inhibitory effects. Additionally, in STZ rats, 
noradrenergic α2 adrenoreceptors showed reduced expression and binding affinity 
(Bittar et al., 1999; Bittar and Pilcher, 2000) while α1 adrenoreceptors are 
hyperresponsive (Teasell and Arnold, 2004). This could imply a reduction in the pre-
synaptic inhibition mediated by noradrenaline. Moreover, the higher responsiveness of 
α1 adrenoreceptors can increase GABA release, which, considering the shift in the 
inhibitory role of GABA at spinal dorsal horn of STZ rats (Jolivalt et al., 2008), may 
concur for neuronal hyperactivity and pain. A detailed study of the function and integrity 
of serotonin and noradrenaline receptors at spinal cord of STZ rats should be 
performed in order to study the relative contribution of pain facilitation and loss of pain 
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inhibition during the PDN. Moreover, that study could support the development of more 
specific pharmacological approaches, directed to the altered receptor(s) and not 
affecting the whole neurotransmitter system.  
 
Since diabetes is a systemic condition, some of the changes detected at the 
spinal cord during diabetes can occur also at the brain. As to oxidative stress, our 
recent data show the occurrence of oxidative stress damage in neurons of the RVM 
and A5 (Morgado et al., 2010). We also showed that oxidative stress occurs in 
serotoninergic RVM neurons and noradrenergic A5 neurons (Morgado et al., 2011a). 
We are currently evaluating if antioxidant treatments of STZ rats can reverse the 
oxidative stress in those brainstem areas. In the case of the antioxidant α- lipoic acid, it 
was previously reported that it may affect noradrenaline levels in the brain after 
systemic administrations (Santos et al., 2010). Based on the results of our publication 
6, it will be important to study the effects of that antioxidant treatment in the brainstem, 
namely in the A5 noradrenergic cell group. Another issue to consider is microglia 
activation. It was previously shown that microglia is activated in the RVM in other 
models of chronic pain and seems to concur for descending pain facilitation, since pain 
responses normalize upon local administration of microglial inhibitors (Wei et al., 2008; 
Roberts et al., 2009). Furthermore, microglia activation was also observed in the 
thalamus and its inhibition was shown to elicit analgesia (Zhao et al., 2007). 
 
Collectively, the findings obtained in the spinal cord and brainstem of STZ rats 
in this PhD Thesis are summarized in Figure 1.  
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 Figure 1 – Schematic representation of the effects of diabetes in areas of the 
somatossensory system involved in pain transmission/modulation. The diagram takes 
into account the data analyzed in item 1 of this Discussion. 
 
The results obtained show that during PDN the hyperactivity of spinal 
nociceptive neurons probably occurs due to changes in spinal GABAergic 
neurotransmission, caused by the reduction in local expression of KCC2. This might be 
triggered by microglia activation and oxidative stress. The data also suggest that 
descending pain modulation circuits are affected including i) activation of neurons at 
the PAG; ii) increased activity and number of serotoninergic and noradrenergic neurons 
of the RVM and A5 cell group, respectively and iii) increased serotonin and 
noradrenaline content at spinal cord. However, despite the recruitment of descending 
modulation pathways, allodynia and hyperalgesia persisted in STZ rats, which point for 
disturbances in the spinal responses to descending pain modulation. The loss of 
inhibition mediated by serotonin and noradrenaline is probably related with impairments 
on neurotransmitter release or/and changes in the respective receptor activities. The 
first hypothesis is supported by our recent data showing that the release of serotonin is 
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reduced at the spinal cord of STZ-rats with 10 weeks of diabetes when compared with 
age-matched control animals (Morgado et al., 2011b). Curiously, our recent data 
comparing STZ rats with 4 and 10 weeks of diabetes suggest that during the 
progression of diabetes, descending pain modulation is affected in a time-dependent 
manner. Long-term diabetes is associated with decreased numbers of serotoninergic 
RVM neurons and noradrenergic A5 neurons. Curiously, the spinal serotonin content 
remained increased while the opposite occurs with noradrenaline levels (Morgado et 
al., 2011b). The spinal release of serotonin seems to be diminished, considering the 
lower content of serotonin in the cerebrospinal fluid from the spinal lumbar enlargement 
in STZ-rats when compared with control animals (Morgado et al., 2011b). Future 
studies will address the neurobiological mechanisms subserving these changes in 
serotoninergic and noradrenergic neurotransmission during diabetes. 
 
2. New perspectives in the treatment of PDN 
The management of PDN remains a challenge for the clinicians, since it is often 
only partially responsive or even unresponsive to the existing pharmacological 
treatments. Most of therapeutic approaches are symptomatic, with α-lipoic acid and 
epalrestat being the only pathogenetic-related existing drugs (Ziegler et al., 2009, 
Tesfaye, 2009; Obrosova, 2009; Zilliox and Russel, 2011). Besides α-lipoic acid, the 
present PhD Thesis used several compounds that may be valuable for PDN treatment, 
namely gabapentin, minocycline and IGF1. Regarding α-lipoic acid, our study supports 
a role of this antioxidant in neuronal function, considering that it ameliorated KCC2 
expression in the spinal cord of STZ rats, indicating that the benefits of α-lipoic acid 
extend to the central nervous system and not only to the periphery (Publication 4). 
Similar studies of the effects of α-lipoic acid in higher pain-related areas should be 
considered in the future since, as discussed above, we recently detected oxidative 
stress in serotoninergic neurons of the RVM and noradrenergic neurons of the A5 cell 
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group (Morgado et al., 2010). The present findings reinforce the use of α-lipoic acid for 
treat or, eventually, prevent PDN. 
Gabapentin or its structurally related compound pregabalin are commonly used 
in neuropathic pain treatment (Hwang and Yaksh, 1997; Abdi et al., 1998; Field et al., 
1999; Vinik, 2005). Their predominant mechanism of action is the inhibition of calcium 
currents via high-voltage-activated channels containing the α2δ-1 subunit (Marais et 
al., 2001; Dooley et al., 2007), which was shown to be elevated in the spinal cord of 
STZ rats (Luo et al., 2002). Antinociceptive actions of gabapentin were mainly studied 
at the spinal cord. There are studies showing that spinal administration of gabapentin i) 
regulates α2δ-1 subunit neuronal expression (Xiao et al., 2007), ii) interacts indirectly 
with NMDA receptors, reducing the glutamate excitatory action (Partridge et al., 1998; 
Shimoyama et al., 2000); iii) reduces the electrical-evoked and mechanical-evoked 
responses of wide-dynamic neurons (Corderre et al., 2005; Donovan-Rodriguez et al., 
2005; Omori et al., 2009) and iv) reduces the release of excitatory amino acids (Patel 
at al., 2000; Moore at al., 2002; Maneuf et al., 2004). When given systemically, 
gabapentin reduces oxidative stress (Baydas et al., 2005) and spinal microglia 
activation (Wodarsky et al., 2009).  Our study corroborates the spinal effects of 
gabapentin in PDN, showing the normalization of nociceptive spinal cord neurons 
activity upon gabapentin treatment (Publication 5). In addition, we show for the first 
time that gabapentin reversed the neuronal hyperactivity at the PAG of STZ rats, 
supporting the effects of gabapentin on supraspinal pain-related areas (Hayashida et 
al., 2008). This effect could result from a direct action on PAG neurons or/and reduced 
spinal activity and, thereafter, diminished nociceptive ascending input. The expression 
of α2δ-1 subunit of high-voltage-activated calcium channels at the PAG supports a 
direct effect of gabapentin on PAG neurons (Cole et al., 2005). In addition, α2δ-1 
subunit is also expressed in other areas involved in nociceptive processing, as the 
thalamus (Cole et al., 2005), which if inhibited by gabapentin will reduce the ascending 
input to higher centers and, consequently, diminish the activation of the descending 
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pathways. It will be interesting to ascertain the relative contribution of the PAG and the 
thalamus to the gabapentin-induced analgesia by performing local inoculations in each 
brain area. In addition, and based on the effects on PAG activity, it will be important to 
assess the effects of gabapentin in serotoninergic and noradrenergic descending 
pathways recruitment during PDN.  
Considering the increasing amount of data showing that microglia activation is 
involved in the installation of chronic pain (reviewed by Inoue and Tsuda, 2009; 
McMahon and Malcangio, 2009; O’Callaghan and Miller, 2010; Gosselin et al., 2010; 
Gao and Ji, 2010; Ren and Dubner, 2010), it will be important to ascertain the effect of 
microglia inhibition in PDN in humans. Minocycline, a microglia inhibitor, was here 
shown to reverse the hyperalgesia in STZ rats, by inhibiting neuronal hyperactivity and 
normalizing KCC2 expression at the spinal cord. This suggests that minocycline, or 
other agents that inhibit microglia activity (such as inhibitors of SFKs or p38 MAPK; 
Zhou et al., 2011), could be promising therapeutic compounds to treat PDN, alone or in 
combination with other treatments. Indeed, recent studies demonstrated that 
minocycline attenuates morphine tolerance, contributing to increase its analgesic 
efficacy in post-herpetic neuralgia (Chen et al., 2010). Encouraging the use of 
minocycline during PDN, there are studies showing that this drug inhibits 
intraepidermal fiber loss, an important clinical feature of PDN (Boyette-Davis and 
Dougherty, 2011; Loseth et al., 2010). Since minocycline crosses the blood-brain 
barrier (Colovic and Caccia, 2003) systemic administrations could provide dual benefits 
in PDN, by preventing peripheral nerve damage and spinal cord impairments. Besides 
its inhibitory effects on microglia activity, minocycline was shown to reduce oxidative 
stress (Padi and Kulkarni, 2008), inhibit Na+ channels in the primary afferent neurons 
(Kim et al., 2011) and decrease spinal glutamate neurotransmission (Nie et al., 2010). 
It is also likely that minocycline affects supraspinal areas devoted to pain control. In 
fact, minocycline was shown to inhibit microglia in the thalamus (Zhao et al., 2007) and 
RVM (Wei et al, 2008; Roberts et al., 2009) and this may contribute for its analgesic 
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effect. It is important to mention that minocycline exerts neuroprotective effect in 
various experimental models of neurodegenerative diseases (Blum et al., 2004; Kim 
and Suh, 2009) and is currently being tested in humans for the treatment of diabetes 
macular edema and several other neurological conditions (http://www.clinicaltrials.gov). 
Diabetic neuropathy is no longer exclusively attributed to hyperglycemia. Lack 
of insulin and IGF1 play an important role in the ethiopathogeny and severity of this 
complication of diabetes (Ishii, 1995; Sima, 2003; Pierson et al., 2003; Sima, 2006). 
Our study also supports the involvement of IGF1 deficits in PDN, since the 
administration of low doses of IGF1 ameliorated pain responses in STZ rats, prevented 
the functional impairments at the spinal cord and PAG and the neurochemical changes 
at the serotoninergic and noradrenergic pain control areas (Publication 6). The 
mechanisms involved in the antinociceptive action of IGF1 should be evaluated in 
future studies namely by performing direct IGF1 administration at pain control centers 
of the brain. Based in the positive effects of IGF1 on experimental models of PDN, it 
will be important to evaluate if IGF1 is useful to treat diabetic patients. Clinical trials 
show that IGF1 is well tolerated, which point for high compliance rates (Rosenbloom, 
2009). Caution should, however, be taken with monitoring blood glucose levels, 
particularly in diabetic patients under treatment with insulin or antidiabetic drugs, since 
IGF1 increases insulin sensitivity (Mohamed-Ali and Pinkney, 2002) and may induce 
hypoglycemic episodes. 
In conclusion, we show that PDN is associated with several and complex 
changes in the central pain system. In order to achieve complete pain relief in this 
chronic pain condition, combined treatment approaches, addressing the multiple 
changes in several areas of the somatossensory system, should be considered.  
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